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Abstract 
Bacille Calmette Guérin (BCG) immunisation induces variable protection against 
tuberculosis (TB) in adolescents and adults. More information on how it protects, and 
when, is needed. The infant response to BCG immunisation in Uganda and the influence 
of maternal latent Mycobacterium tuberculosis (M.tuberculosis) infection (LTBI) and 
maternal BCG scar on these responses were examined. 
 
Innate responses from 29 mother-infant pairs was measured using a Luminex® assay. 
Gene expression profiles in unstimulated infant samples collected at 1 (n=42) and 6 
(n=51) weeks after birth were also analysed. Frequencies of PPD-specific IFN-γ+CD4+ 
T cells after 24-hour stimulation of infant samples were assessed by flow cytometry, 
and the time course of BCG-induced responses measured using Luminex® assay.  
Immunoglobulin G to PPD and tetanus toxoid was measured in plasma samples. The 
impact of maternal LTBI and maternal BCG scar on infant responses was investigated.  
 
Maternal BCG scar was associated with an increased infant pro-inflammatory response. 
Interferon and inflammation pathways were down-regulated at 1 week, but up-regulated 
at 6 weeks in infants of mothers with LTBI. In contrast, these pathways were both up-
regulated in infants of mothers with a BCG scar at 1 and 6 weeks. PPD-specific IFN-
γ+CD4+ T cells increased at 1 week and decreased at 6 weeks after birth (p=0.031). 
Maternal LTBI was associated with lower frequencies of IFN-γ+CD4+ T cells (p=0.015) 
and IFN-γ+, TNF-α+ and IL-2+ CD4+ T cells, combined (p=0.002), at 1 week after 
BCG. BCG-induced responses peaked around 24 weeks of age, but were not associated 
with maternal LTBI. Antibody responses dropped rapidly at 1 week and were not 
associated with maternal LTBI.  
 
In conclusion, infant responses peaked around 24 weeks of age, and maternal BCG scar 
was associated with increased infant proinflammatory responses. There was evidence of 
a shorter-term influence of maternal LTBI on infant responses.  
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Chapter 1 
Introduction 
1.1. Tuberculosis 
1.1.1. The global burden of tuberculosis 
Tuberculosis (TB) now ranks above Human Immunodeficiency Virus (HIV)/Acquired 
Immunodeficiency Syndrome (AIDS) as the leading cause of infectious disease deaths 
globally. In 2015, 1.4 million HIV-uninfected and 0.4 million HIV-infected people died 
of TB disease (1). Globally, there were an estimated 10.4 million new TB cases in 2015 
(equivalent to 142 cases per 100,000 population), with 5.9 (56%) million among men, 
3.5 (34%) million among women and 1.0 (10%) million among children (1). The 
majority of those infected will remain asymptomatic (latent M.tuberculosis infection 
(LTBI)) (2, 3) and up to 10% will go on to develop active TB disease (4).There was a 
slow fall in the absolute number of incident cases per capita (1.5% and 2.1% average 
rates per year for 2000-2014 and 2013-2014, respectively), and 1.5% average rate per 
year for 2014-2015 (1).  
 
In 2015, the African region contributed 26% (275 cases per every 100,000 population) 
of cases globally, more than the global estimate. In 2015, 0.86 million and 0.38 million 
HIV-negative men and women, respectively, died of TB disease (1). Up to 60% of the 
global burden is borne by India, Indonesia, China, Nigeria, Pakistan and Southern 
Africa (1). 
 
There is effective drug treatment for TB and there has been good progress since the 
introduction of the Directly Observed Therapy Strategy (DOTS) of the World Health 
Organisation (WHO) in 1995 (whose target was treatment of up to 85% of the TB cases 
globally), the Stop TB Strategy of 2006 and the Millenium Development Goals. 
Treatment with a combination of four antibiotics (rifampicin, isoniazid, pyrazinamide 
and ethambutol) for six months forms the current regimen for anti-TB treatment (1). An 
estimated 35 million HIV-uninfected people were effectively treated between 2000 and 
2014 (5). The introduction of a rapid molecular test for TB drug resistance (GeneXpert), 
and the availability of two new drugs (bedaquiline and delamanid) have added to the 
efforts being made.  
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TB treatment efforts have, however, been challenged by the emergence of multidrug 
resistant TB (MDR-TB) (defined as resistance to two of the common drugs isoniazid 
and rifampicin), rifampicin-resistant TB (RR-TB), and extensively drug resistant TB 
(XDR-TB) (defined as resistance to a second-line injectable and fluoroquinolone) 
strains. This is due, mainly, to wrong regimens and dosages. Globally, there are 580,000 
cases of MDR/RR-TB, with MDR-TB alone accounting for 83% of the total. An 
estimated 3.9% of new cases and 21% of cases previously treated for TB have 
MDR/RR-TB globally. In 2015 alone, up to 250,000 people reportedly died of 
MDR/RR-TB. Countries in the WHO regions of Asia (China and India) and eastern 
Europe (Russian Federation) have the highest MDR-TB burden, accounting for 45% of 
the global burden (1, 5, 6). In the African region, the Democratic Republic of the 
Congo, Ethiopia, Kenya, Mozambique, Nigeria and South Africa are among the 30 high 
MDR-TB burden countries (1, 7). Up to 9.5% of patients with MDR-TB have XDR-TB 
(1). In 2012, 15 countries in the African region had at least one XDR-TB case 
notification (6). By 2015, 117 countries had reported XDR-TB (1). Bedaquiline was 
used to treat patients with drug resistance in up to 70 countries in 2015 and delamanid 
was used in 39 countries (1). 
 
Another challenge to TB control efforts is the HIV epidemic. HIV infection is the 
strongest risk factor for TB. The lifetime risk of developing active TB disease is 
estimated at 5-15% in HIV-infected people per year, whereas the lifetime risk for 
developing active TB from LTBI in healthy individuals estimated to be 5% to 10% per 
year (8). Up to 11% of notified cases in 2015 were co-infected with HIV, worldwide. 
The number of TB pateints co-infected with HIV was highest in the WHO African 
region (81%) and the Americas (82%) in 2015. An estimated 9.6 million deaths were 
avereted in TB/HIV co-infected cases between 2000 and 2015 using TB treatment 
supported by antiretroviral therapy (ART) (1). 
 
Diabetes mellitus, alcohol use and smoking are some of the other factors associated 
with high risk of progression to active TB, in addition to poor treatment outcomes (9). 
Compared to those without, patients with diabetes mellitus had up to 3 times higher risk 
of developing TB disease (10-12). Diabetes has been shown to negatively affect the 
functions of alveolar macrophages (13) and the initiation of innate and adaptive immune 
responses in animal studies (14). Alterations in host immune responses are suggested to 
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be responsible for increased TB susceptibility in persons with diabetes (15). 
Interventions targeted at these risk factors would greatly reduce the global burden of TB 
(16, 17). 
 
Responses to challenges to the TB control effort are included in the recent seventeen 
Sustainable Development Goals (SDGs) launched in January 2016. Target 3.3 of Goal 3 
highlights efforts towards ending HIV, TB, malaria and neglected tropical diseases by 
2030 (18, 19). The End TB Strategy, aimed at eliminating TB by 2035 in countries with 
low incidence, has also been established (20, 21). This is a challenging goal with the 
current progress. 
 
1.1.2. The burden of tuberculosis in Uganda 
Previously, Uganda was among the 22 high TB burden countries prioritized globally 
since 2000. In 2015 alone, these countries contributed to 87% of the global estimate of 
TB cases (1). Using the new post-2015 criteria, Uganda is among the 30 highest 
TB/HIV burden countries in the world (1, 7).  
The DOT strategy was adopted by the national TB programme to improve adherence by 
making sure there is regular supply of anti-TB medication that are needed and for 
monitoring of case detection and treatment outcomes (22, 23). There have been reports 
of poor access to anti-TB drugs due to drug sockouts and challenges in drug delivery to 
remote or mobile communities (24, 25). Recent reports have further highlighted poor 
implementation of community-based DOTS in some communities in Uganda (26).  
 
In 2015, the estimated incidence of TB in Uganda was 202 cases per 100,000 people for 
all forms of TB (1, 5). The estimated TB incidence in HIV-infected persons alone was 
66 cases per 100,000 people (27). Between 2007 and 2013, TB case notification 
increased from 41, 612 to 47,650 (28). However, in 2015, 43, 736 TB cases were 
notifed in total (27). TB mortality remains high in Uganda, with annual rates of 14 and 
16 cases per 100,000 population for HIV-negative and HIV-positive persons, 
respectively (1, 27).  
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A study carried out in an urban setting in Uganda reported the prevalence of LTBI in 
adults at 49% (29). Among adolescents of 12-18 years of age in a rural setting in eastern 
Uganda, the prevalence was 16.1% (30).  
 
Challenges of poor health-seeking behaviour, poor adherence to drugs and inadequate 
funding are some of the reasons for the high TB mortality rates in Uganda. Treatment 
success rate in Uganda is reported to be low, with a coverage of 53% (27) mainly due to 
poor case identification and reporting, few trained health workers and noncompliance to 
treatment leading to emergence of drug resistant strains of M.tuberculosis, further 
complicating control efforts (31). Up to 88% of TB/HIV co-infected patients are on 
ART (27). In 2015, the estimated incidence of MDR/RR-TB in Uganda was 4.9 cases 
per 100,000 population (1).  Tables 1.1 and 1.2 illustrate the Ugandan and global 
estimates of TB incidence and mortality, respectively, for 2015.   
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Table 1.1. Ugandan and global estimates of tuberculosis incidence, 2015 
 
 
 
Country/region 
 
Population 
(millions) 
Incidence (including HIV) Incidence (HIV-positive) Incidence (MDR/RR-TB) 
Number 
(thousands) 
 
Rate 
Number 
(thousands) 
 
Rate 
Number 
(thousands) 
 
Rate 
 
Uganda 
 
39 
79  
(47-119) 
202 
(120-304) 
26 
(16-37) 
66 
(42-94) 
1.9 
(1.0-2.8) 
4.9 
(2.6-7.2) 
 
Global 
 
7323 
10400 
(8740-12200) 
142 
(119-166) 
1170 
(1020-1320) 
16 
(14-18) 
580 
(520-640) 
7.9 
(7.2-8.7) 
 
 
Table 1.2. Ugandan and global estimates of tuberculosis mortality, 2015 
 
 
 
Country/region 
 
 
 
Population 
(millions) 
 
Mortality  
(HIV-negative people) 
 
Mortality  
(HIV-positive people) 
Mortality  
(HIV-negative and HIV-positive 
people) 
Number 
(thousands) 
 
Rate 
Number 
(thousands) 
 
Rate 
Number 
(thousands) 
 
Rate 
 
Uganda 
 
39 
 
5.5 (3.3-8.3) 
 
14 (8.5-21) 
 
6.4 (1.7-14) 
 
16 (4.3-36) 
 
12 (6.1-20) 
 
30 (16-50) 
 
Global 
 
7323 
1400 
(1200-1600) 
 
19 (17-21) 
 
390 (320-460) 
 
5.3 (4.4-6.3) 
1800  
(1600-2000) 
 
24 (22-27) 
 
 
Source: Global tuberculosis report, 2016.
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1.1.3. M.tuberculosis as a pathogen 
Mycobacteria are acid-fast gram-positive bacteria with many species, most of which are 
nontuberculous and abundant in the environment. Human TB is mainly caused by 
M.tuberculosis and M. africanum, two members of the M.tuberculosis complex 
(MTBC) (32, 33). M.bovis, another member of the MTBC, affects both humans and 
animals (34). Other animal-adapted members of the MTBC include: M.microti, 
M.canetti, M.caprae, M.pinnipedii, M.suricattae and M.mungi (35). The MTBC 
lineages include: lineage 1 (East Africa, the Philippines, Indian Ocean rim), lineage 2 
(East Asia), lineage 3 (East Africa and Central Asian strain), lineage 4 (Europe, 
America and Africa), lineage 5 (West African 1), lineage 6 (West African 2), lineage 7 
(Ethiopia) (32, 36, 37). TB in Uganda is mainly caused by MTBC Uganda family (a 
sub-lineage of lineage 4 (Euro-American) lineage) (38-40).  Other MTBC lineages 
found in Uganda include lineage 2 (East Asia), lineage 4 non-Uganda (Euro American 
lineages other than Uganda family), and lineage 3 (East Africa, India/Central Asian 
strain). Recently, there has been interest in infections with the M.avium-intracellulare 
complex (MAC) (composed of M.avium, M.intracellulare and M.chimaera). There have 
been reports of a rise in the incidence of nontuberculous mycobacteria (NTM) globally, 
with cases of pulmonary MAC becoming more common (41-43).  
 
1.2. The immune response to M.tuberculosis. 
1.2.1. Innate immune responses 
TB is transmitted when aerosols containing the bacilli are inhaled.  The first line of 
defence against M. tuberculosis infection is formed by the mucosa along the respiratory 
airway (44). The respiratory mucosa is made of the epithelium, which is a layer of 
airway epithelial cells (AECs). These cells form a barrier that stops initial pathogen 
invasion. Though not classified as immune cells, these cells are reported to display anti-
mycobacterial activities in animal (45) and human studies (46). Other components of 
the respiratory mucosa include the lamina propria (a layer of immune cells such as 
lymphocytes and macrophages and connective tissue) and airway surface liquid (ASL), 
which contains immunoglobulin A, mucus and other innate anti-microbial agents. The 
bronchial-or nasal-associated lymphoid tissues with anti-mycobacterial roles are also 
found along the airways (47). The AECs express pattern recognition receptors (PRRs) 
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that sense pathogen associated molecular patterns (PAMPs) on M.tuberculosis (48) and 
can present antigens to mucosal-associated invariant T cells (46). The AECs are also 
capable of secreting cytokines and chemokines that influence the functioning of 
phagocytes (48). There are reports of the presence of antimicrobial peptides such as β-
defensin 2, cathelicidin and hepcidin in the ASL whose composition is determined by 
the AECs (49-51).  Type II epithelial cells in the alveoli produce molecules with 
antimicrobial properties (49) and in particular they secrete hydrolytic enzymes, 
hydrolases and pulmonary surfactants with anti-mycobacterial roles (52, 53).   
 
The bacilli infect alveolar macrophages and DCs and the result of the encounter with 
these cells will determine if an individual becomes latently or actively infected (54, 55).  
Upon infection, the bacteria are contained in a well-defined structure called a 
granuloma, characterized by a ring of lymphocytes and fibroblasts around 
multinucleated giant cells and activated macrophages. Other cells such as γδ T cells also 
get attracted to the granuloma (56). In a study involving a mouse model, the expression 
of chemokines involved in the formation of the granuloma are dependent upon TNF-α 
produced by M.tuberculosis-infected macrophages and T cells, and this is important in 
the initiation of granuloma formation (57). Alveolar macrophages can kill 
M.tuberculosis by producing iNOS and RNI after activation by IFN-γ and TNF-α (58). 
The cells and their products involved in immunity to M. tuberculosis infection are 
summarized in Figure 1.1 below. 
 
There is evidence that the host mounts an effective immune response to the bacilli and 
stops development of active TB disease in about 90% of individuals infected by 
M.tuberculosis, however in most cases the infection persists in a latent state (LTBI) 
(59). This latent state can last for a lifetime or be reactivated based on the state of the 
hosts’ immune system (60, 61).  M.tuberculosis can remain in the lung granulomas and 
the host immune system is unable to completely clear it (56). Latently infected persons 
therefore act as reservoirs of new infections and efforts are being made to identify and 
treat them (62, 63). A dynamic relationship exists between the host and mycobacteria 
resulting in a broad spectrum of responses and outcomes (64, 65). Latently infected 
persons therefore may retain the bacilli in an inactive state or the bacilli may be actively 
replicating without apparent clinical disease (64), a condition referred to as incipient TB 
(66).  
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Figure 1.1. The various contributors to immunity to M.tuberculosis infection. 1. Production of cytokines (including IL-1β, IL-6 and TNF-α) and 
anti-mycobacterial peptides by epithelial cells. 2. M.tuberculosis bacilli are taken up by alveolar macrophages and killed using reactive oxygen 
and nitrogen intermediates. 3. M.tuberculosis bacilli are taken up by dendritic cells (DCs). 4. T and B cells in the lymph nodes are activated by 
mycobacterial antigens delivered by macrophages and DCs. 5. The activated T and B cells migrate to the lungs to form granulomas. Activated 
CD8+ T and NK cells kill infected macrophages and DCs. 6. M.tuberculosis bacilli are contained in the granuloma. Source of elements: Servier 
Medical Art. The M.tuberculosis bacilli shown were designed by me.
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Innate immune cells control infection by phagocytosis of the microbes and initiation of 
immune responses, which kills the pathogen. The host elicits anti-microbial responses 
such as phagosomal maturation, generation of reactive oxygen species (ROS) and 
reactive nitrogen intermediates (RNI) after recruitment of phagocytic cells such as 
macrophages, dendritic cells (DCs) and natural killer (NK) cells.   
 
The M.tuberculosis bacilli are engulfed by macrophages into phagosomes that then fuse 
with lysosomes to create an environment that can disable or kill the mycobacteria (67). 
This is made possible by PRRs from the macrophages or DCs that interact with PAMPs 
on M.tuberculosis. Toll-like receptors (TLRs) (such as TLR 2, TLR 4 and TLR 9) have 
been studied widely and play an important role in immunity to mycobacteria (68). DC-
SIGN, Dectin 1, mannose receptor and mannose-binding lectin (MBL) are the other 
receptors engaged during the phagocytosis of M.tuberculosis (69).   
 
In humans, ten TLR family members have been identified and each one is associated 
with a unique signaling cascade upon activation by the PAMPs (55, 70). Mycobacteria 
have PAMPs such as lipoproteins, lipoglycans and carbohydrates that are targets for 
TLRs (69). Activation of transcription factors such as NF-κβ and inducible nitric oxide 
synthase (iNOS) gene expression results in the production of such cytokines as 
Interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF)-α and gamma interferon (IFN)-
γ. TLR1/6 polymorphisms in South African infants have been shown to positively 
influence BCG-induced T helper (Th) 1 responses (71).  
 
M.tuberculosis is capable of evading host immune responses by modulating both innate 
and adaptive immune responses. Alterations of the phagosomal environment within the 
macrophages and effects on host cytokine responses, antigen presentation and selective 
interactions with PRRs are some of the strategies employed by the bacilli (72). 
 
Neutrophils are another set of effector cells with potential for both anti-mycobacterial 
activity and immunopathology in humans. They can limit the growth of M. tuberculosis 
(73) and once stimulated, they secret chemokines and proinflammatory cytokines that 
influence the recruitment and activation of cells (74). During the respiratory burst, 
neutrophils also release collagenase, myeloperoxidase and elastase from their granules 
and these factors act on both the pathogen and the host. Neutrophils constitute a large 
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percentage of the M.tuberculosis-infected cells in sputum and bronchoalveolar lavage 
from active TB patients (75), and have been linked to high expression of programmed 
death ligand 1 (PD-L1) in whole blood, resulting in dysfunctional or exhausted T cells 
(76).  
 
Studies in animals have shown that DCs make up a large population of cells infected 
with M.tuberculosis (77, 78). Although macrophages are more phagocytic than DCs, 
DCs are surprisingly efficient at phagocytosing M.tuberculosis (79). The engagement of 
lipoarabinomannan (LAM) from mycobacteria by DC-SIGN serves as the main entry 
route for M.tuberculosis in DCs (80). Alveoli DCs mature on uptake of M.tuberculosis 
bacilli and present processed antigens to T cells (81).The interaction between 
M.tuberculosis LAM and DC-SIGN is also associated with an immunoregulatory 
immune profile (82).  
 
NK cells also display anti-mycobacterial properties. Various studies have shown in vitro 
lysis of macrophages infected with M.tuberculosis by human NK cells (83, 84). The 
natural cytotoxicity receptor (NCR) NKp44 on NK cells is capable of ligating various 
PAMPs on M.tuberculosis (85). In vitro, NK cells are capable of secretion of IFN-γ and 
IL-22 (86) or initiation of IFN-γ production and lysis of infected cells by CD8+ T cells 
(87).   
 
 
A recently described group of hematopoietic cells of the innate immune system are the 
innate lymphoid cells (ILCs). These cells can be isolated from the lungs, the gut and 
mucosal surfaces (88-92) and resemble CD4+ T helper cells (88, 91, 93), but do not 
have rearranged antigen-specific receptors. A variety of PAMPs can activate ILCs (91, 
94-96). There are three groups of ILCs: first, NK cells (innate equivalent of CD8+ T 
cells) and other IFN-γ -producing ILCs (innate equivalent of Th1 cells) (ILC1). These 
express T-bet as their signature transcription factor. Second, IL-5 and IL-13 producing 
ILCs express GATA3 (innate equivalent of Th2 cells) (ILC2). Third, IL-17A-, IL-17F 
and IL-22-producing ILCs express transcription factor RORγt (innate equivalent of 
Th17 cells) (ILC3) (90, 91, 97). A study in animals has reported the anti-mycobacterial 
role of ILC1 and ILC3 cells in the lungs of BCG-vaccinated mice (98).    
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Another innate mechanism employed in the control and elimination of M.tuberculosis is 
autophagy (99). Here, the cytoplasmic contents of the cells are degraded in the 
autophagosomes (100). When this happens in infected macrophages, the M.tuberculosis 
bacilli are killed in the process.  
 
1.2.2. The adaptive immune response  
The host cellular immune response to M.tuberculosis is complex and mainly 
characterized by T helper (Th)-1 cell responses (101-103). The immune responses 
generated by activated CD4+ and CD8+ T cells are important in the control of the 
infection (61). CD4+ T cells are activated by M.tuberculosis antigens from antigen 
presenting cells (APCs) in the context of major histocompatibility class II-encoded 
molecules. The importance of CD4+ T cells in protective immunity to M.tuberculosis in 
humans is shown by increased susceptibility of HIV-infected people to infection with 
M.tuberculosis (104-106). Reactivation of TB infection in mice occured when CD4+ T 
cells were blocked using antibodies (107) and there was sustained growth of bacilli in 
the lungs and other organs, and poorer survival in mice without CD4+ T cells (102).  
 
M.tuberculosis-specific CD8+ T cells have been reported in humans (108), and in some 
cases there were more M.tuberculosis-specific CD8+ T cells than M.tuberculosis-
specific CD4+ T cells in some samples (109, 110). M.tuberculosis antigens are 
processed and presented to CD8+ T cells in the context of MHC class I. The importance 
of CD8+ T cells in anti-TB immunity is highlighted by susceptibility to TB in mice 
lacking functional CD8+ T cells due to a deficiency in β2-microglobulin (111).  CD8+ T 
cells are thought to play a greater role in the latent phase of the infection (112), although 
other studies report their importance during chronic infection (113). CD8+ T cells 
produce various cytokines, including IFN-γ and TNF-α (114) and are capable of directly 
killing infected macrophages (115). Granulysin and perforin produced by cytotoxic 
CD8+ T cells are effective anti-mycobacterial agents (116). Cytotoxic CD4+ T cells 
have also been reported, but with a different killing mechanism from CD8+ T cells 
(117). Differential expression of genes in CD4+ and CD8+ T cells in response to 
stimulation with M.tuberculosis has also been reported by Cliff et al. (118).  Recently, 
cytolytic or suppressive HLA-E restricted CD8+ T cells that express GATA3, secrete 
Th2 cytokines including IL-4, IL-5, IL-13, and are capable of B-cell help have been 
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identified. These cells were able to inhibit growth of M.tuberculosis in infected 
macrophages (119).   
 
Non-conventional T cells that recognize lipids, modified peptides and small-molecule 
metabolites have previously been reported. These include CD1-restrcited mucosal-
associated invariant T (MAIT), natural killer T (NKT), gamma delta T, and germ-line 
encoded mycolyl-reactive T cells (120-122). These cells have innate cell-like properties 
and have been demonstrated to have anti-mycobacterial properties (123-126).  
 
1.2.3. Cytokines and chemokines involved in immunity to M.tuberculosis 
Cytokines play important roles in immunity to mycobacteria. In addition to TNF-α, IL-
1α and IL-1β are required for protective immunity against M.tuberculosis infection. 
Human IL-1β gene polymorphism studies and studies in animal models have been 
instrumental in unraveling the importance of this cytokine in anti-TB immunity (127-
130). The requirement of both IL-1α and IL-1β in immunity to TB has been shown by 
Mayer-Barber and colleagues (131). There are reports of marked production of IL-1β by 
M.tuberculosis-infected macrophages. IL-1β has also been implicated in boosting of 
CD4+ T cell responses (132). The recruitment of inflammatory cells to M.tuberculosis 
granulomas is brought about by IL-1β (133-137). 
 
The interleukin-1 receptor antagonist (IL-1Ra) binds competitively to IL-1 receptors 
thus acting as an anti-inflammatory chemokine. The role of IL-1Ra in impairing of IL-4 
and IgE responses (compared to increased IFN-γ and IgG2a) has previously been 
reported in the mouse (138). IL-1Ra is further reported to play a role in delayed-type 
hypersensitivity and TB disease in humans (127). 
 
Cytokines produced by activated T cells are essential in the fight against M.tuberculosis 
infection (139), and among these are IFN-γ, IL-12, TNF-α and IL-2. T cells are able to 
elicit M.tuberculosis-specific immune responses, before establishment of memory 
(140).  
 
One important feature of immunity to TB is the delay in the development of detectable 
adaptive responses, which in humans takes 5-6 weeks after infection (141, 142), and in 
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mice it takes up to 12 days (143). M.tuberculosis is also known to impair antigen 
processing and the initial priming of naïve T cells (144). M.tuberculosis is able to 
induce immunomodulation or immunosuppression by inducing production of IL-10 and 
TGF-β, two cytokines with suppressive effects on T cells (145-147). More work is 
needed to understand the initiation of adaptive responses to M.tuberculosis. 
Alveolar macrophages are activated by IFN-γ and TNF-α to induce production of iNOS 
and RNI that are important for killing M.tuberculosis (58). The importance of these two 
cytokines, including IL-12 and IL-6, in anti-TB immunity was shown in studies where 
animals were treated with cytokines and then infected; use of anti-cytokine antibodies; 
and in animals in which key genes were knocked out (58, 139, 148-153). Individuals 
with defects in the IFN-γ or IL-12 receptor genes were susceptible to M.tuberculosis 
infection (154-158). IL-12p40 secreted by DCs is important for anti-mycobacterial Th1 
responses (159, 160).  
 
Th2 immunity, induced by IL-4, is thought to oppose protective Th1 responses to TB 
(161). Th2 activation of macrophages results in alternatively activated phenotypes that 
are less potent in their antimicrobial activity (162). Intracellular killing of 
M.tuberculosis through the process of autophagy is reportedly impaired in a Th2 
environment (163).  However, Th2-like CD8+ T cells with anti-mycobacterial 
properties have recently been identified (119).   
 
Little is known about the role for B cells in the control of M.tuberculosis infection. The 
roles for B cells and antibodies in anti-TB immune responses has recently been 
discussed, including calls for further studies to understand the mechanisms involved 
(164, 165). Antigen-specific antibodies produced by plasma cells can influence 
activities of phagocytic cells, as well as processes involving antibody-dependent cellular 
cytotoxicity. The receptors involved in the interaction between the host and pathogen 
may also be affected, thus influencing the activities of other immune cells (166, 167). In 
a recent study, antibodies from latently infected persons have been shown to have 
distinct properties from antibodies from active TB patients, including glycosylation 
patterns, antibody Fc properties and FcγRIII binding. These antibodies were able to 
increase antimicrobial activities and reduce survival of bacilli when applied to human 
macrophages infected with M.tuberculosis (168). B cells also play an antigen-presenting 
role, with specific effects on proliferation of T cells (169). There have been reports of 
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changes in the local T cell and cytokine responses, increased bacterial load and 
impaired inflammatory responses in granulomas of nonhuman primates with depleted B 
cells, highlighting the importance of B cells in anti-mycobacterial immune responses 
(170). Activated B cells, plasma cells and antibodies within granulomas have previously 
been reported (171). A study by Ashenafi and colleagues demonstrated that patients 
with active TB, compared to latently infected or controls, had higher proportions of 
IgG-expressing plasmablasts, showing differences in antibody production in humans 
with disease (172). Differential B-cell phenotypes in latent and active M.tuberculosis 
infection, as well as induction, by BCG, of long-lived mycobacteria-specific memory B-
cells in healthy individuals has previously been reported in our setting (173, 174). The 
modulation of genes associated with B-cells has also been reported during TB treatment 
(175). B cells can also act as a source of pro- and anti-inflammatory cytokines (176). 
Recently, IFN-γ -expressing B cells have been described, further highlighting the 
importance of these cells in immune response to infections through activation of 
macrophages (177). TLRs are also expressed by B cells (178). In a recent study by 
Fletcher and colleagues, IgG to Ag85A antigen correlated with a reduced risk of TB 
disease in infants (179). 
 
M.tuberculosis also elicits a variety of chemokines (180). Th1 cells are recruited to the 
site of infection by inflammatory chemokines such as IP-10 (CXCL10), whereas MIP-
1α (CCL3) and MIP-1β (CCL4) are thought to prime cells towards a Th2 phenotype 
(181, 182). Differential expression in the lungs of active pulmonary TB patients of 
chemokines and regulatory protein has previously been reported (183).  Other 
chemokines, such as MCP-1, also play important anti-mycobacterial roles. Studies that 
looked at mutations in MCP-1 and susceptibility to TB have highlighted the importance 
of this chemokine in TB infection (184). 
 
IL-8 (CXCL8) enhances the phagocytic and killing capabilities of immune cells (185) 
and acts as a chemoattractant and activator of lymphocytes during granuloma formation. 
Infected monocytes or macrophages, neutrophils and epithelial cells are thought to be 
the sources of IL-8 (74, 135, 186-188). Recently, production of IL-8 by neonatal T cells 
has been demonstrated as an anti-microbial effector mechanism (189). 
The growth factor GM-CSF acts to promote T cell responses in M.tuberculosis infection 
(190) and plays a pivotal role in the differentiation of alveolar macrophages ((191-193). 
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GM-CSF is also important in the initiation of cellular responses and granuloma 
formation in M.tuberculosis-infected mice (194, 195). Invariant NKT (iNKT) cells are 
among the cells that produce GM-CSF with anti-mycobacterial properties (196)
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1.3. Correlates of protective immunity to tuberculosis 
Many studies aimed at understanding correlates of protective immunity to TB have been 
reported, but this knowledge is still limited, yet it is needed for evaluation of new 
tuberculosis vaccines (197). The production of IFN-γ by activated CD4+ T cells has for 
long been used as a measure of an effective immune response to TB (58). However, 
other studies have shown this immunity to be insufficient (198) or not correlated with 
protection (199, 200), stressing how complex immunity to TB disease is. In a recent 
study by Fletcher and colleagues, IFN-γ -secreting T cells specific for BCG correlated 
with a reduced risk of TB disease in infants (179). 
 
Polyfunctional T cells that produce IFN-γ, TNF-α and IL-2 have been considered 
important T-cell based biomarkers (123). High proportions of polyfunctional T cells 
have been associated with protection against M.tuberculosis infection in vaccinated 
mice (125, 201, 202). However, such associations have not been demonstrated in 
humans where the patterns of cytokine production did not correlate with anti-TB 
protection (199, 200), but a recent report from a study in the UK shows that 
polyfunctional T cells are associated with inhibition of mycobacterial growth in vitro in 
infants vaccinated with BCG (203). A study of human AdHu5Ag85A in BCG 
vaccinated adults showed enhanced expression of polyfunctional CD4+ and CD8+ T 
cells (204). Re-assessment of the use of IFN-γ as a correlate of protection and the role 
of other cell types in protection against TB has therefore been called for (205). CD4+ T 
cells that produce IL-17 or IL-22 are thought to also play a role in anti-mycobacterial 
immune responses (206). Activated CD4+ T cells expressing HLA-DR have also been 
shown recently to be associated with risk of TB disease (179). 
1.4. Infant responses to BCG immunisation 
BCG is the only vaccine against TB currently available (207, 208). BCG has been used 
for almost a century, with its inclusion in the Expanded Programme on Immunisation 
(EPI) of WHO in 1974. It is the most widely used vaccine with a global annual estimate 
of more than 120 million doses (209, 210). There are global differences in BCG policies 
and practices, with some countries vaccinating everyone and others restricting it to 
groups at high risk for TB (211). However, there are reports of high mortality due to 
disseminated BCG disease in infants infected with HIV (212-214), and this is the reason 
why WHO changed its recommendations on use of BCG in infants known to be infected 
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with HIV, and to delay BCG immunisation for HIV-exposed infants until such a time 
that their HIV infection status is ascertained (214). In Uganda, BCG vaccine is 
administered to newborns at birth, in accordance with WHO recommendations for a TB 
endemic area (214), though a study on the timing and coverage of EPI vaccines in low- 
and middle-income countries reports that up to 46% of infants do not receive BCG 
immunisation until after 10 weeks of birth (215). 
 
The infant immune system is “immature” and this would be disadvantageous for 
vaccines given at birth since the induced immune response would not be adequate. 
However, BCG is efficacious against the disseminated form of TB disease in children 
(216-218). Age-related changes in infant immune responses have previously been 
reported (219-222); for example infants have been shown to have poor immune 
responses to polysaccharide antigens (223).  
 
Several studies show that BCG immunisation of infants produces a measurable immune 
response. Infants have been shown to generate BCG-induced cytokine-expressing T 
cells of the same magnitude as adults, though with a bias towards polyfunctional cells 
(224). Infants have been shown to generate Th1 responses to mycobacterial antigens 
following BCG immunisation (225).  
 
Studies in humans and mice have shown induction of effector T cells following BCG 
immunisation (226-228), and effector T cells, compared to memory T cells, are short-
lived (229). However, the induction of memory T cells in infants and adults after BCG 
immunisation has also been reported (230, 231). Memory T cells are of two main types: 
central memory T cells that are found in the secondary lymphoid tissues and blood; and 
effector memory T cells found in peripheral tissues and the blood and the spleen (229, 
232, 233), although there are also distinct tissue-resident memory T cells (233, 234).  
 
In a recent study, clearly different patterns of response to BCG were observed in infants 
immunised with BCG, though there was no evidence of correlates of risk of TB disease 
(235). The induction of granulysin and perforin expression at 10 weeks of age in infants 
immunised with BCG at birth has been demonstrated (236). In a study in South African 
children, T-cell responses to mycobacterial antigens were reported following BCG 
immunisation (237). The complexity of BCG-induced immunity has further been 
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demonstrated by the differential expression of immune genes following BCG 
immunisation of infants (238). In a recent study in Copenhagen, BCG vaccine-related 
severe adverse reactions and BCG-osis were not observed (239). 
 
The sequence in which infant vaccines are given has been a hot topic for discussion 
recently. Several studies have been conducted, each giving contrasting results. Th1 and 
Th2 responses to unrelated childhood vaccines have been shown to be enhanced by 
BCG immunisation (225, 240). Antibody responses to OPV and HBV were also 
increased in BCG immunised infants (240). Fewer deaths and hospital admissions were 
registered when OPV alone was given to children in Bissau, compared to children who 
received both OPV and DPT at the same time (241). Impaired Th1 responses, but 
enhanced humoral responses, have been reported when neonates were administred oral 
polio vaccine (242). This has implications for the control of pathogens where Th1 
responses are required. In a Danish study, OPV was associated with fewer hospital 
admissions (243). In another study in Bissau, co-administration of OPV and BCG was 
associated with reduced infant responses to PPD (244, 245). Girls, compared to boys, 
have a reported high mortality when OPV was missed at birth (246).  
 
Several studies have looked at differences in infant responses when BCG is 
administered at birth or when BCG vaccination is delayed, with contradictory results. A 
study in Uganda demonstrated reduced capacity to elicit IFN-γ-producing T cells and 
polyfunctional cells producing IFN-γ, TNF-α and IL-2 in infants where BCG 
immunisation was delayed to 6 weeks, compared to those that were vaccinated at birth 
(247). In a study in the Gambia, there was a report of reduced BCG-specific cytokine 
responses (IFN-γ, IL-6, IL-17) in vitro in infants where BCG immunisation was delayed 
(248). However, a study by Kagina and colleagues demonstrated increased proportions 
of BCG-induced T cells when BCG immunisation is delayed (226). A recent study by 
Ritz et al. in Australia did not show any differences in responses between infants 
vaccinated at birth and those where BCG immunisation was delayed (249). In another 
study, antibody responses to infant vaccine antigens were not affected by the timing of 
BCG immunisation (250). 
 
There is little information about the peak immune response in infants following BCG 
immunisation, yet this knowledge is important for the design and use of vaccines aimed 
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at boosting immunity primed by BCG (251). An established memory population (after 
the peak effector phases) would be suitable to boost in a prime-boost vaccine strategy. 
This has been highlighted by studies on viral infection models involving T cells (252-
254). It is thought that T cells may be less effective or prone to cell death if boosted 
during the primary effector phase (252, 255, 256). A peak in response between 6 and 10 
weeks has been shown for CD4+ T cell responses following BCG immunisation (220).  
 
Several strains of BCG vaccine have been in use globally and these include genetically 
diverse strains such as Danish 1331, Pasteur 1173, Tokyo 172, Russian and Moreau 
(257-259). UNICEF supplies the most common strains in use in developing countries 
and these include BCG-Denmark, BCG-Japan and BCG-Bulgaria. The influence of 
BCG strains on infant responses is discussed below. 
 
1.5. Heterologous effects of BCG immunisation 
Evidence that BCG immunisation may influence innate responses includes findings in 
both observational studies and randomized controlled trials that have highlighted the 
heterologous effects of BCG on childhood survival in both low- and high-income 
countries (260-264). This has been suggested to be due to BCG-induced increases in 
function of the innate immune system, a phenomenon now termed ‘trained immunity’ 
(265-269).  This is an observation of great global health significance, since mortality 
due to infectious agents other than TB is high in developing tropical countries (270). 
However, a recent study did not observe beneficial heterologous effects of BCG 
immunisation on childhood infection (271). Also, a systematic review of available 
literature did not find sufficient evidence of non-specific immunological effects 
following BCG immunisation (272). The data showing heterologous effects mostly has 
come from West Africa, with potential biases in the observation that could affect the 
findings, and there were methodological and epidemiological issues with some of them, 
with infants receiving vaccine or no vaccine based on vaccine availability, and thus not 
a proper randomised trial, and with the possibility of confounding. Many of the effects 
were also seen in low birth weight infants. If non-specific effects of some vaccines truly 
exist, these would be heterogeneous, and may differ between populations (273). 
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1.6. BCG immunisation scars 
The presence or absence of a scar has for long been used as a sign of previous 
immunisation with BCG, in place of or in addition to vaccination records (274-276). 
From 52% to 97% of newborns immunized with BCG develop a scar, with strain of 
BCG vaccine used, the administrator and age of administration accounting for the 
differences observed (274, 277-280). However, not all BCG vaccinated babies will scar. 
Previous studies have shown a correlation between the presence of a scar and protection 
against TB (281, 282), and infants with a BCG scar have been shown to have better 
survival with fewer respiratory infections (278, 283, 284), fewer skin infections and 
sepsis (285).  
Little is known about the link between the development of a BCG scar in mothers and 
immune responses in infants. Maternal BCG scar has been shown to be associated with 
lower T helper (Th) 2 responses to crude culture filtrate proteins of mycobacteria in the 
infants in one of our studies (286). Effects of maternal BCG scar on innate immune 
responses in infants are not known. 
1.7. Latent M.tuberculosis infection 
The infected host and mycobacteria are in a dynamic relationship resulting in a broad 
spectrum of responses and outcomes (64, 65). The baccili may therefore be in an 
inactive form in latently infected individuals or are actively replicating without resulting 
in clinical disease (64). 
We therefore proposed the hypothesis that maternal latent M. tuberculosis infection 
(LTBI) influences the neonatal response to BCG (and to M.  tuberculosis), rendering the 
response to BCG less effective, and susceptibility to tuberculosis greater.  Maternal 
latent infection with M. tuberculosis might lead to exposure to mycobacterial antigens 
in utero and the development of a modified profile of response to mycobacteria after 
birth – involving either sensitisation (287), or the induction of tolerance (288, 289) in 
the fetus.  
In Uganda, where the annual incidence of infection is estimated at 3%, up to 60% of 
young women of childbearing age are likely to be infected with M. tuberculosis. Latent 
maternal infection with M. tuberculosis is likely to have a more important effect on the 
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infant than for example a remote history of maternal immunisation with the BCG 
vaccine.  
 
1.8. Clinical trials and efficacy of BCG vaccination 
There have been a number of efficacy trials and epidemiological studies carried out 
since BCG was introduced in the 1920s, with variable results. The results for severe 
extrapulmonary forms of TB in children (TB meningitis and miliary disease) show that 
BCG provides between 60-80% protective efficacy (216-218). For pulmonary TB in 
adults and adolescents, the efficacy of BCG vaccine ranges between 0-80% (290). 
Several hypotheses have been put forward to explain the variability in efficacy of BCG 
vaccine and these include the following: first, the genetically diverse strains of BCG 
vaccine used in the different trial sites. BCG strains have been passaged many times and 
sub-strains prepared resulting in the use of different strains. Human and animal studies 
have demonstrated differences in BCG-induced responses with strains of the BCG 
vaccine used (277, 280, 291, 292). However, it is difficult to relate the observed 
differences in immune responses to the variability in protection from BCG. Meta-
analyses of current research evidence shows that BCG strains are not associated with 
lack of efficacy of BCG vaccine (293, 294). It is not possible for strain differences alone 
to account for the observed differences in efficacy, though it may contribute somewhat 
to the differences observed (290, 293, 295). Second, there have been differences in dose 
and route of administration of BCG vaccine with time and trial locations. Initially 
administered as an oral vaccine, BCG is now given through the intradermal route. 
However, no differences in efficacy were reported for studies where BCG was 
administered intradermally versus percutaneously in a study in South Africa (296). 
Third, meta-analyses of trials of BCG immunisation indicate that latitude is a significant 
factor in the protection achieved in adolescents and adults (290, 293, 294, 297). One 
suggested explanation for the variability in BCG efficacy, and its relationship to 
latitude, is that of helminth infection, which is widespread in the tropics and has an 
influence on immune responses, both impairing the response to BCG immunisation and 
increasing susceptibility to TB itself (298).  An extension of this hypothesis is that in 
utero exposure to maternal helminth infection may influence the neonatal response to 
BCG given at birth.  This idea is supported by a finding in Kenya where infant 
responses to BCG were skewed towards a Th2 profile if they were sensitised in utero to 
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schistosome or filarial antigens (299). This hypothesis has been further explored in a 
study in Uganda (300), with results showing that maternal helminth infections do not 
have a major effect on responses to BCG immunisation (301). Another hypothesis is 
that sensitisation to NTM, which is more common in lower latitudes (302), alters the 
protection induced by BCG (303).  Induction of a protective effect by BCG might be 
blocked by exposure to NTM, or an equivalent protection to BCG might be generated, 
obscuring or masking the benefit provided by BCG (304-306).  A recent meta-analysis 
of the literature shows that previous exposure to NTM or to M.tuberculosis is associated 
with lower efficacy of BCG (294). A study in mice showed that oral exposure to NTM 
(M. avium) after BCG immunisation also reduced BCG-induced protective immunity 
(307). The neonatal response to BCG given at birth may be influenced by in utero 
exposure to maternal M.tuberculosis or NTM infection. Maternal BCG immunisation or 
exposure to NTM, or exposure to M. tuberculosis are possible ways through which 
mothers can get exposed to mycobacteria, resulting in infant exposure to mycobacterial 
antigens in utero. This may be associated with sensitisation (287), or the induction of 
tolerance (as reported for maternal helminths) (288, 289). However, in a recent study, 
there were no associations between maternal M.tuberculosis and infant responses (308), 
although the study design was unable to conclusively rule in or out M.tuberculosis 
exposure, and so the conclusions of the study are not as powerful as they otherwise 
might have been. 
 
1.9. Tuberculosis vacines under development 
New and effective vaccines against TB are urgently needed due to the slow reduction in 
the incidence of TB worldwide and the emergence of drug-resistant strains of the 
bacilli. The current TB candidate vaccines being developed (Table 1.3) (1, 309) are 
targeted at boosting responses to BCG (subunit vaccines and whole-mycobacterial-cell) 
or replacing BCG (whole-mycobacterial-cell). These vaccines are whole-mycobacterial-
cell-derived and viral vectored or adjuvanted protein subunit vaccines aimed at 
improved protection by preventing infection, progression to disease at the initial stages, 
or latent TB reactivation (5, 309) and include: The subunit vaccine, MVA85A, is a live 
attenuated vaccinia vectored vaccine candidate expressing an immunogenic antigen 
(Ag85A) of M.tuberculosis. It has recently been intensively evaluated in infants and 
adults. A study by McShane et al. showed that this vaccine was able to boost responses 
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in volunteers who had previously received BCG (310). In other trials, the vaccine 
showed no efficacy against M.tuberculosis infection or TB disease, but was 
immunogenic and well tolerated in infants (200) and adults (311).  The failure to show 
protective efficacy was associated with a slight increase in incidence of TB disease, and 
the vaccine did induce memory T cell responses, although these may not have been 
sufficient in frequency. MVA85A has been shown to induce increased inflammatory 
responses in South African children a day after immunisation (312). The induction of 
long-lasting T cell responses by MVA85A in persons infected with HIV has been 
shown in another study in South Africa (313). Further studies are now investigating 
delivering MVA85A by the aerosol route. More data from the MVA85A trial shows 
potential benefit of antibodies and negative effect of activated CD4+ T cells (179), and 
that QuantFERON conversion rates with high cytokine levels suggest increased 
susceptibility to disease (314). Other viral vectored vaccines include Ad5Ag85A, 
ChAdOx185A and TB/FLU-04L all expressing antigen 85A (Ag85A) from 
M.tuberculosis. Another vaccine that shows promise in terms of safety and 
immunogenicity is the AERAS-402 vaccine. This is an adenovirus 35-vectored infant 
TB vaccine candidate that is administered as a boost following a prime with BCG. 
There was a dose-dependent response in BCG immunised infants when AERAS-402 
was given to them (315). Adjuvanted protein subunit vaccines developed with the aim 
of boosting BCG-primed immune responses include M72: AS01E, H4: IC31, H1: IC31, 
H56: IC31 and ID93: GLA-SE. Another vaccine candidate designed to replace BCG in 
infants and to prevent recurrent TB disease in adults following successful completion of 
treatment for active pulmonary TB is VPM1002. It is the only recombinant BCG 
vaccine candidate currently in clinical trials with an insertion of a gene for listeriolysin 
and the deletion of urease gene in the BCG DNA. MTBVAC, another candidate 
vaccine, is the only whole cell candidate derived from M.tuberculosis. It is being 
developed as a BCG replacement vaccine in infants and is in phase II trials. Another 
vaccine candidate DAR-901, like M. vaccae (VaccaeTM, AnHui Longcom Biologic 
Pharmacy Co., Ltd [Longcom], Beijing, China), is a heat-inactivated whole cell, NTM. 
RUTI
®
 
(Archivel Farma, Barcelona, Spain) has been developed for immunotherapeutic 
use in active TB patients.  
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Table 1.3. Tuberculosis vaccines in the pipeline 
 
 
Phase I 
 
Phase IIa 
 
Phase IIb 
 
Phase III 
MTBVAC 
TBVI, Zaragoza, 
Biofabri 
DAR-901 
Dartmouth 
VPM1002 
Max Planck, VPM, 
TBVI, SII 
Vaccae
TM
 
Anhui Zhifel 
Longcom 
Ad5Ag85A 
McMaster, CanSino 
 
RUTI 
Archivel Farma, 
S.L 
M72+ AS01E 
GSK, Aeras 
 
ChAdOx1.85A/ 
MVA85A 
Oxford, Birmingham 
H1/H56: IC31 
SSI, Valneva, 
Aeras 
  
 
MVA85A/ MVA85A 
(ID, Aerosol) 
Oxford 
H4: IC31 
SSI, Sanof Pasteur, 
Aeras 
  
TB/FLU-04L 
RIBSP 
ID93+GLA-SE 
IDRI, Aeras, 
Wellcome Trust 
  
 
Source: Global tuberculosis report, 2016 
 
 
 
We still do not know when the peak of the response to BCG immunisation is, and we 
still have no correlate of protection against TB. We also do not know the influence 
NTM or maternal LTBI have on effectiveness of BCG. 
 
1.10. Hypothesis and objectives of the study 
The work in this thesis was designed to test the hypothesis that maternal infection with 
M.tuberculosis is associated with an impaired infant response to BCG immunisation. 
The objectives of the study included: 
 
1. To investigate innate immune responses and gene expression profiles in infants. 
2. To assess the time course of BCG-induced priming of the infant response, and the 
    establishment of the peak in response after BCG immunisation. 
3. To determine whether maternal LTBI and maternal BCG scar influence the response  
    to BCG immunisation in infancy. 
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Chapter 2 
Materials and Methods 
2.1. The pilot infant BCG study 
2.1.1. Study design 
The pilot study was an exploratory investigation in a relatively small number of 
subjects.  The number of infants included in the study was chosen to be feasible within 
the time frame and resources available, and analyses were restricted to infants who had 
relevant results at all time points. This study was designed to generate pilot data for the 
hypothesis that maternal infection with M.tuberculosis influences infant responses to 
BCG immunisation. 
2.1.2. Study setting 
The study was conducted at Entebbe General Hospital where the Co-infection Studies 
Programme (CiSP) has a long-established collaboration with the maternity department.  
Mothers residing within Entebbe Municipality and Katabi sub-county were recruited 
(Figure 2.1). 
2.1.3. The Co-infection Studies Programme 
The CiSP developed from an interest in the immunomodulating effects of chronic 
helminth infection, and the impact of such effects on major infectious diseases including 
TB, malaria and HIV infection. It has evolved to encompass interactions between 
infectious and non-communicable diseases (NCDs). The aim is to investigate the 
epidemiological and immunological interactions between chronic, immunomodulating 
infections and both NCDs and infectious disease outcomes. This pilot study was 
embedded within the Programme as a separate study. 
2.1.4. Ethical considerations 
Ethical approval was given for this study by the Uganda Virus Research Institute 
(UVRI) Research Ethics Commitee (Appendix A), Uganda National Council for 
Science and Technology (UNCST) (Appendix B) and the London Schoool of Hygiene 
& Tropical Medicine (LSHTM) (Appendix C).  
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Figure 2.1. Map showing the study setting. 
Entebbe 5 km
Entebbe-Kampala highway
Katabi sub-county boundary
Entebbe Municipality
Lake Victoria
swamp
principal towns
Katabi
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2.1.5. Recruitment procedures 
2.1.5.1. Consent process 
Information about the study was made available at the antenatal clinics, so that mothers 
were aware of the study before they came for delivery (Appendices D and M). Women 
were counseled regarding the study by a maternity ward midwife.  On presentation in 
early labour, mothers were given a detailed explanation of the study and asked to 
provide consent for participation, collection of cord blood and follow up procedures for 
their infants and for access to their clinical records (Appendices E and N).  The timing 
of the consent procedure was considered carefully. Consent at antenatal clinics was not 
feasible for this study because of the likely time delay and loss to follow up. A two-
stage procedure with limited consent during labour (for collection of cord blood) and 
further consent for follow up procedures after delivery was considered. Advice was 
sought from colleagues at Mulago Hospital, Kampala, who were undertaking a study 
requiring placental blood and cord sampling, and we were advised that they had been 
able to obtain full consent satisfactorily in early labour. This was therefore the 
procedure used for this study. At follow up visits (and especially on the day after 
delivery and at the one week visit) study staff confirmed that the mother had understood 
the study and its requirements, before further procedures were conducted. 
2.1.5.2. Inclusion and exclusion criteria 
Women delivering in the hospital were eligible for inclusion, and approached for 
consent if they were willing to participate in the study, they had a normal singleton 
pregnancy, they resided in Entebbe Municipality and Katabi sub-county, and they were 
HIV negative (based on records available for HIV testing performed during antenatal 
care for this pregnancy). 
 
Neonates were excluded if cord blood was not obtained, the delivery was not normal, 
the mother was unwilling to undergo a repeat HIV test or was found to be HIV positive 
on repeat testing, birth weight was below 2500g, the neonate was clinically unwell, as 
judged by the midwife, the mother had an indeterminate TB infection status (as 
described below), or the neonate presented with significant congenital abnormalities 
likely to impair the child’s general health, growth and development, as judged by the 
attending midwife. Minor abnormalities such as birthmarks and extra digits, did not 
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constitute exclusion from the study. Copies of eligibility forms are in Appendices F and 
G. 
2.1.5.3. Procedures at the maternity ward 
A cord blood sample was collected from the umbilical vein by needle and syringe, after 
the cord had been clamped, from the placental side of the cord. 
 
A questionnaire was completed regarding demographic and socio-economic 
characteristics and clinical history (including personal or family history of TB, and 
current symptoms) (Appendix H).  Characteristics during pregnancy were obtained from 
the antenatal and delivery records. BCG immunisation was given to the neonate at birth 
or soon afterwards.  A single batch of the BCG vaccine, BCG-Russia (BCG-1 Moscow 
strain, Serum Institute of India, India) was administered intradermally for all infants.   
2.1.6. Procedures at the CiSP clinic 
Mothers were asked to return to the clinic one week after delivery. At this time, 
maternal blood (15 ml) was drawn for immunological studies and for investigation of 
LTBI (see below) and participants were evaluated by the clinical team. 
2.1.6.1. Tests for latent TB infection 
2.1.6.2. Tuberculin skin testing 
Women were investigated for LTBI using the tuberculin skin test (TST) or Mantoux test 
involving injection of 0.1 ml (2 TU) of M. tuberculosis PPD RT 23 (Statens Serum 
Institut, Copenhagen, Denmark) intradermally on the volar aspect of the forearm, 
midway between the elbow and wrist joints using a 27G syringe. The injection site was 
marked with a waterproof pen, and the date and time noted. Mothers were advised to 
neither scratch nor apply any soap or chemical solution to the site. Trained research 
nurses interpreted results 48 to 72 hours later using the ballpoint pen method. Mothers 
with a TST induration equal to, or more than, 10mm were classed as positive as 
induration of this size is less likely to be due to exposure to NTM (316). Tuberculin 
skin testing was performed in the mother after the mother’s blood sample had been 
obtained. 
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2.1.6.3. T-SPOT.TB assay 
In addition to the TST test, maternal LTBI was further investigated using the T-
SPOT.TB assay (Oxford Immunotec, Abingdon, UK). This modification of the ELISpot 
assay examines IFN-γ responses to peptide pools from M.tuberculosis -specific antigens 
(6 kDa Early Secreted Antigenic Target of M.tuberculosis (ESAT-6) and 10 kDa culture 
filtrate protein (CFP10)) as is described in detail elsewhere (317). Briefly, PBMCs 
purified from the mother’s blood collected one week after delivery were stimulated for 
16-20 hours at 37°C in 5% CO2. Medium was used as a negative control and 
phytohaemagglutinin (PHA) served as a positive control. The release of IFN-γ by 
stimulated cells was counted as spots using an ELISpot plate reader (AID, Strasberg, 
Germany). A positive response to ESAT-6 and CFP-10 in the T-SPOT.TB was 
considered likely to represent M. tuberculosis infection in this setting, although a small 
number of other mycobacterial species do express these antigens (318-320). 
A test was regarded as positive if the negative control (medium alone) had five or less 
spot forming units (SFUs), and the wells containing ESAT-6 (panel A) or CFP-10 
(panel B) peptides had six or more SFUs. The positive control was expected to have 
more than 20 SFUs. If the positive control well had less than 20 SFUs or the negative 
control well had 10 or more spots, the test was regarded as indeterminate.  
2.1.6.4. Definition of LTBI 
Because the TSPOT.TB assay is a commercial kit, positivity is assessed according to 
the manufacturer’s instructions. According to the manufacturer, the specificity of the 
TSPOT.TB assay is 100% with sensitivity of 98.8%, but in previous studies in Uganda 
we have observed discordance between TST and T-SPOT.TB (317). For this reason, 
and to minimise possible effects of exposure to NTM, we carried out both tests and 
enrolled participants who were either positive on both tests or negative on both tests. 
When mothers returned for their TST reading, all mothers with LTBI and a systematic 
sample (the second or the third) of uninfected mothers and their infants, were asked to 
continue in the study. Mothers with LTBI were investigated for active tuberculosis 
based on symptoms, sputum examination (if available) and chest x-ray. 
 
A repeat HIV test was also performed using the standard rapid test algorithm (usually 
Determine (Inverness Medical, Tokyo, Japan) confirmed by HIV 1/2 STAT-PAK 
Dipstick test (Chembio Diagnostic Systems, Medford, NY, USA) with Uni-Gold HIV 
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test (Trinity Biotech plc, Bray, Ireland) as a tie-breaker. Mother-baby pairs were 
excluded if the mother was found to be HIV-positive. 
2.1.6.5. Tests for helminth infection 
Two stool samples from mothers were obtained on separate days.  Stool samples were 
examined by trained staff of the Clinical Diagnostic Laboratory Services (CDLS) of 
MRC/UVRI Unit using the Kato-Katz method (321).  Two Kato-Katz slides were 
prepared from each sample, each examined within 30 minutes for hookworm, and the 
following day for other parasites. Blood from mothers obtained at one week after 
delivery was examined for Mansonella perstans by a modified Knott’s method (322). 
Intensity of infection was assessed by microfilaria counts in blood. 
2.1.6.6. Sampling strategy 
The original plan for the pilot study was to identify approximately 40 mothers with and 
40 without LTBI, but 21 mothers with and 50 without LTBI were recruited because 
there were fewer infected mothers than expected and the study had a short recruitment 
period. The infants born to these mothers were followed up at one and six weeks after 
BCG immunisation. Two milliliters (2 ml) of blood was collected at each time point and 
processed within four hours. The follow up visits coincided with the EPI vaccine 
schedules of the Ministry of Health. Mothers were therefore advised to first bring the 
babies to the research clinic for study procedures before taking them to the 
immunisation clinic. The flow of the participants in the pilot infant BCG study and the 
numbers included for the various assays are illustrated in Figures 2.2 to 2.4. 
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Figure 2.2. Flow of participants through the pilot infant BCG study for Luminex assays 
for innate responses 
 
Approached for consent 
(n= 175) 
Enrolled 
(n=145) 
Excluded (n=30) 
- Lives outside study area (n=3) 
- Did not consent (n=24) 
- Complicated labour (n=1) 
- Language barrier (n=2) 
Discontinued (n=51) 
- Cord blood not collected (n=5) 
- Baby underweight (n=3) 
- Address not taken (n=40) 
- Sickness (n=2) 
- Changed address (n=1) 
 
Tested for latent 
tuberculosis infection 
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LTBI uninfected 
(n=50) 
LTBI-infected 
for 
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(n=12) 
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(n=21) 
Discontinued (n=23) 
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Figure 2.3. Flow of participants through the pilot infant BCG study for gene expression 
microarray. 
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 33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Flow of participants through the pilot infant BCG study for flow cytometry 
assay. 
Approached for consent 
(n= 175) 
Enrolled 
(n=145) 
Excluded (n=30) 
- Lives outside study area (n=3) 
- Did not consent (n=24) 
- Complicated labour (n=1) 
- Language barrier (n=2) 
Discontinued (n=51) 
- Cord blood not collected (n=5) 
- Baby underweight (n=3) 
- Address not taken (n=40) 
- Sickness (n=2) 
- Changed address (n=1) 
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(n=21) 
Discontinued (n=23) 
- Discordant results (n=20) 
- Indeterminate results (n=1) 
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all time points 
(n=17) 
 
 34 
2.1.7. Laboratory procedures 
2.1.7.1. Major equipment, supplies and reagents 
The list of equipment, supplies and reagents is shown in Appendix I. 
2.1.7.2. Antigens for 24-hour whole blood assay (WBA) for innate responses 
 Lipopolysaccharide (LPS) (toll-like receptor (TLR) 4 agonist, 100ng/ml), the 
mycoplasma lipopeptide FSL-1 (TLR2/6 agonist, 50ng/ml), and the 
oligodeoxynucleotide CpG-ODN2006 (TLR9 agonist, 5μg/ml) all came from 
InvivoGen, San Diego, CA, USA. 
 The synthetic triacylated lipopeptide PAM3Cys-Ser (TLR1/2 agonist; ECM 
Microcollections GmbH, Tubingen, Germany; 100ng/ml), Mannan (DC-SIGN 
agonist; Sigma-Aldrich; 100μg/ml), Curdlan (Dectin-1 agonist; Wako 
Chemicals GmbH, Neuss, Germany; 100μg/ml and Phytohaemaglutinin (PHA, 
Sigma-Aldrich, MO, USA) at 10μg/ml. 
2.1.7.3. Antigens for 24-hour PBMC stimulation for flow cytometry 
 RPMI 1640 medium (Life Technologies Corporation, NY, USA). 
 PPD (RT 50 (for in vitro use), Statens Serum Institut (SSI), Copenhagen, 
Denmark) at 20μg/ml final concentration. 
 Staphylococcal Enterotoxin B  (SEB, Sigma-Aldrich, MO, USA) at 200ng/ml 
final concentration. 
2.1.7.4. Antigens for antibody assays 
 PPD (RT 50, SSI, Copenhagen, Denmark) at 10μg/ml final concentration. 
 Tetanus toxoid (TT)  (T155-1, SSI, Copenhagen, Denmark) at 12.12 Lf/ml final 
concentration. 
2.1.7.5. Immunological techniques  
 Luminex® assay for innate responses. 
 Intracellular cytokine staining and flow cytometry for adaptive responses. 
 ELISA for anti-PPD and anti-TT total IgG antibodies.  
 Microarray on unstimulated infant blood samples. 
2.1.7.6. Main outcome measures 
 Cytokine and chemokine responses in 24-hour WBA stimulated with a panel of 
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Toll-like receptor ligands and analysed by 17-plex Luminex® assays.  
 PPD-specific intracellular cytokine responses measured by flow cytometry. 
 PPD-and TT-specific anti-TB antibody responses measured by ELISA. 
 Gene expression profiles measured by microarray. 
2.1.7.7. Innate immune responses measured using Luminex® assay 
The flow of cord blood and maternal samples are shown in Figures 2.5 and 2.6. 
 
 
 
 
 
 
Figure 2.5. Flow of cord blood sample for separating plasma and for whole blood 
cultures. 
10 ml Cord blood 
Plasma for 
antibodies to PPD 
and TT 
6 ml in Heparin tube 4 ml in EDTA tube 
Whole blood 
assay/Luminex and cells 
for flow cytometry 
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Figure 2.6. Flow of maternal and infant blood for T-SPOT.TB test on maternal blood, 
plasma separation for IgG measurement by ELISA and whole blood cultures for 
cytokine and chemokine measurement by Luminex® assay. 
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2.1.7.8. Stimulation of whole blood with TLR ligand  
Heparinized blood from 29 mother-cord blood pairs were diluted 1:1 with RPMI 1640 
medium and stimulated with LPS, FSL-1, PAM3Cys-Ser, Mannan, Curdlan and CpG-
ODN2006. An unstimulated well was included to act as a negative control, and PHA 
served as a positive control. After 24 hours of incubation at 37°C in 5% CO2, culture 
supernatants were harvested and stored at -80°C for analysis of cytokines and 
chemokines. 
2.1.8. Measurement of cytokines and chemokines by multiplex assay system 
The concentrations of analytes in the culture supernatants were measured using a 
Bioplex multiplex cytokine assay system (Bio-Rad Laboratories, Hercules, CA, USA), 
following instructions from the manufacturer. Briefly, 50μl of standard and the test 
samples along with 50μl of mixed beads were added in the wells of a 96-well microtitre 
plate. The plates were incubated for 1 hour on a rocker and washed; 25μl of detection 
antibody mixture was then added per well and the plates incubated for 30 minutes on a 
rocker. After washing with wash buffer, 50μl of streptavidin-PE was added per well and 
plates incubated for 10 minutes, washed and beads suspended in 75μl of assay buffer 
per well. The beads were analysed using a Bio-Plex 200 System (Bio-Rad Laboratories, 
Hercules, CA, USA) and the Bio-Plex Manager software (version 6.0; Bio-Rad 
Laboratories, Hercules, CA, USA) was used. According to the manufacturer’s 
instructions, a curve fit was applied to standard curves (illustrated in Figure 2.7) that 
were then used to extract sample concentrations. Limits of the assay working range 
(lower limit of quantification (LLOQ) and upper limit of quantification (ULOQ)) 
quoted by the manufacturer for each cytokine and chemokine were used to clean the 
data. For values below the acceptable range, half of the LLOQ was used and for values 
above the ULOQ, the ULOQ value for that particular analyte was used. The following 
analytes were assayed: interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-
13, IL-17A, interferon (IFN)-γ, IFN-γ-induced protein-10 (IP-10/CXCL10), monocyte 
chemotactic protein-1 (MCP-1/CCL2), macrophage inflammatory protein (MIP)-1α 
(CCL3), MIP-1β (CCL4), tumour necrosis factor (TNF)-α, granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and vascular endothelial growth factor (VEGF).  
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Figure 2.7. Example of standard curves from 17-Plex Luminex®. Curves for TNF-α 
(top panel) and MIP-1β (bottom panel) are shown. A 5PL curve fit was used. 
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2.1.9. Intracellular cytokine staining and flow cytometry 
2.1.9.1. Separation of mononuclear cells  
Mononuclear cells were isolated from cord blood (n=31), and from infant blood 
obtained at one (n=31) and six (n=31) weeks after birth by standard Ficoll-Paque 
(Sigma-Aldrich, St. Louis, MO) density gradient centrifugation, and cryopreserved in 
50% fetal calf serum (FCS) (Sigma-Aldrich, St. Louis, MO), 40% RPMI 1640 medium 
(Life Technologies Corporation, NY, USA) containing 2 mM L-glutamine, 100 U/ml 
penicillin G, 100 μg/ml streptomycin sulphate and HEPES and 10% dimethylsulphoxide 
(DMSO) (Sigma-Aldrich, St. Louis, MO) according to standard protocols. 
2.1.9.2. Intracellular cytokine staining assay 
The cells were thawed and rested for 24 h at 37°C in 5% CO2, viability and numbers 
were checked using a Cellometer Vision Cell Profiler (Nexcelom Bioscience, LLC-
Lawrence, MA, USA). All thawed cells were stimulated with PPD (20 mg/ml batch RT 
50 for in vitro use, Statens Serum Institut, Copenhagen, Denmark). Medium alone was 
used as a negative control, and Staphylococcal Enterotoxin B (SEB, 200 ng/ml, Sigma-
Aldrich) served as a positive control. The co-stimulatory antibodies anti-CD28 and anti-
CD49d (1 mg/ml, BD Biosciences, San Jose, CA, USA) were included in all conditions. 
The cells were incubated at 37°C in 5% CO2 for a total of 24 h. Brefeldin A (10 mg/ml, 
Sigma-Aldrich) was added to SEB wells after 2 h, and to PPD and negative control 
wells after 20 h. The cells were then stained with aqua viability dye (Life Technologies, 
OR, USA), and antibodies directed against the following human molecules: CD3 
(QDot655, S4.1) and CD4 (QDot605, S3.50), both obtained from Life Technologies, 
OR, USA; CD8 (BV570, RPAT8, BioLegend, San Diego, CA, USA); and IFN-γ (APC, 
B27), TNF-α (PE-Cy7, Mab11) and IL-2 (FITC, 5344.111), all obtained from BD 
Biosciences, NJ, USA. Stained cells were acquired on an LSRII flow cytometer (BD 
Biosciences, NJ, USA) and the gating strategy used for analysis is shown in Figure 2.8. 
Flow cytometry was not performed blinded to the maternal LTBI status, but the infants’ 
samples were tested in a randomized sequence to limit the possibility of bias in the 
results due to day-to-day variation in the assay. 
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Figure 2.8. Gating strategy for ICS analysis. Gating of Lymphocytes (A), Singlet 
cells (B), Live cells (C), CD3+ T-cells  (D) and CD3
+
CD4
+
/CD3
+
CD8
+
 T-cells (E) was 
sequentially performed for each sample. Cytokine gates set on unstimulated tubes (F) 
was applied to results obtained with PPD (G) and SEB (H) tubes. 
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2.1.10. Humoral responses in BCG-immunised infants  
2.1.10.1. Optimisation of IgG ELISA protocol 
The reagents, antigens and samples used in the IgG ELISA were titrated to obtain 
suitable concentrations for the assay. Figure 2.9 is an illustration of this. 
The IgG standard concentrations that gave the best curve fit ranged from 0.01-
0.625µg/ml (Figure 2.9A). For PPD, the concentration chosen was 5-10µg/ml (Figure 
2.9B). A sample dilution of 1/100 was suitable for testing IgG in the maternal and infant 
samples (Figure 2.9B).
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A                                                                                                                 B 
          
      C 
 
Figure 2.9. Optimisation of human purified IgG standard, PPD and samples for antibody ELISA. IgG standard was titrated to determine 
the points for the best curve fit (A); PPD was titrated to determine the suitable concentration for the assay (B) and samples titrated to determine 
the suitable dilution for maternal and infant samples (C).  
 43 
 
Figure 2.10. Representative standard curves for the IgG standard for the PPD and TT ELISAs and sample IgG concentrations. IgG 
standard curves showing OD versus concentration (A and B for pilot and infant BCG studies, respectively), and sample IgG concentrations 
(pg/ml) (C and D for pilot and infant BCG studies, respectively). Columns 1 and 2 show concentrations for serially diluted IgG standard, 
columns 3-7 show responses to PPD and columns 8-12 show response to TT. Values shown by ???? are where the OD is negative and <0.008 is 
for values less than the lowest standard concentration of 0.01 pg/ml. 
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2.1.10.2. ELISA for anti-PPD and anti-TT total IgG antibodies 
Plasma samples were collected from heparinized cord blood (n=53), and from infant 
blood samples (n=53) at the time of PBMC purification. Total plasma immunoglobulin 
(Ig) G specific for PPD and TT was assayed using an “in-house” indirect Enzyme-
linked Immunosorbent Assay (ELISA). Briefly, flat-bottomed 96-well Microlon plates 
(Greiner Bio-One, Germany) were coated with either purified IgG standard (GenScript, 
NJ, USA) in bicarbonate coating buffer at a maximum concentration of 0.625 μg/ml and 
minimum concentration of 0.01 μg/ml, (10µg/ml, RT 50, Statens Serum Institut, 
Copenhagen, Denmark) or TT (12.12 Lf/ml, T155-1, Statens Serum Institut, 
Copenhagen, Denmark). Each PPD and TT well had a control comprising 0.1% Marvel 
milk powder (Premier International Foods, UK) in coating buffer. After overnight 
incubation, the plates were blocked with 150μl/well of 1% milk powder/PBS for one 
hour at room temperature. Samples diluted 1 in 100 in 0.1% milk powder/PBS were 
added to the plates and left overnight at 4 
o
C. Polyclonal anti-human IgG Horse Radish 
Peroxidase (Poly HRP, 0.5µg/ml, Dako, Denmark) was added at 50μL/well and plates 
incubated for one hour at room temperature. A total of 100μl/well of o-
phenylenediamine (OPD, Sigma-Aldrich, MO, USA) substrate mixture (3 mg OPD, 0.1 
M citric acid, 0.2 M Na2HPO4, 3 ml 30% hydrogen peroxide in distilled water) was 
added for 15 min at room temperature (in the dark). The reaction was stopped with 
25µl/well 2M Sulphuric acid and the plates were read at test wavelength 490nm and 
reference wavelength 630nm using an MRX1.1 plate reader and Gen5 1.07 software 
(BioTek Instruments, Inc., VT, USA). The sensitivity of the test was determined as the 
lowest standard concentration above which antibody concentrations were detectable 
(0.01 μg/ml).
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2.1.11. RNA amplification and microarray 
The original plan for performing gene expression microarray was to acquire equipment 
and train personnel to perform assays at the Uganda Virus Research Institute. However, 
we lacked equipment and expertise to perform these assays in Uganda. As a result, the 
samples collected were sent to our collaborating partner at the Vaccine and Gene 
Therapy Institute (VGTI) in Florida (Dr. Rafick Pierre Sakaly’s group) where RNA 
extraction and microarray were performed. I was shown how the analysis and 
interpretation of the generated data was done. 
 
Gene expression microarrays were undertaken using unstimulated whole blood samples 
obtained from 42 and 51 infants at one and six weeks, respectively, to assess gene 
expression profiles after BCG immunisation (Figure 2.11). The Illumina RNA 
Amplification Kit (Ambion, Austin, TX, USA) was used to amplify a median of 124 ng 
(range 63-174 ng) of the extracted RNA. A Biotin-16-UTP label was incorporated into 
amplified RNA during the in vitro transcription process (Perkin Elmer Life and 
Analytical Sciences, Woodbridge, Ontario, Canada). Amplification gave yields ranging 
from 1 μg to 25 μg. Amplified RNA (1000 ng per array) was hybridized to the 
IlluminaHumanHT-12_V4 BeadChip according to the manufacturer's instructions 
(Illumina, San Diego, CA, USA). The IlluminaHumanHT-12_V4 bead chip comprises 
42,000 sequences representing 31,000 annotated genes from the curated portion of the 
NIH Reference Sequence Database (http://www.ncbi.nlm.nih.gov/RefSeq/). Each 
sequence is represented at least 30 times on the array. Arrays were scanned with an 
Illumina bead array confocal scanner, according to the manufacturer's instructions. 
Array data processing and analysis was performed using Illumina BeadStudio software. 
I participated in sample collection and shipment to VGTI where gene arrays were 
performed. 
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Figure 2.11. Flow of infant samples for gene expression microarray. 
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2.2. The main infant BCG Study 
2.2.1. Cohort and immunisation schedule 
A cohort of 284 pregnant women was recruited at the Maternity Wards of Entebbe 
Hospital. The experiences from the pilot study showed that it would take 18 months to 
recruit 150 mothers with and 150 without M.tuberculosis infection. Because there was 
another study involving infant recruitment also ongoing at the same time as our study, 
enrolment was staggered between the two studies, to ensure both studies fulfilled their 
recruitment numbers. Based on the pilot study it was anticipated that, to maintain a 
balanced rate of recruitment to the two arms, it was appropriate to invite every second 
uninfected mother to continue in the study, but this was adjusted according to the 
recruitment rates achieved. During the pilot study, it was also found that mothers 
actually returned for their “one-week” check between 4 and 14 days post delivery. Thus, 
infant blood was collected from day 6 post delivery, up to day 17. Further follow up 
samples were obtained at 4, 6, 10, 14, 24 weeks (2 ml), and at 1 year (5 ml). It was 
hoped that these time points would provide a clear picture of the evolution of the infant 
response, while fitting in with visits required for additional immunisations. Additional 
infant immunisations comprised Oral Polio Virus (OPV) at birth, Diphtheria, Pertussis, 
Tetanus (DPT), Haemophilus influenzae type B (HiB), hepatitis B (HBV) and OPV at 6, 
10 and 14 weeks of age, and measles at 9 months (Table 2.1). At each visit, estimates of 
prior malaria episodes in the infants were recorded using a questionnaire.  
 
Other factors may also have important effects on the infant response to BCG 
immunisation. In Uganda, we have shown that BCG strain is an important determinant 
of the response (277) and a single strain (BCG Denmark) and a single batch (113033C) 
was used. This strain of BCG has been used before in Uganda (277), and was also 
selected so that comparisons with infants vaccinated in the UK would be possible.  
 
Other factors that we, or others, have found to be associated with the infant response to 
BCG and that are potential confounders of an association with maternal M.tuberculosis 
infection included HIV infection (HIV-positive mothers were excluded) and a range of 
factors which were measured, and accounted for in multivariate analyses including 
maternal age, parity, nutritional status, BCG scar, Mansonella perstans infection, infant 
weight and length for age, and placental malaria infection (286, 308, 323, 324). We also 
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collected stool samples from mothers and from one year olds to examine for presence of 
intestinal helminths (by Kato Katz and by PCR), and also blood for M. perstans. 
 
Table 2.1. Summary of sample collection time-points and amount of blood collected 
 
Timelines (weeks) 0 1 4 6 10 14 24 36 52 
Time window (days)    3  3  3  3  3  3  3 
Vaccination  
BCG ✔         
Oral polio virus (OPV) ✔     ✔    
Diphtheria, Pertussis  
and Tetanus (DPT) 
   ✔ ✔ ✔    
Haemophilus 
influenzae  
type B (HIB) 
   ✔      
Hepatitis B (HBV)     ✔     
Measles        ✔  
Samples collected  
Cord blood ✔         
Whole blood (ml)  2  2 2  2 2  2  2  5 
Stool  
 
✔ 
(Mother) 
      ✔ 
(Infant) 
Assays performed  
T-SPOT.TB assay  
 
✔ 
(Mother) 
       
Whole blood assay for 
Luminex®  
✔ ✔ ✔ ✔ ✔ ✔ ✔  ✔ 
ELISA for antibodies ✔ ✔ ✔ ✔ ✔ ✔ ✔  ✔ 
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2.2.2. Sampling Strategy 
This is an ongoing study, and data was collected from early time points and available 
samples from infants who have completed follow up. Because the sampling procedure 
was frequent, it was considered unreasonable to request samples from all babies at each 
time point. Infants were randomly assigned into two separate sampling strategies: 150 
infants (75 from M.tuberculosis infected, and 75 from uninfected, mothers) gave blood 
at the first routine visit (approximately 1 week) and at week 6 and 14, and the remaining 
infants gave blood at week 4, 10 and 24. All infants were requested to give blood at age 
one year. Overall, there were 134 mothers who were infected with M.tuberculosis and 
150 uninfected with M.tuberculosis (Figure 2.12) according to the test criteria described 
in section 2.1.6.1. For this analysis, 55 M.tuberculosis-infected and 85 uninfected 
mothers were considered for Luminex assays for T cell responses (Figure 2.12) and 100 
M.tuberculosis-infected and 122 uninfected mothers were considered for antibody 
ELISA (Figure 2.13). The numbers of infants considered for analysis of Luminex® 
results after follow up to 52 weeks are shown in Table 2.2. There were very few 
mothers (three) who returned at the 14
th
 week time point and their infants were not 
included in the analysis. 
By sampling both early and late time points, we aimed to accurately define the timing of 
the peak immune response in infants following BCG immunisation and to determine 
whether maternal M.tuberculosis status affects the priming and/or recall response to 
BCG antigens in infants. 
 
Table 2.2. Details of samples for analysis of Luminex® results. 
 
 
LTBI groups 
Age (weeks) 
0 1 4 6 10 24 52 
LTBI-negative 85 36 42 32 37 9 65 
LTBI-positive 55 27 23 25 25 6 38 
Total 140 63 65 57 62 15 103 
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Figure 2.12. Flow of participants through the main infant BCG study whole blood 
assay/Luminex for T cell responses.  
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Enrolled and tested 
for latent 
tuberculosis infection 
(n=1124) 
LTBI-uninfected 
(n=150) 
Numbers considered 
for Luminex for PhD 
study at baseline 
(cord blood) 
(n= 55) 
LTBI-Infected 
(n=134) 
Numbers considered 
for Luminex PhD 
study at baseline 
(cord blood) 
 (n=85) 
Discontinued (n=840) 
- Discordant results (n=250) 
- Indeterminate results (n=21) 
- Negative test results (n=569) 
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Figure 2.13. Flow of participants through the main infant BCG study ELISA for 
antibody responses.  
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2.2.3. Recruitment procedures 
The consent process and the inclusion and exclusion criteria used in the pilot infant 
BCG study were used in the main infant BCG study (see section 2.1.5.2 above). 
2.2.3.1. Sample size determinations 
Previous studies have shown extreme differences in cytokine responses between 
African and UK infants, of the order of >0.7log10 (230, 325). However, we expected 
differences between infants of infected and uninfected Ugandan mothers to be smaller. 
Using a significance level of 1% to allow for the multiple testing arising from the fact 
that we examined many cytokines (since many of the cytokine responses were expected 
to be correlated, a Bonferroni adjustment which assumes independence would be too 
stringent), and assuming the standard deviation of log10 cytokine responses in Uganda 
to be approximately 0.9 (15), we had 80% power to detect a difference of 0.35log10 
between 150 infants from M.tuberculosis-infected mothers and 150 from uninfected 
mothers in cord blood, and at one year of age. For all other time points, 75 children 
from each group were sampled, allowing us 80% power to detect a difference of 
0.5log10 between the two groups. 
2.2.3.2. Ethical considerations for main infant BCG study 
This was an exploratory observational study without the use of investigational products. 
TST is a standard procedure that may occasionally cause some discomfort and scarring. 
Mothers with a positive TST result were followed up, had a chest X-ray performed and 
were seen by a physician at the CiSP clinic. Further investigations (such as sputum 
examination) were conducted if clinically indicated. If found to have active TB, mothers 
were referred for treatment at the Entebbe Grade B Hospital TB clinic. If a mother was 
found to be sputum smear positive, isoniazid preventive therapy was provided for the 
infant and, although the infant was retained in the study, the results were considered 
separately as a case study, since isoniazid may itself influence the response to BCG 
immunisation. Mothers with LTBI were not offered prophylactic isoniazid treatment. 
Current policy in Uganda recommends this only for children under five years of age and 
people with HIV infection, and the benefit-risk balance in favour of treatment versus 
side effects decreases with increasing age. If a mother was found to be HIV positive on 
analysis of the post delivery blood sample, a CD4+ T cell count was performed and she 
was referred to an HIV care provider. Anti-retroviral therapy for prevention of mother-
to-child HIV transmission (PMTCT) was offered for the infant within the PMTCT 
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programme at Entebbe Hospital. Nurses from the CiSP team with appropriate 
experience and expertise performed bleeding of very young infants. Small blood 
volumes were collected and so this procedure was not detrimental to the infants. 
Mothers found to be infected with helminths were treated when results were available, 
at the four or six week post-delivery visit. Two-step consent was taken where mothers 
gave verbal consent during labour and written consent before discharge. Mothers were 
free to withdraw from the study, with their infants, at any time. Fathers were 
encouraged to fully participate with their child and family in this study. To this end, 
after consent had been obtained from the mother, we sent home to the father an 
information sheet for him to read, and to encourage him to turn up at routine visits to 
ask the study staff any questions he had. Ethical approval was sought from UVRI 
(Appendix J), UNCST (Appendix K), and LSHTM (Appendix L). 
2.2.4. Laboratory methods 
The details of cord blood, maternal and infant blood samples are shown in Figures 2.14 
and 2.15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14. Flow of cord blood sample for separating plasma and for whole blood 
cultures. 
10 ml Cord blood 
Plasma for antibody 
analysis 
6 ml in Heparin tube 4 ml in EDTA tube 
For immunological tests 
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Figure 2.15. Flow of maternal and infant blood for T-SPOT.TB test (maternal), plasma 
separation and whole blood cultures. 
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2.2.4.1. Outcome measures 
 Time course of PPD-specific responses at 1, 4, 6, 10, 14, 24 and 52 weeks after. 
BCG immunisation measured using Luminex®  (for cytokines and chemokines) 
and ELISA (for anti-TB antibodies). 
 The influence of maternal infection with M.tuberculosis on the infant responses. 
2.2.4.2. Immunological techniques 
 Six-day WBA for Luminex® assay. 
 ELISA for anti-PPD and anti-TT total IgG antibodies. 
2.2.4.3. Antigens for 6-day WBA   
 RPMI 1640 medium (Life Technologies Corporation, NY, USA). 
 M.tuberculosis PPD (RT 50, Statens Serum Institut (SSI), Copenhagen, 
Denmark) at 10μg/ml final concentration. 
 ESAT-6 (BEI Resources, Manassas, VA, USA) at 5μg/ml final concentration 
(recombinant protein). 
 CFP-10 (BEI Resources, Manassas, VA, USA) at 5μg/ml final concentration 
(recombinant protein). 
 PHA (Sigma-Aldrich, MO, USA) at 10μg/ml final concentration. 
2.2.4.4. Antigens for ELISA 
 PPD at 5μg/ml final concentration. 
 TT at 2μg/ml final concentration. 
2.2.4.5. Stimulation of infant whole blood 
Supplemented RPMI 1640 was pre-warmed at room temperature for 15 minutes. 
Up to 450µl of heparinized venous blood was diluted with 1350µl of supplemented 
RPMI to make a 1:4 dilution. Up to 200µl of diluted blood was added to each well, in 
duplicate. To give a final concentration of 10µg/ml, 2µl of a 1mg/ml PPD stock was 
added to 200µl of diluted blood per well. Both ESAT-6 and CFP-10 antigens were 
prepared into 1mg/ml stock solutions. These were pooled during stimulation and 1µl of 
each was added to 200µl of diluted blood to give a final concentration of 5µg/ml. PHA 
was reconstituted to a 1mg/ml solution. To give a final concentration of 10µg/ml, 2µl of 
the solution was added to 200µl of diluted blood. PHA served as a positive control and 
RPMI alone was used as a negative control. Testing was done to identify the optimum 
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concentration for these stimulants (data not shown). Plates were incubated at 37 ᵒC in 
5% CO2 for 6 days. 
2.2.4.6. Harvesting supernatants 
Culture plates were removed from the incubator and spun at 800g for 5 minutes to attain 
a cleaner supernatant. Microtubes for storage of supernatants were labeled with study 
participant laboratory number and antigen code. Up to 150µl of supernatant was 
removed from the culture plates and transferred into the labeled microtubes. 
Supernatants from duplicate wells were pooled in a single microtube, mixed gently by 
pipetting up and down and freezing until analysis. 
2.2.5. Measurement of cytokines and chemokines by multiplex assay system 
2.2.5.1. Quality control  
In order to assess inter and intra plate variability, two quality control samples (Control 1 
and Control 2) supplied by the manufacturer were added in duplicate wells to the plates. 
Figure 2.16 illustrates the values for the 23 plates that were run, A for absolute values in 
pg/ml and B for log10 values.  
 
For Control 1, the concentrations for most cytokines and chemokines are between 100-
250pg/ml, except for MIP-1α which had a higher concentration (greater than 250pg/ml) 
overall (Figure 2.16A, left panel). 
 
Control 2 values are higher than for Control 1 for all plates, ranging between 550-
1100pg/ml. As for Control 1, MIP-1α values were higher than for other analytes 
(>11000pg/ml). IP-10 showed inconsistent values across plates (Figure 2.16A, right 
panel). 
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                                   Control 1                                                   Control 2 
               A 
 
 
 
           B 
 
 
Figure 2.16. Luminex® quality control results for the 17 cytokines and chemokines 
measured. To control for inter and intra plate variability, two positive controls supplied 
by the manufacturers were used on each plate. The results are shown above for Control 
1 (left panel) and Control 2 (right panel). The top panels (A) show values in pg/ml and 
the bottom panels (B) are values in log10.  
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2.2.5.2. The Luminex® assay 
The concentrations of analytes in the culture supernatants were measured using a 
Millipore Milliplex assay system (Merck Millipore, Abingdon, United Kingdom) 
following instructions from the manufacturer. Briefly, working standard solutions were 
prepared by double-diluting them serially. The bead mixture, controls and wash buffer 
were also prepared. Up to 200 µL of wash buffer was added into each well of the plate. 
Plates were sealed and mixed on a plate shaker for 10 minutes at room temperature (20-
25
0
C). Wash buffer was decanted and the residual amount removed from all wells by 
inverting the plate and tapping it smartly onto paper towels several times. Next, 25 µL 
of each Standard or Control was added into the appropriate wells. Assay buffer was 
used for 0 pg/mL standard (background). Up to 25 µL of Assay buffer was added to the 
sample wells, background, standards, and control wells. The mixing bottle containing 
the prepared beads was vortexed and 25 μL of the mixed beads was added to each well. 
(Note: During addition of the beads, the bead bottle was shaken intermittently to avoid 
settling of the beads). Plates were sealed with a plate sealer and wrapped with foil and 
incubated with agitation on a plate shaker (speed 600rpm) for 2 hours at room 
temperature (20- 25
0
C).  After the 2 hours of incubation, the plates were removed from 
the plate shaker, unsealed one at a time and placed on the plate washer magnet for 60 
sec, then washed 2 times using the MAG2X protocol.  Then 25 µL of detection 
antibody was added into each well. Plates were sealed, covered with foil and incubated 
with agitation on a plate shaker at 600rpm for 1 hour at room temperature (20- 25
0
C). 
After the 1 hour incubation, 25 µL of the Streptavidin-Phycoerythrin conjugate was 
added to each well containing the 25 µL of detection antibody. Plates were sealed, 
covered with foil and incubated with agitation on a plate shaker (at 600rpm) for 30 
minutes at room temperature (20-25
0
C). Plates were washed 2 times with wash buffer 
and 50 µL of sheath fluid was added to all wells. Beads were resuspended on a plate 
shaker (at 600rpm) for 5 minutes and plates were run on Bio-plex 200™ Luminex® 
machine, and the median fluorescent intensity (MFI) data were saved and analyzed 
using a 5-parameter logistic or spline curve-fitting method for calculating 
cytokine/chemokines concentrations in samples. The following analytes were assayed: 
IL-1β, IL-Rα, IL-2, IL-5, IL-8, IL-10, IL-12p40, IL-13, IL-17, IFN-γ, IP-10, MCP-1, 
MIP-1α, MIP-1β, TNF-α and GM-CSF. 
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2.2.5.3. ELISA for anti-PPD and anti-TT total IgG antibodies 
The antibody concentrations were measured using the ELISA protocol for the pilot 
study described in section 2.1.10.2. 
2.2.6. Statistical and data collection methods 
Datasets were generated from questionnaires and from immunological and molecular 
assays including Luminex®, ELISA and gene expression microarray.  
Data were entered using Microsoft Access and Excel. Analysis was done using Flowjo 
v. 9.5.2 (Tree Star Inc., Ashland, OR, USA), Stata version 13.1 (College Station, Texas, 
USA) and GraphPad Prism v7.0a (GraphPad software, Inc., La Jolla, CA, USA). All of 
these formats allowed for sharing and long-term validity of stored data. Dr Emily L. 
Webb, the study statistician, as well as the MRC Statistics Unit were consulted for the 
correct statistical analysis of the data. 
2.2.7. Analysis of innate responses and gene expression profiles in BCG-vaccinated 
infants 
The objective of this analysis was to investigate the effects of maternal LTBI and 
helminth infection on infant innate immune responses. In the event, helminth infections 
were rare in this study group (326), so the principal exposures considered were maternal 
LTBI and maternal BCG scar. In the multivariate analysis, the effects of maternal LTBI 
and maternal BCG scar were adjusted for. Maternal and infant factors such as maternal 
age, gravidity status, infant birth weight and gender were not crudely associated with 
infant innate responses and were not adjusted for, and the numbers involved were 
generally small.  
 
Cytokine and chemokine concentrations showed skewed distributions. Results were 
transformed to log10 (cytokine concentration+1) for graphical representation using 
GraphPad Prism v7.0a (GraphPad software, Inc., La Jolla, CA, USA) and for analysis 
by linear regression using bootstrapping (327) using STATA v. 13.1 (College Station, 
TX, USA). Results from regression analyses are presented as adjusted geometric mean 
ratios (aGMR) [95% confidence interval (CI)]. Multiplex data values below the lowest 
concentration were assigned as 1.6 pg/mL. Unstimulated responses were subtracted 
from antigen-stimulated results and negative values were set to zero. The Mann–
Whitney U-test was used to compare responses between infants of mothers with and 
without LTBI and those with and without a BCG scar and correlation between two 
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continuous variables was assessed using the Spearman rho test. For the different stimuli, 
the median maternal and cord blood responses, as well as the associations of infant 
responses with maternal LTBI and maternal BCG scar were analysed. In addition to 
looking at single cytokines and chemokines, Principal Component Analysis (PCA) 
(328) was performed on the cytokine and chemokine variables to summarize them. For 
this, an average cytokine or chemokine response was worked out for each infant by 
calculating the mean concentration obtained from the seven different stimuli (after 
subtracting unstimulated responses). The R programme (v3.2.2. R Foundation for 
Statistical Computing, Vienna, Austria) was used for further assessment of the 
associations.  
 
For microarray, raw Illumina probe data were exported from BeadStudio and screened 
for quality. Pre-processing and statistical analysis was conducted using the R statistical 
language and various software packages from Bioconductor (329). Quantile 
normalization was applied, followed by a log2 transformation. The LIMMA package 
was used to fit a linear model to each probe and (moderated) t tests or F tests were 
performed on the groups being compared. To control the expected proportions of false 
positives, the FDR for each unadjusted p value was calculated using the Benjamini and 
Hockberg method implemented in LIMMA. The microarray data are available through 
the National Center for Biotechnology Information Gene Expression Omnibus 
(GSE87801). Pathway analysis was performed using Gene Set Enrichment Analysis 
(GSEA), a non-parametric annotation-driven statistical analysis method (330), to assess 
which biological processes are associated with the different LTBI and BCG scar groups. 
We tested gene sets from the Molecular signature Database (MsigDB, 
http://www.broad.mit.edu/gsea/msigdb Hallmark collection (h.all.v5.0.symbols.gmt) 
which summarise and represent specific well-defined biological states or processes 
displaying coherent expression. Statistical significance was set for p value below 0.05. 
This analysis was done by Dr. Rafick Pierre Sekaly’s group at the VGTI (now at Case 
Western Reserve University School of Medicine, Cleveland, Ohio, United Satates). I 
was later shown how the analysis was done and results interpreted. 
 
2.2.8. Analysis of cellular immune responses in BCG-vaccinated infants  
Antibody concentrations were summarised using medians and interquartile ranges 
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(IQR) and compared between different time points using paired student’s t-test. 
Antibody levels showed a skewed distribution with large numbers of undetectable 
results, therefore results were transformed to log10 (antibody concentration+1) for 
graphical presentation. 
 
Flow cytometry data were analysed using FlowJo v9.5.2 (Tree Star Inc., Ashland, OR, 
USA). Results were expressed as the frequency of positive events above the negative 
control. Prism v6.0e (GraphPad software, Inc., La Jolla, CA, USA) was used for crude 
analyses and data presentation. Characteristics of mothers with and without LTBI were 
compared using the Mann-Whitney U test. Responses at different time points were 
compared using the Wilcoxon signed rank test. Differences in responses between LTBI 
exposed and unexposed infants were analysed using the Mann-Whitney test. Stata 
version 13.0 (College Station, Texas, USA) was used for multivariate linear regression 
to adjust for potential confounders (maternal age, gravidity status and infant gender) 
(illustrated in causal diagram in Figure 2.17), with 95% CI estimated by bootstrapping. 
Results from regression analyses were presented as crude and adjusted mean difference 
(95% CI). P-values <0.05 were considered statistically significant.  
 
Multiplex data values below the lowest concentration were assigned as 1.6 pg/mL. 
Unstimulated responses were subtracted from antigen-stimulated results and negative 
values were set to zero. The Mann–Whitney U-test was used to compare responses 
between infants of mothers with and without LTBI and correlation between two 
continuous variables was assessed using the Spearman rho test. Linear regression with 
random effects were used to compare responses between infants of mothers with and 
without LTBI. 
 
 
 
 
 
 
 
 
 
 62 
 
 
 
 
 
 
 
 
Figure 2.17. Causal diagram 
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Chapter 3 
Investigation of immune responses in mothers and 
infants: the pilot infant BCG study  
3.1. Introduction 
Innate cells such as APCs take up microbes and initiate direct killing of the microbes or 
lysis of microbe-infected cells. DCs and macrophages have sensors (PRRs) that interact 
with microbial PAMPs, resulting in initiation of immune responses. Neonates have been 
shown to have reduced responses to innate stimuli (331-333), though concentrations of 
IL-6 have been reported to be high at the time of birth (334, 335). The assessment of 
infant responses to innate stimuli and their associations with maternal and infant factors 
has not yet been extensively studied, and further research in this area is required. A 
recent study conducted in South Africa showed that maternal LTBI had no association 
with adaptive immune responses in the infants following BCG immunisation (308). In 
this study, the impact of maternal LTBI on innate responses in infancy was not 
assessed. 
 
Innate immune responses are now known to directly affect the quality of the adaptive 
response.  Immunisation with BCG, for example, has been suggested to prime 
heterologous immunity through the innate immune system, through a process termed 
innate training (265-269).   In addition, maternal genetics and response to BCG may 
play a role. Evidence from observational studies and randomized controlled trials have 
shown this priming to be associated with beneficial effects on childhood survival in 
both low- and high-income countries (260-264). The association between maternal BCG 
scar and lower T helper (Th) 2 responses to mycobacterial antigens has previously been 
demonstrated in infants (286), although the effects of maternal BCG scar on innate 
immune responses in infancy were not examined in this study. 
 
Differential expression of immune genes following BCG immunisation of infants has 
previously been demonstrated (238), but again the effects of maternal and infant factors 
were not assessed. 
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In this Chapter, the associations between maternal BCG scar and immune response 
profiles in the offspring was evaluated in a study designed to investigate the effects of 
maternal infections, including LTBI, on infant immune responses. 
 
This chapter is based on a manuscript in press in Vaccine and titled “Maternal BCG scar 
is associated with increased infant proinflammatory immune responses. Mawa, P.A, 
Webb, E.L., Filali-Mouhim, A., Sekaly, R.P., Nkurunungi, G., Lule, S.A., Prentice, S., 
Nash, S., Dockrell, H.M., Elliott, A.M., and Cose, C” (Appendix R) with additional 
unpublished data. After a description of the socio-demographic and clinical 
characteristics of the study population, the concentrations of innate stimulus-induced 
cytokines and chemokines in maternal post-delivery blood and in infant cord blood 
(measured by Luminex® assay), as well as the associations between the innate 
responses and maternal and infant factors are presented. Gene expression profiles 
following BCG immunisation in infancy and their associations with maternal LTBI and 
maternal BCG scar was also assessed.  
 
The specific objectives for this Chapter were: 
1. To measure the concentrations of cytokines and chemokines in maternal post-
delivery blood and infant cord blood after stimulation with innate stimuli. 
2. To assess the correlations between concentrations of cytokines and chemokines 
measured. 
3. To analyse the associations between maternal and infant factors, and innate 
responses in the mothers and their infants.  
4. To investigate the effect of maternal LTBI and maternal BCG scar on gene 
expression profiles in BCG-immunised infants. 
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3.2. Results 
3.2.1. Characteristics of participants in the pilot infant BCG study 
Between February and May 2012, 175 women were approached to participate. Of these, 
145 were enrolled in the study (Figures 2.2 to 2.4, Chapter 2). Fifty-one mothers who 
were enrolled into the study were excluded, mainly because their contact details were 
not taken and they could not be traced when they defaulted from further follow-up. Of 
the remaining 94 mothers who were tested for LTBI, 23 had discordant LTBI test 
results and were excluded. Twenty-one mothers were identified as LTBI-positive by 
both T-SPOT.TB and TST testing and 50 as LTBI-negative. On repeat testing, none of 
the mothers was found to be infected with HIV.  
 
Twenty-nine mothers were included for the analysis of infant innate responses, and of 
these, 12 had LTBI and 16 had a BCG scar. Information on BCG scar was missing from 
three mothers, and these women were excluded from analysis. Mothers with and 
without a BCG scar were comparable in terms of LTBI (31% versus 50%, p=0.42), age 
(25 years versus 26 years, p=0.78) and gravidity status (37% versus 50% primigravida, 
p=0.70). Their infants were comparable in terms of male gender (19% versus 40%, 
p=0.38) and birth weight (3.09 Kg versus 3.22 Kg, p=0.47) (Table 3.1).  
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Table 3.1. Characteristics of participants by maternal BCG scar status. 
 
 
Characteristics of 
mothers and infants 
 
BCG Scar present 
(n=16) 
 
BCG Scar absent 
(n=10) 
 
 
P-value 
 
Mothers 
 
Age, mean (years) 
 
25 
 
26 
 
0.78 
Latent TBI status,  
Present, no (%) 
 
5 (31) 
 
5 (50) 
 
0.42 
Gravidity,  
Primigravida, no (%) 
 
6 (37) 
 
5 (50) 
 
0.70 
 
Infants 
Sex,  
Male, no (%) 
 
3 (19) 
 
4 (40) 
 
0.38 
 
Mean birth weight (Kg) 
 
3.09 
 
3.22 
 
0.47 
 
 
The figures are given as numbers with percentage (%) in brackets, or as mean values. P 
value is based on an unmatched t test for differences in maternal age and infant birth 
weight, and a two-sided Fisher’s exact test for differences in maternal LTBI, gravidity 
status and infant gender between scar-positive and scar-negative groups.  
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3.2.2. Responses to innate stimuli 
3.2.2.1. Combined and individual innate immune responses 
Maternal blood collected at approximately one week after delivery and infant cord 
blood samples (collected at delivery) were stimulated with innate stimuli for 24 hours 
and the cytokines and chemokines in culture supernatants were measured by Luminex® 
assay. 
 
The median cytokine and chemokine responses to the different stimuli and for 
combined responses were analysed (after subtraction of background unstimulated 
responses). These are illustrated in Figure 3.1A for mothers and Figure 3.1B for infants 
(for combined responses) and Table 3.2 for mothers and Table 3.3 for infants (for 
responses to individual stimuli). There were overall low to moderate concentrations of 
cytokines, chemokines and growth factors in both maternal and cord blood samples, 
except for IL-6, IL-8, MCP-1, MIP-1α, MIP-1β and CL097-specific IP-10 responses, 
where concentrations were high for the different stimuli (Figure 3.1 and Tables 3.2 and 
3.3). Infant responses, in the combined analyses, mirrored those of maternal responses.
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             A 
               B 
 
Figure 3.1.  Concentrations of cytokines and chemokines in culture supernatants of 
maternal and cord blood samples measured using Luminex® assay. Panels A and B 
show concentrations in maternal blood and cord blood, respectively. Cytokine 
concentrations are expressed as log10 (concentration+1). The mean response was 
calculated per cytokine and chemokine for the seven different stimuli that were used in 
the WBA. Box plots represent median and interquartile ranges, and the whiskers 
represent minimal and maximal concentrations. Samples from 26 mother-infant pairs 
were tested.
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Table 3.2. Cytokine and chemokine responses to individual innate stimuli, showing concentrations in culture supernatants from mothers’ 
stimulated post-delivery blood.  
 
Cytokine/ 
Chemokine 
PAM3Cys-
Ser (TLR 1/2 
agonist) 
FSL-1 
(TLR 2/6 
agonist) 
LPS 
(TLR 4 
agonist) 
CL097 
(TLR 7/8 
agonist) 
CpG-
ODN2006 
(TLR 9 
agonist) 
Mannan 
(DC-SIGN 
agonist) 
Curdlan 
(Dectin-1 
agonist) 
IFN-γ 33.29 15.22 43.17 42.75 1.1399 10.31 49.81 
TNF-α 51.22 5.15 350.52 262.39 0 3.24 854.78 
IL-2 2.86 0.95 4.04 3.07 0 0.75 4.21 
IL-12p70 0.45 0 2.27 2.98 0 0.929 2.61 
IL-1β 17.32 0.82 149.47 121.94 0 0 3255.72 
IL-6 188342.53 183.94 18871.69 18861.84 0.67 18.43 18875.71 
IL-4 0.08 0 0.26 0 0 0 0.33 
IL-5 1.55 1.55 1.55 1.55 1.55 1.55 1.55 
IL-13 0.49 0 0.69 0 0 0 4.09 
IL-10 75.53 16.22 206.31 156.46 0 1.44 454.08 
IL-17A 21.76 15.03 26.85 23.84 1 9.98 31.54 
IP-10 5.50 39.13 231.29 26710.98 0 26.39 378.16 
IL-8 26403 981.56 26403 890.59 203.7 1389.14 26403 
GM-CSF 33.34 23.9 45.34 35.74 18.17 22.61 43.9 
VEGF 0 0 9.84 1.09 1.80 3.92 21.75 
MCP-1  1445.21 1445.21 1445.15 1339.21 0 1401.2 1059.21 
MIP-1α  831.82 47.91 831.83 831.82 1.78 25.84 831.83 
MIP-1β  1533.27 1533.27 1533.27 1529.29 0 100 1533.27 
RANTES 0 0 0 0 0 0 0 
 
The values are median responses in pg/ml, measured by Luminex® assay, on blood samples from 26 mothers.  
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Table 3.3. Cytokine and chemokine responses to individual innate stimuli, showing concentrations in culture supernatants from stimulated cord 
blood. 
 
Cytokine/ 
Chemokine 
PAM3Cys-
Ser (TLR 1/2 
agonist) 
FSL-1 
(TLR 2/6 
agonist) 
LPS 
(TLR 4 
agonist) 
CL097 
(TLR 7/8 
agonist) 
CpGODN2006 
(TLR 9 
agonist) 
Mannan 
(DC-SIGN 
agonist) 
Curdlan 
(Dectin-1 
agonist) 
IFN-γ 0 0 5 5 0 0 10 
TNF-α 51.76 7.05 245.18 142.02 0 3.61 396.22 
IL-2 2 1 3 3 0 0 3 
IL-12p70 2 1 2 0 0 1 4 
IL-1β 31 4 130 125 0 2 3257 
IL-6 16025 338 18873 18765 0 44 18873 
IL-4 0 0 0 0 0 0 0 
IL-5 1 1 1 1 1 1 1 
IL-13 0.63 0.23 0 2 0 0 4 
IL-10 67 11 108 156 0 2 483 
IL-17A 27 20 31 29 2 15 33 
IP-10 5 9 15 26756 0 4 14 
IL-8 26403 1532.49 26403 26403 181.31 2712.5 26403 
GM-CSF 55 45 62.36 55 39 42 64 
VEGF 37.17 9.69 6.60 0.91 0.23 13.41 62.42 
MCP-1  1797 1597 1794 1797 0 1597 1798 
MIP-1α  831 73 832 832 0 18 832 
MIP-1β 1545 1544.98 1545 1544.98 0 1516.97 1544.98 
RANTES 0 0 0 0 0 0 0 
 
The values are median responses in pg/ml, measured by Luminex® assay. Cord blood samples from 26 infants were tested.  
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3.2.2.2. Correlations between concentrations of innate cytokines and chemokines in 
maternal post-delivery blood and in cord blood 
The data above showed that the combined innate cytokine data in infants was similar to 
that of their mothers.  To assess the responses in each group (mothers or infants), 
correlations between concentrations of cytokines and chemokines measured were 
assessed using Spearman rank correlation.  This enabled the strength and direction of 
relationships between the cytokines and chemokines measured to be examined.  
 
The results for mothers and infants are summarized in Tables 3.4 and 3.5, respectively. 
Values with statistical evidence of correlation are shown in bold. 
 
 For mothers, there were strong correlations observed between proinflammatory 
cytokines (IL-6 versus IL-1β (r=0.72)), and between proinflammatory cytokines and IL-
10: (IL-1β versus IL-10 (r=0.71), IL-6 versus IL-10 (r= 0.75). There were more 
cytokines and chemokines correlated with TNF-α (IL-1β, IL-2, IL-6 and IL-10) than 
IFN-γ (IL-2 and IL-12p70) (Table 3.4). 
 
In the infants, 5 cytokines and chemokines showed statistical evidence of correlation 
with both IFN-γ and TNF-α, and these included IL-1β, IL-2, IL-4, IL-8 and IL-10. The 
cytokines and chemokines that were strongly correlated included TNF-α versus IL-4 
(r=0.70), TNF-α versus IL-8 (r=0.80), IL-2 versus IL-1β (r=0.75), IL-4 versus IL-1β 
(r=0.79), IL-4 versus IL-2 (r=0.98), IL-8 versus IL-2 (r=0.75), IL-8 versus IL-4 
(R=0.72), IL-10 versus IL-1β (r=0.71) and MIP-1α versus IL-4 (r=0.73) (Table 3.5).  
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Table 3.4. Pairwise Spearman rank correlation coefficients for concentrations of cytokines and chemokines in maternal blood measured by 
Luminex®assay. 
  IL-1β IL-2 IL-4 IL-6 IL-8 IL-10 IL-12 IL-13 IL-17A GMCSF IFN-γ IP-10 MCP-1 MIP-1α MIP-1β RANTES TNF-α 
IL-2 0.22 1.00                               
IL-4 0.30 0.53 1.00                             
IL-6 0.72 0.38 0.44 1.00                           
IL-8 0.43 0.38 0.42 0.53 1.00                         
IL-10 0.71 0.40 0.38 0.75 0.47 1.00                       
IL-
12p70 0.26 0.23 0.08 0.06 0.17 0.15 1.00                     
IL-13 0.28 0.22 0.26 0.31 0.15 0.57 0.06 1.00                   
IL-17A -0.23 0.37 -0.09 -0.02 0.12 -0.19 -0.01 -0.08 1.00                 
GMCSF 0.21 0.37 0.11 0.20 0.10 0.12 0.16 -0.04 0.50 1.00               
IFN-γ -0.03 0.56 0.10 0.00 0.19 0.04 0.41 -0.23 0.36 0.33 1.00             
IP-10 0.37 0.12 0.13 0.25 0.25 0.30 0.53 0.24 -0.23 -0.03 0.23 1.00           
MCP-1 -0.29 -0.10 -0.54 -0.23 -0.10 -0.27 -0.10 -0.17 0.44 0.02 0.37 -0.01 1.00         
MIP-1α 0.23 0.16 0.15 0.50 0.40 0.31 -0.20 0.10 0.32 0.50 -0.08 -0.22 -0.01 1.00       
MIP-1β -0.41 0.18 -0.31 -0.23 -0.01 -0.24 -0.36 -0.24 0.52 -0.01 0.23 -0.22 0.49 0.07 1.00     
RANTES -0.09 -0.19 0.13 0.03 -0.32 -0.31 -0.10 -0.21 -0.01 0.15 -0.13 -0.23 -0.09 0.20 -0.18 1.00   
TNF-α 0.52 0.46 0.30 0.39 0.33 0.48 0.01 0.06 0.04 0.32 0.34 -0.13 0.00 0.13 -0.11 -0.10 1.00 
VEGF 0.14 0.01 -0.15 0.05 0.20 -0.01 0.03 0.19 0.17 -0.21 -0.35 -0.05 0.18 0.09 0.10 -0.44 -0.04 
 
Correlation between concentrations of cytokines and chemokines from stimulated samples from 26 mothers was assessed using the Spearman 
rho test. P values less than 0.05 are shown in bold. 
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Table 3.5. Pairwise Spearman rank correlation coefficients for concentrations of cytokines and chemokines in cord blood measured by 
Luminex®assay.  
  IL-1β IL-2 IL-4 IL-6 IL-8 IL-10 IL-12 IL-13 IL-17A GMCSF IFN-γ IP-10 MCP-1 MIP-1α MIP-1β RANTES TNF-α 
IL-2 0.75 1.00                               
IL-4 0.79 0.98 1.00                             
IL-6 0.62 0.61 0.56 1.00                           
IL-8 0.56 0.75 0.72 0.36 1.00                         
IL-10 0.71 0.61 0.67 0.43 0.53 1.00                       
IL-12p70 0.38 0.33 0.36 0.22 0.34 0.23 1.00                     
IL-13 0.31 0.56 0.52 0.23 0.22 0.14 0.11 1.00                   
IL-17A 0.26 0.55 0.53 0.21 0.47 0.33 0.32 0.03 1.00                 
GMCSF 0.41 0.42 0.40 0.18 0.27 0.28 0.55 0.41 0.11 1.00               
IFN-γ 0.47 0.68 0.69 0.19 0.67 0.46 0.37 0.46 0.44 0.53 1.00             
IP-10 0.12 -0.05 -0.01 0.21 -0.22 0.14 -0.07 -0.11 0.01 0.20 0.01 1.00           
MCP-1 0.20 0.34 0.36 0.00 0.39 0.25 -0.10 0.11 0.43 0.15 0.48 0.20 1.00         
MIP-1α 0.58 0.66 0.73 0.48 0.46 0.58 0.18 0.40 0.31 0.25 0.35 -0.12 0.36 1.00       
MIP-1β -0.14 0.04 0.01 -0.02 0.05 0.01 0.10 -0.06 0.42 -0.05 0.10 -0.17 0.19 -0.17 1.00     
RANTES 0.09 -0.15 -0.10 0.06 -0.40 0.13 -0.07 0.04 -0.48 0.07 -0.05 0.19 -0.13 0.02 -0.19 1.00   
TNF-α 0.61 0.68 0.70 0.28 0.80 0.58 0.16 0.22 0.32 0.19 0.64 -0.10 0.34 0.48 -0.15 -0.02 1.00 
VEGF 0.46 0.34 0.38 0.24 0.34 0.30 0.93 0.15 0.30 0.45 0.39 -0.08 -0.10 0.21 0.08 0.04 0.22 
 
Correlation between concentrations of cytokines and chemokines from stimulated cord blood samples from 26 infants was assessed using the 
Spearman rho test. P values less than 0.05 are shown in bold.  
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3.2.2.3. Principle Component Analysis of maternal and infant innate immune 
responses 
Having shown correlations for cytokines and chemokines, a PCA was performed to 
better visualize the data and see whether the data grouped according to particular 
characteristics – for example whether the pro-inflammatory cytokines grouped together. 
These are illustrated in Tables 3.6 (for mothers) and 3.7 (for infants).  
For the mothers, two principle components (PCs) were identified that summarized the 
cytokines and chemokines measured. Together, these accounted for 43% of the variance 
in the dataset. The first PC (PC1) explained 25% of the total variance and was 
characterized by IFN-γ, TNF-α, IL-12p70, IL-1β, IL-6, IL-4, IL-10, IL-13 and the 
second PC (PC2) explained a further 18% of the total variance and was characterized by 
MCP-1, MIP-1α, MIP-1β, IL-8, and IL-17A based on factor loadings > 0.1 (Table 3.6, 
Figure 3.2A).  
 
In the mothers, most cytokines and chemokines measured were positively loaded in 
PC1, except for IL-17A, VEGF, MCP-1, MIP-1β and RANTES which were negatively 
loaded, meaning an increase of PC1 would represent an increase in the first set of 
cytokines and chemokines and a simultaneous decrease in the second set of cytokines 
and chemokines (Table 3.6, right panel).  
 
For the infants, two PCs identified accounted for 53% of the variance in the dataset. 
PC1 explained 39% of the total variance and was characterized by most of the cytokines 
measured (IFN-γ, TNF-α, IL2, IL-12p70, IL-4, IL-13, IL-10, IL-1β, IL-6, IL-8, VEGF 
and GM-CSF) (Table 3.7, Figure 3.2C). PC2 explained a further 14% of the total 
variance and was characterized by MCP-1 and MIP-1β.  In the infants, most cytokines 
and chemokines measured were positively loaded in PC1, except for MIP-1β and 
RANTES which were negatively loaded, meaning an increase of PC1 would represent 
an increase in the first set of cytokines and chemokines and a simultaneous decrease of 
MIP-1β and RANTES (Table 3.7, right panel).  
 
Mothers with and without a BCG scar were scattered all over the two PCs (Figure 
3.2B), whereas infants of mothers with a BCG scar, compared to those without, grouped 
towards PC1 (Figure 3.2D).
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Table 3.6. Principal Component Analysis of cytokine concentrations in maternal post-delivery blood. 
Principal components analysis of 18 cytokines from supernatants from 26 maternal post-delivery blood samples stimulated with innate stimuli. 
In bold are cytokines and chemokines with important contributions (≥0.20) in the component. Linear combination of the variables listed in Table 
10 (right panel) constitute component 1. For example Component 1= 0.31 log IFN-γ + 0.28 log TNF-α+ 0.37 log IL-2 +0.23 log IL-12p70 +0.31 
log IL-1β + 0.26 log IL-6 + 0.24 log IL-4 + 0.25 log IL-13 + 0.39 log IL-10 + -0.06 log IL-17A + 0.32 log IP-10 + 0.07 log IL-8+ 0.13 log GM-
CSF + -0.05 log VEGF + -0.09 log MCP-1 + 0.01 log MIP-1α + -0.20 log MIP-1β  + -0.15 log RANTES. 
Component Eigenvalue Difference Proportion Cumulative  
Component 1 4.36 1.31 0.25 0.25 
Component 2 3.05 1.03 0.18 0.43 
Component 3 2.02 0.36 0.11 0.54 
Component 4 1.67 0.29 0.09 0.63 
Component 5 1.37 0.15 0.08 0.69 
Component 6 1.22 0.27 0.07 0.71 
Component 7 0.96 0.14 0.06 0.77 
Component 8 0.82 0.10 0.05 0.82 
Component 9 0.72 0.24 0.04 0.86 
Component 10 0.48 0.14 0.03 0.89 
Component 11 0.35 0.06 0.02 0.91 
Component 12 0.28 0.07 0.02 0.92 
Component 13 0.21 0.02 0.02 0.94 
Component 14 0.19 0.04 0.01 0.95 
Component 15 0.15 0.06 0.01 0.96 
Component 16 0.09 0.06 0.01 0.97 
Component 17 0.35 0.03 0 1.00 
Component 18 0 - 0 1.00 
 
Variable Component 1 Component 2 
IFN-γ 0.31 0.13 
TNF-α 0.28 -0.01 
IL-2 0.37 0.18 
IL-12p70 0.23 0.09 
IL-1β 0.31 -0.17 
IL-6 0.26 -0.02 
IL4 0.24 -0.10 
IL-13 0.25 -0.03 
IL-10 0.39 -0.11 
IL-17A -0.06 0.47 
IP-10 0.32 0.14 
IL-8 0.07 0.48 
GM-CSF 0.13 0.22 
VEGF -0.05 0.05 
MCP-1 -0.09 0.16 
MIP-1α 0.01 0.47 
MIP-1β -0.20 0.33 
RANTES -0.15 -0.07 
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Table 3.7. Principal Component Analysis of cytokine and chemokine concentrations in cord blood 
Principal components analysis of 17 cytokines from supernatants from cord blood from 26 infants stimulated with innate stimuli. In bold are 
cytokines and chemokines with important contributions (≥0.20) in the component. Linear combination of the variables listed in Table 11 (right 
panel) constitute component 1. For example Component 1= 0.29 log IFN-γ + 0.27 log TNF-α+ 0.36 log IL-2 +0.25 log IL-12p70 +0.30 log IL-
1β + 0.17 log IL-6 + 0.36 log IL-4 + 0.16 log IL-13 + 0.30 log IL-10 + 0.24 log IL-17A + 0.30 log IL-8+ 0.22 log GM-CSF + 0.23 log VEGF + 
0.07 log MCP-1 + 0.20 log MIP-1α + -0.01 log MIP-1β  + -0.05 log RANTES. 
Component Eigenvalue Difference Proportion Cumulative  
Component 1 6.90 4.51 0.39 0.39 
Component 2 2.39 0.54 0.14 0.53 
Component 3 1.85 0.41 0.12 0.65 
Component 4 1.43 0.45 0.08 0.73 
Component 5 0.98 0.18 0.07 0.80 
Component 6 0.80 0.07 0.05 0.85 
Component 7 0.74 0.28 0.04 0.89 
Component 8 0.46 0.08 0.03 0.92 
Component 9 0.37 0.08 0.02 0.94 
Component 10 0.29 0.03 0.02 0.96 
Component 11 0.26 0.09 0.01 0.97 
Component 12 0.17 0.02 0.01 0.98 
Component 13 0.15 0.03 0.01 0.99 
Component 14 0.12 0.06 0.01 1.00 
Component 15 0.05 0.02 0. 1.00 
Component 16 0.03 0.03 0 1.00 
Component 17 0  0 1.00 
 
Variable Component 1 Component 2 
IFN-γ 0.29 -0.13 
TNF-α 0.27 -0.05 
IL-2 0.36 -0.01 
IL-12p70 0.25 -0.18 
IL-1β 0.30 -0.01 
IL-6 0.17 -0.01 
IL4 0.36 0.04 
IL-13 0.16 -0.42 
IL-10 0.30 0.11 
IL-17A 0.24 0.41 
IL-8 0.30 -0.05 
GM-CSF 0.22 -0.19 
VEGF 0.23 -0.15 
MCP-1 0.07 0.51 
MIP-1α 0.20 0.47 
MIP-1β   -0.01 0.21 
RANTES -0.05 0.05 
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Figure 3.2. Scatterplots of first and second factor loadings for mothers’ post-
delivery blood and infant cord blood, derived from Principal Component Analysis 
of cytokines and chemokines measured. The graphs show cytokines and chemokines 
for mothers (A) and infants (C), with individual mothers (B) and neonates (D) 
represented as discrete plots. For mothers, the first principal component (PC) was 
characterized by a mixture of cytokines and the second PC consisted of chemokines. 
For neonates, the first PC was characterized by proinflammatory cytokines and the 
second PC consisted of chemokines, based on factor loadings >0.1.  Red circles 
represent BCG scar-positive (Scar+) mothers or their infants. BCG scar-negative (Scar-) 
mothers or their infants are represented by blue circles. Samples from 26 mother-infant 
pairs were tested. 
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3.2.2.4. Analysis of clusters of concentrations of cytokines and chemokines 
The finding that infants of mothers with a BCG scar, compared to those without, 
grouped towards PC1 was an unexpected finding.  To further examine sets of cytokines 
and chemokines that might be expressed coordinately in infants of mothers with and 
without a BCG scar, a hierarchical bicluster analysis of the stimulated innate cytokine 
and chemokine responses was performed. This was done to determine whether the 
cytokines and chemokines grouped together in a particular pattern. As illustrated in 
Figure 3.3, three cytokine and chemokine clusters were identified: Cluster (C) 1 was 
characterized by MCP-1, MIP-1α, MIP-1β, IL-17A; C2 by VEGF, GM-CSF, IL-12p70 
and C3 by IL-1β, IL-8, TNF-α, IFN-γ, IL-2, IL-4, IL-10.  There was an additional 
cluster (C4) that contained high concentrations of the pro-inflammatory cytokines IFN-
γ, TNF-α, IL-1β, IL-6 and IL-8, mainly produced by infants of mothers with a BCG 
scar.  
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Figure 3.3. Cluster analysis of the stimulated innate cytokine and chemokine responses using the average linkage distance between 
clusters using R. Clusters go from root to leaf node for each cytokine and for the individual infants. Clusters in between are based on their 
agglomeration value. The branch shows the similarity; the shorter the branch, the higher the similarity. Expression levels of individual cytokines 
(log10 [pg/ml]) are represented by shades of blue to red based on their correlations according to the dendrogram on the left, with highest values in 
dark red and the lowest in dark blue. Three distinct sets of correlated cytokines “clusters” (C) are indicated as C1, C2 and C3 on the left. In 
addition, eleven cytokines (C4) formed a cluster that had mainly inflammatory cytokines. Most infants of mothers with a BCG scar (top, green) 
clustered together in one discrete group, distinct from infants of mothers without a BCG scar (top, light blue).
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3.2.3. Factors associated with maternal and infant innate immune responses 
3.2.3.1. Maternal latent M. tuberculosis infection 
Having shown that the cytokines and chemokines measured formed clusters, the 
associations between innate infant and maternal responses and maternal LTBI was 
assessed. This is important because if infant responses differed based on maternal LTBI, 
then this may argue for treatment of LTBI in pregnant mothers and/or may be a 
contributing factor to the poor efficacy of BCG in this setting. 
 
The median cytokine and chemokine responses in mothers without and with LTBI, and 
in their infants, based on the innate stimulated cytokine data, are shown in Table 3.8, 
and the associations between maternal LTBI and maternal responses are illustrated in 
Figure 3.4. For the combined responses, maternal responses were not associated with 
their own LTBI, except for IL-13 where mothers without LTBI had higher median 
responses than those with LTBI.  
 
Figure 3.5 illustrates the associations between maternal LTBI and infant innate 
responses. Maternal LTBI was not associated with innate infant responses in the cord 
blood, except for IP-10 where mothers with LTBI, compared to those without, had 
overall higher responses, with an aGMR [95% CI] of 5.10 [1.21, 21.48] (Table 3.9). 
This was after adjusting for the effect of maternal BCG scar on infant responses.  
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Table 3.8. Cytokine and chemokine responses in mothers without and with LTBI, and in their infants, measured by Luminex® assay. 
 
 
Cytokine/ 
Chemokine 
Mothers without 
LTBI 
(n=16) 
Mothers with 
LTBI 
(n=10) 
 
 
p value 
 
Cytokine/ 
Chemokine 
Infants of mothers 
without LTBI 
(n=17) 
Infants of mothers 
with LTBI 
(n=12) 
 
 
p value 
IFN-γ 26 (24, 32) 35 (20, 37) 0.370 IFN-γ 4 (1, 9) 6 (0, 9) 0.790 
TNF-α 343 (138, 485) 150 (60, 369) 0.171 TNF-α 114 (59, 223) 89 (54, 331) 0.658 
IL-2 2 (2, 3) 2 (2,3) 0.268 IL-2 2 (1, 2) 2 (1, 2) 0.579 
IL-12p70 1 (1, 3) 2 (1, 3) 0.399 IL-12p70 3 (0, 5) 1 (0, 3) 0.658 
IL-1β 312 (73, 560) 497 (77, 520) 0.544 IL-1β 499 (70, 533) 338 (63, 540) 0.859 
IL-6 10796 (6383, 10880) 10809 (5588, 10846) 0.493 IL-6 9475 (4805, 10857) 10350 (8336, 10828) 0.400 
IL-4 0 (0, 0) 0 (0, 0) 0.09 IL-4 1 (1, 2) 1 (1, 2) 0.707 
IL-13 2 (1, 3) 1 (0, 1) 0.03 IL-13 2 (1, 4) 2 (0, 8) 0.790 
IL-10 135 (99, 216) 123 (61, 141) 0.188 IL-10 130 (78, 180) 107 (64, 181) 0.757 
IL-17A 18 (12, 20) 24 (17, 28) 0.082 IL-17A 22 (18, 26) 24 (20, 29) 0.376 
IP-10 3878 (3843, 4041) 2683 (818, 4004) 0.343 IP-10 2063 (123, 3849) 3838 (3826, 3852) 0.215 
IL-8 12112 (11447, 17370) 11607 (9661, 15039) 0.399 IL-8 15448 (10811, 22658) 15433 (12532, 22669) 0.757 
GM-CSF 13 (10, 18) 14 (13, 16) 0.673 GM-CSF 53 (45, 59) 51 (42, 66) 1.00 
VEGF 7 (2, 15) 8 (3, 16) 0.874 VEGF 54 (3, 67) 13 (6, 76) 0.790 
MCP-1 1093 (74, 1905) 1417 (774, 2918) 0.225 MCP-1 1329 (1076, 1529) 1397 (1222, 1524) 0.215 
MIP-1α 505 (479, 596) 495 (480, 627) 0.916 MIP-1α 481 (442, 652) 505 (480, 600) 0.425 
MIP-1β 0 (0, 1377) 1273 (0, 1407) 0.233 MIP-1β 1204 (0, 1366) 1328 (1222, 1391) 0.163 
 
The values are shown as medians in pg/ml with the interquartile range in brackets. The p values shown were obtained using Mann-Whitney test. 
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Figure 3.4. The association between maternal LTBI and maternal innate immune responses.  Median cytokine and chemokine production 
following overnight stimulation with LPS (TLR 4 agonist), FSL-1 (TLR2/6 agonist), CpG-ODN2006 (TLR9 agonist), PAM3Cys-Ser (TLR1/2 
agonist), CL097 (TLR7/8 agonist), Mannan (DC-SIGN agonist) and Curdlan (Dectin-1 agonist) are shown. Cytokines representing 
Th1/proinflammatory responses (IFN-γ, IL-12p70, TNF-α and IL-1β), immunoregulatory responses (IL-10) and chemokines/growth factors (IP-
10, VEGF and GM-CSF) measured by Luminex® assay are shown for mothers without (n=17) and with (n=12) LTBI. Data presentation was 
performed using GraphPad Prism. 
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Figure 3.5. The association between maternal LTBI and infant innate immune responses.  Median cytokine and chemokine production 
following overnight stimulation with LPS (TLR 4 agonist), FSL-1 (TLR2/6 agonist), CpG-ODN2006 (TLR9 agonist), PAM3Cys-Ser (TLR1/2 
agonist), CL097 (TLR7/8 agonist), Mannan (DC-SIGN agonist) and Curdlan (Dectin-1 agonist) are shown. Cytokines representing 
Th1/proinflammatory responses (IFN-γ, IL-12p70, TNF-α and IL-1β), immunoregulatory responses (IL-10) and chemokines/growth factors (IP-
10, VEGF and GM-CSF) measured by Luminex® assay are shown for cord blood samples from infants of mothers without (n=17) and with 
(n=12) LTBI. Data presentation was performed using GraphPad Prism. 
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Table 3.9. The association between maternal LTBI and infant immune responses. 
 
Cytokine/ 
Chemokine 
Crude GMR, 
95% CI 
Adjusted GMR, 
(95% CI)
 a
 
IFN-γ 0.99 (0.41, 2.45) 0.95 (0.41, 2.24)  
TNF-α 1.17 (0.57, 2.40) 1.23 (0.60, 2.57) 
IL-2 1.07 (0.85, 1.35) 1.07 (0.85, 1.38) 
IL-12p70 0.85 (0.48, 1.55) 0.78 (0.43, 1.38) 
IL-1β 0.91 (0.37, 2.34) 0.79 (0.27, 2.24) 
IL-6 1.35 (0.91, 1.95) 1.38 (0.89, 2.09) 
IL-4 1.10 (0.89, 1.35) 1.10 (0.89, 1.38) 
IL-13 1.10 (0.57, 2.04) 0.87 (0.44, 1.74) 
IL-10 1.07 (0.68, 1.70) 1.07 (0.69, 1.66) 
IL-17A 1.12 (0.81, 1.55) 1.12 (0.85, 1.51) 
IP-10 3.80 (1.02, 14.45) 5.10 (1.21, 21.38) 
IL-8 1.15 (0.85, 1.55) 1.12 (0.83, 1.55) 
GM-CSF 0.99 (0.83, 1.17) 0.95 (0.81, 1.15) 
VEGF 0.74 (0.22, 2.51) 0.54 (0.16, 1.78) 
MCP-1 2.40 (0.81, 7.08) 2.24 (0.79, 6.46) 
MIP-1α 1.51 (0.72, 3.09) 1.44 (0.74, 2.75) 
MIP-1β 5.89 (0.63, 54.95) 9.77 (0.83, 114.81) 
 
 
The values are shown as crude and adjusted geometric mean ratios (GMR) with 95% CI 
for 29 infant samples. 
a
 adjusted for maternal BCG scar. 
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3.2.3.2. Associations between maternal LTBI and infant responses to the individual 
stimuli 
Having shown little association with maternal LTBI in the combined cytokine and 
chemokine response analysis, it was possible that there were subtle differences between 
individual stimuli that were lost due to the averaging process. Infant responses to 
individual innate stimuli were therefore analysed to assess their associations with 
maternal LTBI. Figures 3.6A and 3.6B illustrate these analyses. The following CpG-
specific cytokines and chemokines were positively associated with maternal LTBI: IL-
12p70 (p=0.014), MCP-1 (p=0.011) and MIP-1β (p=0.007) (Figure 3.6B).  No other 
analyte measured, or stimulus, was associated with maternal LTBI.
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                                       PAM3Cys-Ser  (TLR 1/2 agonist)                                                                  FSL-1 (TLR 2/6 agonist) 
 
 
                                                  LPS (TLR 4 agonist)                                                                            CL097 (TLR 7/8 agonist) 
 
Figure 3.6A. Cytokine and chemokine responses to TLR1/2, TLR2/6, TLR4 and TLR7/8 agonists.  Concentrations in cord blood are 
shown. Clear and grey bars represent infants of mothers without (n=17) and with LTBI (n=12), respectively. The horizontal lines represent the 
median. Statistically significant differences are shown by (*). Kruskal-Wallis test was used to compare the two groups of infants. 
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                                         CpG-ODN2006 (TLR 9 agonist)                                                                     Mannan (DC-SIGN agonist) 
 
 
                                            Curdlan (Dectin-1 agonist) 
 
Figure 3.6B. Cytokine and chemokine responses to TLR 9, DC-SIGN and Dectin-1 agonists.  Concentrations in cord blood are shown. Clear 
and grey bars represent infants of mothers without (n=17) and with (n=12) LTBI, respectively. The horizontal lines represent the median. 
Statistically significant differences are shown by (*). Kruskal-Wallis test was used to compare the two groups of infants.
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3.2.3.3. Maternal BCG scar 
Having shown that there was little association between maternal LTBI and the innate 
infant response to BCG immunisation, and that infants of mothers with a BCG scar 
clustered together, the effect of maternal BCG scar on infant innate responses was 
examined. This was important to query because maternal BCG scar has been associated 
with differential infant T cell responses, and we know that a good innate immune 
response leads to a better quality adaptive immune response (336). 
 
For the combined responses, maternal responses were not associated with their own 
BCG scar, except for VEGF where mothers without a BCG scar, compared to those 
with, had higher concentrations (p=0.031, Figure 3.7). For IL-4, mothers with a BCG 
scar, compared to those without, had higher responses (p=0.012, Table 3.10). 
Compared to those without a BCG scar, cord blood samples obtained from infants of 
mothers with a BCG scar had overall higher responses to innate stimuli for the 
following analytes: IFN-γ (aGMR 2.69 [1.15, 6.17]), IL-12p70 (1.95 [1.10, 3.55]), IL-
10 (1.82 [1.07, 3.09]), VEGF (3.55 [1.07, 11.48]) and IP-10 (6.76 [1.17, 38.02] (Figure 
3.8, and Tables 3.10 and 3.11) after adjusting for the effect of maternal LTBI.  
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Table 3.10. Cytokine and chemokine responses in mothers without and with a BCG scar, and in their infants, measured by Luminex® assay.  
 
 
Cytokine/ 
Chemokine 
Mothers without  
a BCG scar 
(n=10) 
Mothers with  
a BCG scar 
(n=16) 
 
 
p value 
Cytokine/ 
Chemokine 
Neonates of mothers 
without a BCG scar 
(n=10) 
Neonates of mothers 
with a BCG scar 
(n=16) 
 
 
p value 
IFN-γ 24 (19, 36) 29 (25, 36) 0.215 IFN-γ 0 (0, 5) 6 (2, 11) 0.035 
TNF-α 197 (60, 391) 328 (107, 486) 0.327 TNF-α 55 (29, 166) 164 (69, 232) 0.076 
IL-2 2 (2, 2) 2 (2, 3) 0.215 IL-2 1.2 (1, 2) 2 (1, 3) 0.146 
IL-12p70 2 (1, 3) 1 (1, 2) 0.333 IL-12p70 0 (0, 1) 3 (1, 5) 0.017 
IL-1β 497 (62, 556) 309 (85, 590) 0.989 IL-1β 110.04 (52, 505) 512 (82, 557) 0.076 
IL-6 10792 (5181, 10843) 10814 (6235, 10877) 0.504 IL-6 10069 (7045, 10795) 9694 (5730, 12844) 0.643 
IL-4 0.00 (0, 0) 0.147 (0, 2) 0.012 IL-4 1.23 (1, 2) 1 (1, 2) 0.070 
IL-13 1 (0, 2) 1 (1, 3) 0.219 IL-13 2 (0.25, 2) 2 (0, 7) 0.443 
IL-10 105 (58, 160) 135 (113, 197) 0.085 IL-10 77 (47, 119) 132 (89, 198) 0.010 
IL-17A 19 (14, 24) 19 (12, 26) 0.89 IL-17A 19 (16, 23) 24 (20, 27) 0.085 
IP-10 3950 (866, 4028) 3863 (2007, 3998) 0.89 IP-10 2085 (35, 3842) 3847 (1796, 3854) 0.076 
IL-8 11587 (9634, 12750) 13423 (11466, 9634) 0.256 IL-8 15289 (8122, 17340) 15499 (12230, 22671) 0.215 
GM-CSF 13 (10, 16) 15 (12, 18) 0.328 GM-CSF 46 (40, 54) 56 (46, 63) 0.046 
VEGF 16 (7, 22) 6 (2, 11) 0.031 VEGF 8 (2, 15) 55 (8, 75) 0.035 
MCP-1 1399 (1092, 2407) 1007 (118, 2110) 0.391 MCP-1 1166 (1084, 1480) 1359 (1247, 1541) 0.196 
MIP-1α 486 (478, 597) 506 (482, 601) 0.328 MIP-1α 480.10 (478, 533) 503 (449, 677) 0.382 
MIP-1β 1260 (0, 1437) 587 (0, 1381) 0.521 MIP-1β 1317 (850, 1381) 1304 (0, 1377) 0.683 
 
The values are shown as medians in pg/ml with the interquartile range in brackets. The p values shown were obtained by Mann-Whitney test. 
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Figure 3.7. The association between maternal BCG scar and maternal innate immune responses.  Median cytokine and chemokine 
production following overnight stimulation of maternal blood with LPS TLR) 4 agonist), FSL-1 (TLR2/6 agonist), CpG-ODN2006 (TLR9 
agonist), PAM3Cys-Ser (TLR1/2 agonist), CL097 (TLR7/8 agonist), Mannan (DC-SIGN agonist) and Curdlan (Dectin-1 agonist) are shown. 
Cytokines representing Th1/proinflammatory responses (IFN-γ, IL-12p70, TNF-α and IL-1β), immunoregulatory responses (IL-10) and 
chemokines/growth factors (IP-10, VEGF and GM-CSF) measured by Luminex® assay are shown for the scar-negative (n=10) or scar-positive 
(n=16) mothers’ blood. Data presentation was performed using GraphPad Prism. 
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Figure 3.8. The association between maternal BCG scar and infant innate immune responses.  Median cytokine and chemokine production 
following overnight stimulation with LPS (TLR 4 agonist), FSL-1 (TLR2/6 agonist), CpG-ODN2006 (TLR9 agonist), PAM3Cys-Ser (TLR1/2 
agonist), CL097 (TLR7/8 agonist), Mannan (DC-SIGN agonist) and Curdlan (Dectin-1 agonist) are shown. Cytokines representing 
Th1/proinflammatory responses (IFN-γ, IL-12p70, TNF-α and IL-1β), immunoregulatory responses (IL-10) and chemokines/growth factors (IP-
10, VEGF and GM-CSF) measured by Luminex® assay are shown for cord blood from infants of mother without (n=10) and with (n=16) a BCG 
scar. Data presentation was performed using GraphPad Prism. 
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Table 3.11. The association between maternal BCG scar and infant responses. 
 
 
Cytokine/ 
Chemokine 
 
Crude GMR, 
95% CI 
 
Adjusted GMR, 
(95% CI)
 a
 
IFN-γ 2.69 (1.24, 5.83) 2.69 (1.15, 6.17)  
TNF-α 2.04 (0.98, 4.36) 1.99 (0.69, 5.89) 
IL-2 1.25 (1.00, 1.57) 1.23 (0.89, 1.70) 
IL-12p70 2.06 (1.24, 3.43) 1.95 (1.10, 3.55) 
IL-1β 1.90 (0.71, 5.25) 1.55 (0.37, 6.61) 
IL-6 0.98 (0.62, 1.55) 0.89 (0.45, 1.74) 
IL-4 1.23 (1.00, 1.51) 1.20 (0.89, 1.62) 
IL-13 1.35 (0.79, 2.34) 1.17 (0.63, 2.24) 
IL-10 1.82 (1.14, 2.88) 1.82 (1.07, 3.09) 
IL-17A 1.12 (0.81, 1.55) 1.10 (0.71, 1.70) 
IP-10 5.01 (0.79, 30.90) 6.76 (1.17, 38.02) 
IL-8 1.29 (0.91, 1.82) 1.35 (0.78, 2.29) 
GM-CSF 1.19 (1.02, 1.39) 1.15 (0.95, 1.38) 
VEGF 3.97 (1.38, 11.40) 3.55 (1.07, 11.48) 
MCP-1 0.46 (0.14, 1.44) 0.49 (0.10, 2.34) 
MIP-1α 0.76 (0.35, 1.62) 0.68 (0.22, 2.09) 
MIP-1β 0.29 (0.02, 3.80) 0.69 (0.05, 9.77) 
 
 
The values are shown as crude and adjusted geometric means ratios (GMR) with 95% 
CI for 26 infant samples. 
a
 adjusted for maternal LTBI. 
 
 
 
 
 
 
 
 
 
 
 93 
3.2.3.4. Associations between maternal BCG scar and infant responses to the 
individual stimuli 
Although these results showed that there was an association with maternal BCG scar in 
the combined cytokine and chemokine response analysis, it was also possible that 
averaging of infant responses to innate stimuli led to a loss of other, perhaps more 
subtle, changes between individual stimuli. Infant responses to individual innate stimuli 
were therefore analysed to assess their associations with maternal BCG scar.  
The associations between infant responses to the different stimuli and maternal BCG 
scar were analysed. The following cytokines and chemokines were positively associated 
with maternal BCG scar: IL-10 (p=0.017) and GM-CSF (p=0.042) to PAM3Cys-Ser; 
TNF-α (p=0.044), IL-2 (p=0.019), IL-1β (0.005), IL-6 (p=0.017), IL-10 (p=0.001), GM-
CSF (p=0.014) and VEGF (p=0.048) to FSL-1; TNF-α (0.017) to LPS; IFN-γ 
(p=0.018), IL-12p70 (p=0.023), GM-CSF (p=0.047) to CL097 (Figure 3.9A); IL-2 
(p=0.048), IL-1β (0.017), IL-10 (p=0.040), IL-8 (p=0.011), GM-CSF (p=0.027) to 
Mannan; TNF-α (p=0.027), IL-12p70 (P=0.012) and VEGF (p=0.003) to Curdlan 
(Figure 3.9B).  This data showed that different innate stimuli elicited different responses 
in the infants, and that such small differences might be lost when responses to 
individual stimuli are combined. 
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                                     PAM3Cys-Ser  (TLR 1/2 agonist)                                                               FSL-1 (TLR 2/6 agonist) 
 
                                                LPS (TLR 4 agonist)                                                                                CL097 (TLR 7/8 agonist) 
 
Figure 3.9A. Cytokine and chemokine responses to TLR1/2, TLR2/6, TLR4 and TLR7/8 agonists.  Concentrations in cord blood are 
shown. Clear and grey bars represent infants of mothers without (n=17) and with (n=12) LTBI, respectively. The horizontal lines represent the 
median. Statistically significant differences are shown by (*). Kruskal-Wallis test was used to compare the two groups of infants. 
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                                        CpG-ODN2006 (TLR 9 agonist)                                                                   Mannan (DC-SIGN agonist) 
 
                                             Curdlan (Dectin-1 agonist) 
 
Figure 3.9B. Cytokine and chemokine responses to TLR 9, DC-SIGN and Dectin-1 agonists.  Concentrations in cord blood are shown. Clear 
and grey bars represent infants of mothers without (n=17) and with (n=12) LTBI, respectively. The horizontal lines represent the median. 
Statistically significant differences are shown by (*). Kruskal-Wallis test was used to compare the two groups of infants.  
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3.2.4. Principal Component Analysis of the associations between maternal and 
infant factors, and innate responses in the mothers and their infants 
Having examined the associations between maternal LTBI and maternal BCG scar and 
infant responses, a PCA was performed to better visualize the data and see whether the 
data grouped according to particular patterns. In addition to maternal LTBI and 
maternal BCG scar, other maternal and infant factors were also analysed. 
 
Figures 3.10 to 3.13 illustrate the associations between maternal and infant factors, and 
the innate responses in the mothers and their infants.  Neither maternal LTBI (p=0.535 
for PC1 versus p=0.092 for PC2, Figure 3.10A) nor maternal BCG scar (p=0.225 for 
PC1 versus p=0.673 for PC2, Figure 3.10B) was associated with mothers’ own PC 
scores. There were no associations between maternal LTBI and levels of PCs in the 
infants (p=0.859 for PC1 versus p=0.425 for PC2, Figure 3.11A). Maternal BCG scar 
was, however, associated with high levels of PC1 in the infants (median level of scores: 
1.44 in scar-positive versus -0.94 in scar-negative, p=0.020, Figure 3.11B). There was 
no association between maternal BCG scar and levels of PC2 in the infants (median 
level of scores: -0.002 in scar-positive versus 0.754 in scar-negative, p=0.065, Figure 
3.11B). Maternal age (p=0.463 for PC1 versus p=0.183 for PC2, Figure 3.12A), 
maternal gravidity status (p=0.071 for PC1 versus p=0.961 for PC2, Figure 3.12B), 
infant gender (p=0.542 for PC1 versus p=0.309 for PC2, Figure 3.13A) and infant birth 
weight (p=0.688 for PC1 versus p=0.789 for PC2, Figure 3.13B) were not associated 
with infant responses. 
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Figure 3.10. The association between maternal LTBI, maternal BCG scar and the 
innate immune responses in mother’s post-delivery blood. PCA was used to assess 
the association between maternal LTBI, maternal BCG scar and maternal responses. 
The association between maternal LTBI and maternal responses (A), and between 
maternal BCG scar and maternal responses (B) are shown. Two PCs that explained 43% 
of the variance in the dataset were identified. The box plots represent the median and 
the interquartile range of the levels of the two PCs. The whiskers show the minimum 
and maximum values.  P values are from Wilcoxon rank sum test. 
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Figure 3.11. The association between maternal LTBI, maternal BCG scar and the 
innate immune responses in infant cord blood. PCA was used to assess the 
association between maternal LTBI, maternal BCG scar and infant responses. The 
association between maternal LTBI and infant responses (A), and between maternal 
BCG scar and infant responses (B) are shown. Two PCs that explained 53% of the 
variance in the dataset were identified. The box plots represent the median and the 
interquartile range of the levels of the two PCs. The whiskers show the minimum and 
maximum values.  P values are from Wilcoxon rank sum test.    
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Figure 3.12. The association between maternal age, maternal gravidity status and 
the innate immune responses in infant cord blood. PCA was used to assess the 
association between maternal age (in years), maternal gravidity status and infant 
responses. The association between maternal age and infant responses (A), and the 
association between maternal gravidity status and infant responses (B) are shown. Two 
PCs that explained 53% of the variance in the dataset were identified. The box plots 
represent the median and the interquartile range of the levels of the two PCs. The 
whiskers show the minimum and maximum values.  P values are from Wilcoxon rank 
sum test 
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Figure 3.13. The association between infant gender, infant birth weight and the 
innate immune responses in infant cord blood. PCA was used to assess the 
association between infant gender, infant birth weight (in kilograms) and infant 
responses. The association between infant gender and infant responses (A), and between 
infant birth weight and infant responses (B) are shown. Two PCs that explained 53% of 
the variance in the dataset were identified. The box plots represent the median and the 
interquartile range of the levels of the two PCs. The whiskers show the minimum and 
maximum values.  P values are from Wilcoxon rank sum test. 
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3.2.5. Gene expression profiles in BCG-immunised infants, and associations with 
maternal LTBI and maternal BCG scar. 
To assess the associations between maternal LTBI and maternal BCG scar and their 
infants’ immune responses in a more unbiased way, gene expression analysis by 
microarray was used. Unstimulated whole blood obtained from 42 and 51 infants at one 
and six weeks post-BCG immunisation, respectively, were sent to VGTI for RNA 
extraction and gene expression microarray. 
 
This analysis aimed to further examine the associations observed (and perhaps pathways 
involved) with the innate immune responses using the Luminex® assay. Gene 
expression profiles in the infants of mothers with and without LTBI, and those of 
mothers with and without a BCG scar were compared. 
3.2.5.1. Participant characteristics 
Of the mothers considered for gene expression microarray, 21 had a LTBI and 38 had a 
BCG scar. Mothers with and without a BCG scar were comparable in terms of LTBI 
(26% versus 41%, p=0.26), age (24 years versus 25 years, p=0.34), gravidity status 
(39% versus 45% primigravida, p=0.78). Their infants were comparable in terms of 
birth weight (3.24 versus 3.21, p=0.77) and male gender (40% versus 47%, p=0.77)  
(Table 3.12).   
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Table 3.12. Characteristics of participants for gene expression profiling, by maternal 
BCG scar status. 
 
 
Characteristics of 
mothers and infants 
 
BCG Scar 
present (n=38) 
 
BCG Scar 
absent (n=22) 
 
 
P-value 
 
Mothers 
 
Age, mean (years) 
 
24 
 
25 
 
0.39 
Latent TBI status,  
Present, no (%) 
 
10 (26) 
 
9 (41) 
 
0.26 
Gravidity,  
Primigravida, no (%) 
 
14 (39) 
 
10 (45) 
 
0.78 
 
Infants 
Sex,  
Male, no (%) 
 
14 (40) 
 
8 (47) 
 
0.77 
 
Mean birth weight (Kg) 
 
3.24 
 
3.21 
 
0.77 
 
The figures are given as numbers with percentage (%) in brackets, or as mean values. P 
value is based on an unmatched t test for differences in maternal age and infant birth 
weight, and a two-sided Fisher’s exact test for differences in maternal LTBI, gravidity 
status and infant gender between scar-positive and scar-negative groups.  
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3.2.5.2. Associations between maternal LTBI and maternal BCG and gene 
expression profiles in infancy 
Infants of mothers with LTBI, compared to those of mothers without LTBI, had down-
regulated interferon (IFN-α, IFN-γ), and inflammatory response (TNF-α, IL-6 
JAK/STAT3) pathways one week after BCG immunisation. In total, the following 
additional genes were down-regulated: IL-1β, NAMPT, CCL2, GOS2, DUSP1, 
GADD45B, STAT1, JUNB, FOS, FOSB, PTGS2, TNFA1P3, PARP9, AQP9, ADM, 
TNFSF15, IL-8, RGS1, IRF7, IFIT2, HLA-A, IFIT1, ZBP1, IFI44, UBE2L6, TRIM25, 
IFI44L, MX1, OASL, ISG15, IFIT3 (Figure 3.14A). Six weeks post immunisation, 
interferons (IFN-α, IFN-γ), IL-2/STAT5, MTORC1 and inflammatory response (TNF-
α, IL-6 JAK/STAT3) pathways were up-regulated in infants of mothers with LTBI 
compared to infants of mothers without LTBI. In total, the following additional genes 
were up-regulated: IRF1, CXCL10, PLEK, MARCKS, IL-13RA1, LY6E, EIF2AK2, 
IFITM1, PARP9, OAS1, STAT2, IFITM3, SAMD9L, EPST11, IFITM2, IFI27, 
UBE2L6, IFI44, IFI35, OASL, PRIC285, RSAD2, IFIT3, ISG15, MX1, IFI44L, ZBP1, 
FCGR1A, MT2A, OAS2, IFIT1, MX2, TNFA1P6, IFIT2, TAP1, IRF7, PSMB9, 
SERPING1, HLA-DQA1, STAT1, WARS, GBP2 (Figure 3.14B).  
 
In contrast, the interferons (IFN-α, IFN-γ) and inflammatory response (IL-6 
JAK/STAT3) pathways were both up-regulated in infants of mothers with a BCG scar 
at one (Figure 3.15A and Figure 3.16) and six (Figure 3.15B and Figure 3.17) weeks 
after BCG immunisation. DNA replication (E2F targets) and cell cycle progression 
(G2M checkpoint) pathways were also up-regulated in infants of mothers with a BCG 
scar at one week (Figure 3.15A). The following additional genes were up-regulated at 
one week after BCG: RPAI, PNN, RANBP1, ABCE1, RPS6, HSPD1, EEF1B2, 
HNRNPA261, B2M, IFI27, IFI44, SP110, IFI44L, ISG15, PNPT1, OAS3, HLA-G, 
CCL2, XAF1, CD69, PTGS2, HMGN2 (Figure 3.15A). At six weeks after BCG 
immunisation, the following genes were up-regulated: SAMD9, NUB1, FAM46A, 
PARP9, OAS1, IFITM1, LAMP3, STA2, STAT1, CD38, SERPING1, FCGR1A, ZBP1, 
XAF, MX2, OAS2, MT2A, OAS3, IFIT1, HLA-DRB1, FTSJD2, TAP1, TRAFD1, 
ISG20, ADAR, UBE2L6, WARS, DDX60, HERC6, IFI35, PRIC285, SAMD9L, 
PARP14, LAP3, EPST11, OASL, MX1, RSAD2, IFI44, IFI44L, IFIT2, ISG15, IFIT3, 
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CASP3, PLSCR1, IFITM3, GBP4, TNFSF10, AHR, CYBB, CXCL10, IRF1, 
EIF2AK2, BST2, LY6E, IRF7 (Figure 3.15B). 
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Figure 3.14. Gene Set Enrichment Analysis for the comparison of gene expression in infants of mothers with and without LTBI. The 
checkerboard maps show the top enriched pathways on the y-axis and top leading edge genes (gene members contributing most to the 
enrichment score) on the x-axis for infant samples collected at one (A) and six (B) weeks after BCG immunisation.  The scale at the right 
represents the gene expression fold change (log2 (exposed/unexposed)). Red and blue indicate genes that are up-and down-regulated, 
respectively, among infants of mothers with LTBI. Interferon and inflammation response pathways were up regulated in infants of mothers with 
LTBI at six weeks. FDR adjusted p-value cut off of < 0.25 was applied for pathways significance. 
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Figure 3.15. Gene Set Enrichment Analysis for the comparison of gene expression in infants of mothers with and without a BCG scar. 
The checkerboard maps show top enriched pathways on the y-axis and top leading edge genes (gene members contributing most to the 
enrichment score) on the x-axis for infant samples collected at one (A) and six (B) weeks after BCG immunisation.  The scale at the right 
represents the gene expression fold change (log2 (scar+/scar-). Red and blue indicate genes that are up-and down-regulated, respectively, among 
infants of scar-positive mothers. Interferon and inflammation response pathways are up regulated in infants of mothers with a BCG scar at one 
and six weeks after BCG immunisation. FDR adjusted p-value cut off of < 0.25 was applied for pathways significance.
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Figure 3.16. Heatmap showing the level of expression of the differentially expressed genes between infants of mothers with and without a 
BCG scar measured at one week post-BCG immunisation. The genes selected are the top significantly differentially expressed genes selected 
on fold change (1.3 fold up- or down- regulation) and p value (p<0.05) basis. The colour scale shows the level of gene expression (scaled across 
infants) using z score, where red and green correspond to up- and down-regulation, respectively. 
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Figure 3.17. Heatmap showing the level of expression of the differentially expressed genes between infants of mothers with and without a 
BCG scar measured at six weeks post-BCG immunisation. The genes selected are the top significantly differentially expressed genes selected 
on fold change (1.3 fold up- or down- regulation) and p value (p<0.05) basis. The colour scale shows the level of gene expression (scaled across 
infants) using z score, where red and green correspond to up- and down-regulation, respectively.  
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3.3. Discussion 
This work was part of a larger consortium to dissect the immunological interplay 
between poverty-related diseases and helminth infections. The panel of cytokines and 
chemokines studied was not selected specifically for this piece of work, but the focus 
was on innate responses (including IFN-γ responses) (expected to be detectable at 24 
hours of stimulation) using stimuli known to interact with innate receptors. Innate cells 
(such as innate lymphoid cells (group 1 and group 2)) are known to produce these 
cytokines and would certainly contribute within the 24-hour period. 
 
It was hypothesized that maternal LTBI would affect the innate infant responses pre- 
and post-BCG immunisation, but this was not found to be the case for innate responses 
measured in culture supernatants after stimulation of cord blood (pre-BCG). However, 
maternal BCG scar did show a stronger association with infant responses in cord blood, 
with an increased proinflammatory immune profile.  
 
Post-BCG immunisation, both maternal LTBI and maternal BCG scar showed 
associations with gene expression profiles in the infants. 
 
Overall, the concentrations of pro-inflammatory and immunoregulatory cytokines, and 
chemokines were high in both the stimulated maternal post-delivery blood collected on 
average one week post-delivery, and the stimulated infant cord blood. Neonates have 
been shown to demonstrate adult-like concentrations of certain cytokines and 
chemokines soon after birth (337). This is attributed to the effect of the birth process 
(such as increased acute phase responses in normal delivery process) (334) or due to in 
utero sensitization to maternal infections (287). 
 
The concentrations of proinflammatory cytokines measured in cord blood in response to 
stimulation with innate stimuli using the Luminex® assay were increased in infants of 
mothers with a BCG scar. The expression of genes in the interferon and inflammation 
response pathways measured using gene transcription microarray was also increased in 
infants of mothers with LTBI at six weeks post BCG immunisation, and in infants of 
mothers with a BCG scar at one and six weeks after BCG immunisation. This unbiased 
approach showed the same general trend as the infant cytokine data where pro-
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inflammatory responses were increased in infants of mothers with a BCG scar, and that 
infants of mothers with a BCG scar, in general, clustered together and those of mothers 
without clustered differently. 
 
Innate immune responses may determine how effective adaptive responses are (336) 
and lead to either biased (338) or regulatory immune profiles (299, 301, 339). The 
increased responses reported here may therefore impact on immune responses to 
vaccines given at birth and on the course of infection and disease in childhood.  
There were no associations between the mothers’ own innate immune responses and 
maternal BCG scar; associations were only observed in the infants. The presence of a 
maternal BCG scar was used as an indicator of BCG immunisation of a mother during 
infancy. Positive associations between IFN-γ responses and reactions at the site of BCG 
immunisation have previously been reported (340, 341), and in other studies the 
presence of a scar has been shown to be associated with protection against LTBI (281, 
282). Scar might therefore be a good measure of protective immune responses. 
However, it is difficult to reconcile how a response to a vaccine administered to mothers 
in their infancy would exert its effects decades later in the offspring. It is possible that 
there may be common genetic factors between the mothers and their infants that 
determine scar formation and subsequent responses in the infants, or that the factors 
associated with scar formation in the mothers are transmitted to the infants. The lack of 
association between maternal BCG scar and the mother’s own responses could be 
attributed to cumulative life-time exposures that alter the initial maternal innate immune 
responses after BCG immunisation. We did not collect data on scarring in these infants, 
but the ongoing main infant BCG study (Chapter 4.0) with a longer follow up provides 
the opportunity to assess relationships between scarring and immune responses in 
mothers and their infants. 
 
The development of a scar is also dependent upon the strain, dose and method of 
administration of the BCG vaccine (342). The Danish strain of BCG vaccine, compared 
to BCG Russia, has been shown to elicit stronger responses in infants one year later and 
to cause more scarring (244, 277-279, 343), and the intradermal route of administration 
is associated with the formation of distinctive scars (344, 345). We were unable to 
ascertain the strain of the vaccine the women received in infancy, although the most 
common strain currently in use in Uganda is BCG Russia. Since BCG immunisation is 
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administered in the neonatal period, it is difficult to obtain information about BCG 
immunisation status of adults in a country where hospitals do not routinely record 
vaccine strain. There is therefore the possibility of misclassification of women based on 
the presence or absence of a scar. It is possible that the scar-negative women may have 
been BCG vaccinated without developing a scar, or that scars were lost with time. Scar 
formation has also been reported to depend on the way the vaccine is handled and 
delivered, and the period within which the vaccine is administered (better scar 
formation when the vaccine is given over 3 months of age, versus within a month after 
birth) (274). In infants, scars have been reported to be poor indicators of BCG 
immunisation (346). Our observed differences in infant response may therefore relate 
either to the mother’s BCG immunisation status or to the quality of the mother’s 
response to BCG immunisation. 
 
Previous studies have reported the presence (347-349) or absence (350) of maternal 
cells in cord blood samples. It is therefore possible that the high proinflammatory 
response observed in cord blood could be due to responses from maternal cells in cord 
blood, but the method we used for collecting cord blood (by needle and syringe, with no 
“milking” of the cord, coupled with the use of trained midwives, see section 2.1.5.3) 
should have minimized contamination. Previous tests carried out on maternal and cord 
blood samples in our studies (comparing levels of β-human chorionic gonadotropin) 
showed that contamination of cord blood by maternal blood was rare (unpublished 
data).   
 
Interferon and inflammatory pathways were down-regulated in infants of mothers with 
LTBI at one week, but up-regulated at six weeks after BCG immunisation; this offers 
some support to the hypothesis that prenatal exposure to maternal LTBI modifies the 
infant response to BCG, but the change in direction of effect as the immune response 
matured was unexpected, and these findings would need to be confirmed in a larger 
study. Up- and down -regulation of genes following BCG immunisation of infants has 
previously been reported (238). A recent study by Zak and colleagues identified 
tuberculosis risk signature genes (351), some of which have also been identified in the 
pilot infant BCG study (GBP4, STAT1, TAP1, TRAFD1, GBP2, FCGRIA and 
SERPINGI). Some of the interferon response genes such as GBP1, STAT1, and TAP1 
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have protective roles in TB disease, highlighting the need to further understand the role 
of interferon and inflammation responses in immunity to TB. 
 
Limitations of the study were its observational and explorative nature, and its small 
sample size relative to the many outcomes assessed. Maternal and infant factors such as 
maternal age, gravidity status, infant birth weight and gender were not adjusted for since 
these were not crudely associated with infant responses, and the numbers involved were 
generally small. Given the large number of statistical tests performed (or comparisons 
made), there is a chance of false positive findings, and statistically significant results 
should be interpreted with caution. 
 
In summary, maternal BCG scar had a stronger association with innate infant responses 
than maternal LTBI, with an increased pro-inflammatory profile of immune responses. 
The mechanisms that underlie this association need to be further examined in a larger 
study.  
 
Having shown that maternal LTBI is not associated with infant innate immune 
responses pre-BCG immunisation, but that there is some association with gene 
expression profiles in the infants post-BCG immunisation, and that maternal BCG scar 
is associated with infant responses pre-and post-BCG immunisation, the next chapter 
reports results for T cell responses in infancy and the effect of maternal LTBI on infant 
responses to BCG immunisation.  
 
The pilot infant BCG study generated interesting results and many lessons were learnt. 
The study proceedures (for example cord blood collection), including appointment 
visits, used in the main infant BCG study were optimized in the pilot infant BCG study. 
Learning from the pilot infant BCG study, infant samples were collected at all time 
points in RNALater solution for further investigation of gene expression profiles.  
 
Further analysis of the innate immune responses in infancy was not investigated in the 
main infant BCG study whose results are presented later, but in a “sister” project that 
investivated the nonspecific effects of BCG immunisation (352).  Analysis of the results 
of this study is still on hold as the principal investigator is on maternity leave.  
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Figure 3.14. illustrates one of the preliminary results from the pilot infant BCG study 
that was used in the grant application for the main infant BCG study. The results 
showed that infants of mothers with a LTBI produced more TNF-α than infants of 
mothers without such exposures, highlighting the importance of investigating, in a 
larger study, the impact of maternal LTBI on the infant responses to BCG immunisation. 
The flow cytometry assays for the main infant BCG study have been completed and 
analysis is underway.  
 
 
 
Figure 3.18. Flow cytometry of SEB-stimulated cells from the blood of infants one 
week post birth. Panels on left hand side are from an infant of a mother without LTBI, 
panels on right hand side are from an infant of a mother with LTBI.  Infants of mothers 
with LTBI produced more TNF-α. 
 
 
 
 
No LTBI LTBI 
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Chapter 4 
T cell immune responses in BCG vaccinated infants  
4.1. Introduction 
BCG is the only vaccine against TB currently available. There is little information about 
the peak immune response in infants following BCG immunisation, yet this knowledge 
is needed for the design and use of vaccines aimed at prime-boost strategies (251). It 
was proposed that maternal infection with M. tuberculosis, which is endemic in this 
setting, may result in the poor effectiveness of BCG in the tropics, If maternal M. 
tuberculosis infection impacts on the infant response to BCG, the timing, magnitude, or 
quality of the BCG-indiced immune response may be modified in infants of M. 
tuberculosis-infected women compared to those without. This may result in a delayed 
peak in response to BCG immunisation, or a lower overall recruitment of cells in the 
priming phase following BCG immunisation, leading to a lower set point of BCG-
specific immunological memory, and as differences in the effector response profile. The 
timing and magnitude of the peak immune response in BCG vaccinated infants was 
investigated. Previous studies had looked at the earliest sampling time point only up 
to three months post-immunisation (353). Other published studies have examined 
early post-immunisation time points in adolescents and adults (354, 355), but not the 
earliest stages of the immune response to BCG in human infants. This is important 
since the size of the pool of cells recruited into the primary immune response directly 
affects the resulting pool of memory T-cells capable of responding to subsequent 
infection (356). Thus, understanding the time course and peak response to BCG 
immunisation in infants is important in understanding the poor efficacy of BCG in 
the tropics.  
 
 
The protective efficacy of BCG against TB varies between populations, and latitude has 
been suggested to explain this variation for adolescents and adults (290, 293, 297). It is 
thought that sensitisation to NTM, which is more common in lower latitudes (302) 
modifies the protection induced by BCG (303).   
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In Uganda, up to 49% of adults are reported to have LTBI (29). Maternal LTBI might, 
in the same way as NTM, lead to exposure to mycobacterial antigens in utero and the 
development of a modified profile of response to mycobacteria after birth (287). For 
example the passive transfer of maternal anti-mycobacterial antibodies might interfere 
with development of the BCG “infection” required to elicit protective immunity. Or, 
maternal infection could influence the maternal and placental immunological milieu, 
and hence the fetal and neonatal response on exposure to immunisation (357). 
 
 
It has therefore been proposed that maternal LTBI influences the neonatal response to 
BCG (and to M. tuberculosis), resulting in less effective response to BCG.   
Here I report T-cell response results from a published article titled “The impact of 
maternal infection with Mycobacterium tuberculosis on the infant response to bacille 
Calmette-Guérin immunisation”. Mawa, P.A., Nkurunungi, G., Egesa, M., Webb, E.L., 
Smith, S.G., Kizindo, R., Akello, M., Lule, S.A., Muwanga, M., Dockrell, H.M., Cose, 
S., Elliott, A.M. Philos Trans R Soc Lond B Biol Sci. 2015 Jun 19; 370 (1671)” (326) 
(Appendix S), and results from additional work from a larger ongoing infant BCG 
study. 
 
After describing the socio-demographic and clinical characteristics of the study 
participants in the pilot infant BCG study, results from PPD-specific CD4+ and CD8+ T 
cell responses, measured by intracellular cytokine staining and flow cytometry, are 
presented. These experiments were designed to identify optimal time points for the main 
infant BCG study (whose results will be presented later in this Chapter, section 4.3), 
and to investigate whether LTBI infection in the mothers would influence how their 
infants’ T cells respond to BCG vaccination.  
The specific objectives of this include: 
 
1. To analyse the longitudinal changes in frequencies of PPD-specific CD4+ and 
CD8+ T cells in infancy. 
2. To examine the impact of maternal infection with M. tuberculosis on PPD-
specific CD4+ and CD8+ T cell responses in infancy. 
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4.2. Results for the pilot infant BCG study 
4.2.1. Demographic and clinical characteristics of the participants 
The socio-demographic and clinical characteristics of the study participants have been 
described in Chapter 3.0, section 3.2.1. For the participants included in this analysis, 
mothers with LTBI, compared to those without LTBI, were older (mean age 27.5 versus 
23 years, p=0.002), less likely to have a BCG scar (47% versus 70%, p =0.001) and less 
likely to be primigravida (32% versus 48%, p=0.001), and their children were more 
likely to be of male gender (53% versus 35%, p=0.001) (Table 4.1). 
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Table 4.1. Demographic and clinical characteristics of the mothers and their infants 
used for analysis of T cell responses in the pilot infant BCG study. 
 
Characteristics of 
mothers and infants 
Mothers without 
LTBI 
(n=50) 
Mothers with 
LTBI 
(n=21) 
 
 
p-value 
 
Maternal factors 
 
 
BCG scar present, no (%) 
 
35 (70) 
 
9 (47) 
 
<0.001 
 
Maternal age, years, mean 
 
23.0 
 
27 
 
0.002 
 
Primigravida, no (%) 
 
24 (48) 
 
6 (32) 
 
<0.001 
 
Infant factors 
 
 
 
Male gender, no (%) 
 
17 (35) 
 
10 (53) 
 
<0.001 
 
Birth weight (Kg) 
 
3.2 
 
3.4 
 
0.09 
 
 
The figures are given as numbers with percentage (%) in brackets, or as mean values. P 
value is based on unmatched t test for differences in maternal age and infant birth 
weight, and a two-sided Fisher’s exact test for differences in maternal LTBI, gravidity 
and infant gender between LTBI-positive and LTBI-negative groups.  
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4.2.2. Longitudinal changes in frequencies of cytokine-expressing PPD-specific 
CD4+ and CD8+ T cells in the pilot infant BCG study 
To assess changes in frequencies of PPD-specific CD4+ and CD8+ T cells expressing 
cytokines, mononuclear cells from cord blood, and from infant samples obtained at one 
and six weeks after BCG immunisation were stimulated overnight with PPD, and 
cytokine expression was measured by intracellular cytokine staining and flow 
cytometry. Thirty-one samples were assayed at each time point, 17 from infants of 
mothers without LTBI and 14 from infants of mothers with LTBI. The gating strategy is 
illustrated in Figure 2.8 in the Methods Chapter. 
 
Compared to responses in cord blood, the frequency of PPD-specific IFN-γ+ CD4+ T 
cells increased at one week and decreased at six weeks after birth. There was a 
statistically significant difference between frequencies at one and six weeks after birth 
(p=0.031). The frequencies of cells expressing IL-2 and TNF-α were, by contrast, 
higher at six weeks compared to one week (p=0.018 and p=0.009, respectively; Figure 
4.1A). 
 
The frequencies of PPD-specific CD8+ T cells making any of the three cytokines 
assessed were higher in cord blood compared to six weeks (p=0.044), and higher at one 
week compared to six weeks (p=0.003; Figure 4.1B). 
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                     %IFN-γ+ T cells                            %IL-2+ T cells                                %TNF-α+ T cells                  %Total Cytokine+ T cells 
A 
B 
 
Figure 4.1. Longitudinal changes in frequencies of PPD-specific cytokine expressing T-cells during the first six weeks of life measured by 
intracellular cytokine staining and flow cytometry. Each symbol represents an individual, and for each plot the horizontal line represents the 
median. Frequencies of PPD-specific, total IFN-γ+, total IL-2+, total TNF-α+, or total cytokine+ (IFN-γ+ or IL-2+ or TNF-α+) CD4+ (A) and 
CD8+ (B) T cells are shown. Statistical analysis was performed using Wilcoxon matched-pairs signed rank test. n=31 for all time points. 
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4.2.3. Impact of maternal LTBI on PPD-specific immune responses in infancy 
In the previous section, longitudinal infant response to PPD over time was shown.  Here 
I now show whether these responses differ according to maternal LTBI status. Cytokine 
expression in cord blood and in infant blood samples obtained at one and six weeks 
after birth were tested to assess the effect of maternal LTBI. There were no differences 
in frequencies of T cells expressing any cytokines in cord blood in samples from infants 
of mothers with and without LTBI (Table 4.2).  
 
In a crude analysis, maternal LTBI was associated with lower frequencies of CD4+ T 
cells expressing PPD-specific IFN-γ (crude geometric mean ratio (cGMR) (95% 
confidence interval (CI)) 0.89 (0.83, 0.98), Table 4.2, Figure 4.2A), TNF-α (cGMR) 
(95% CI 0.98 (0.95, 0.99) and of CD4+ T cells expressing any of the three cytokines 
assessed, combined (cGMR) (95% CI 0.89 (0.81, 0.95), Table 4.2, Figure 4.2D) at one 
week after BCG immunisation. 
 
Seven infants had samples with less than 5000 events acquired (12 out of 93 samples 
that were analysed), and were subsequently excluded. The exclusion of these infant 
samples from the analysis weakened the association between maternal LTBI and lower 
frequencies of CD4+ T cells expressing PPD-specific IFN-γ at one week after birth 
(p=0.068), but that of TNF-α was strengthened (p=0.045) (data not shown). There was 
therefore an overall maintenance of the evidence for an association between maternal 
LTBI and infant Th1 responses. 
 
After adjusting for maternal age, maternal gravidity and infant gender in multivariate 
analyses (incorporating all samples), the association between maternal LTBI and 
frequencies of CD4+ T cells expressing IFN-γ one week after BCG immunisation was 
weaker than in the crude analysis (adjusted geometric mean ratio (aGMR) (95% 
confidence interval (CI)) 0.94 (0.85, 1.04), but the association with a reduced frequency 
of CD4+ T cells expressing TNF-α became stronger (0.97 (0.95, 0.99)), and the 
association with reduced frequencies of PPD-specific CD4+ T cells expressing any of 
the three cytokines, combined, remained strong (aGMR, 95% CI 0.91 (0.83, 0.99)) 
Table 4.4A. 
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For CD8+ T cells, cord blood samples obtained from infants of mothers with LTBI, 
compared to those without LTBI, showed a weak trend towards higher T-cell responses 
for TNF-α (p=0.067, Figure 4.3C), and for all cytokines, combined. At one week after 
BCG immunisation, in univariate analyses, maternal LTBI was weakly associated with 
lower frequencies of CD8+ T cells expressing PPD-specific IFN-γ (p=0.073, Figure 
4.3A). 
In multivariate analyses incorporating all samples, after adjusting for maternal and 
infant factors mentioned above, there was a weak association between maternal LTBI 
and low frequencies of PPD-specific CD8+ T cells at one week (aGMR , 95% CI 0.96 
(0.91, 1.01)) Table 4.4B.  
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Table 4.2. Crude associations between maternal and infant factors and infant CD4+ T 
cell response to PPD 
 
Cord blood 
Factor IFN-γ IL-2 TNF-α Total cytokines 
Maternal LTBI 0.98 (0.93, 1.02) 1.00 (0.99, 1.02) 1.02 (0.95, 1.07) 0.99 (0.91, 1.07) 
Maternal age 1.05 (1.02, 1.10) 1.02 (1.01, 1.02) 1.05 (0.99, 1.07) 1.10 (1.02, 1.15) 
BCG Scar 1.00 (0.93, 1.07) 1.01 (0.99, 1.02) 0.98 (0.93, 1.01) 0.98 (0.91, 1.07) 
Gravidity 0.99 (0.93, 1.05) 0.99 (0.98, 1.01) 1.02 (0.98, 1.07) 1.01 (0.93, 1.10) 
Infant gender 1.02 (0.95, 1.07) 0.99 (0.98, 1.00) 1.00 (0.95, 1.07) 1.00 (0.91, 1.07) 
Birth weight 0.98 (0.93, 1.02) 1.00 (0.98, 1.02) 1.02 (0.91, 1.05) 1.02 (0.89, 1.17) 
 
1 week after BCG immunisation.  
Factor IFN-γ IL-2 TNF-α Total cytokines 
Maternal LTBI 0.89 (0.83, 0.98) 1.00 (0.98, 1.01) 0.98 (0.95, 0.99) 0.89 (0.81, 0.95) 
Maternal age 0.91 (0.81, 1.05) 1.01 (1.00, 1.02) 1.01 (0.98, 1.02) 0.95 (0.85, 1.07) 
BCG Scar 0.98 (0.89, 1.05) 1.00 (0.99, 1.02) 1.00 (0.98, 1.02) 0.95 (0.89, 1.02) 
Gravidity 1.02 (0.95, 1.10) 1.00 (0.98, 1.01) 1.00 (0.98, 1.02) 1.02 (0.95, 1.10) 
Infant gender 0.98 (0.87, 1.07) 1.00 (0.99, 1.02) 1.01 (0.99, 1.02) 0.98 (0.89, 1.07) 
Birth weight 1.05 (0.91, 1.17) 0.99 (0.98, 1.00) 0.98 (0.95, 1.00) 0.98 (0.87, 1.10) 
 
6 weeks after BCG immunisation. 
Factor IFN-γ IL-2 TNF-α Total cytokines 
Maternal LTBI 0.99 (0.93, 1.07) 1.02 (0.99, 1.05) 1.02 (0.98, 1.07) 1.02 (0.93, 1.10) 
Maternal age 0.98 (0.93, 1.05) 1.02 (0.98, 1.05) 1.02 (0.98, 1.07) 1.05 (0.95, 1.12) 
BCG Scar 1.02 (0.98, 1.05) 1.00 (0.98, 1.02) 0.99 (0.93, 1.05) 1.00 (0.93, 1.07) 
Gravidity 1.02 (0.98, 1.07) 0.98 (0.95, 1.02) 0.95 (0.91, 1.01) 0.98 (0.89, 1.07) 
Infant gender 0.99 (0.95, 1.02) 0.99 (0.95, 1.02) 1.00 (0.95, 1.05) 1.01 (0.93, 1.10) 
Birth weight 0.99 (0.91, 1.07) 1.00 (0.95, 1.05) 0.98 (0.91, 1.05) 0.95 (0.87, 1.07) 
 
Data are crude GMR and 95% CI for 31 infants at all the time points. Linear regression 
with bootstrapping was used for analysis. Confidence intervals not including one (1) are 
highlighted in bold.   
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Table 4.3. Crude associations between maternal and infant factors and infant CD8+ T 
cell response to PPD 
 
Cord blood 
Factor IFN-γ IL-2 TNF-α Total cytokines 
Maternal LTBI 1.00 (0.93, 1.07) 1.00 (0.93, 1.07) 1.05 (0.95, 1.15) 1.05 (0.95, 1.15) 
Maternal age 0.95 (0.87, 1.05) 1.05 (1.01, 1.10) 1.05 (1.00, 1.10) 1.05 (0.95, 1.15) 
BCG Scar 1.07 (0.98, 1.15) 1.05 (0.95, 1.12) 1.02 (0.93, 1.15) 1.10 (0.98, 1.20) 
Gravidity 0.93 (0.89, 1.00) 0.98 (0.91, 1.05) 0.98 (0.89, 1.07) 0.98 (0.89, 1.07) 
Infant gender 0.95 (0.89, 1.02) 1.05 (0.98, 1.10) 0.98 (0.91, 1.05) 0.98 (0.89, 1.07) 
Birth weight 0.95 (0.89, 1.05) 0.99 (0.89, 1.10) 0.98 (0.89, 1.05) 0.98 (0.85, 1.10) 
 
1 week after BCG immunisation.  
Factor IFN-γ IL-2 TNF-α Total cytokines 
Maternal LTBI 0.95 (0.89, 1.00) 1.01 (0.98, 1.05) 0.99 (0.91, 1.07) 0.98 (0.87, 1.07) 
Maternal age 1.00 (0.95, 1.07) 1.02 (1.00, 1.05) 1.07 (1.01, 1.15) 1.07 (0.98, 1.17) 
BCG Scar 0.98 (0.93, 1.05) 0.98 (0.95, 1.00) 0.95 (0.89, 1.00) 0.91 (0.83, 1.00) 
Gravidity 0.95 (0.91, 1.02) 1.02 (0.99, 1.07) 1.07 (1.00, 1.15) 1.07 (0.98, 1.20) 
Infant gender 0.98 (0.91, 1.05) 1.01 (0.98, 1.05) 1.02 (0.95, 1.10) 1.01 (0.91, 1.12) 
Birth weight 1.02 (0.95, 1.07) 1.01 (0.98, 1.05) 1.02 (0.95, 1.12) 1.10 (0.99, 1.23) 
 
6 weeks after BCG immunisation. 
Factor IFN-γ IL-2 TNF-α Total cytokines 
Maternal LTBI 0.99 (0.95, 1.02) 0.98 (0.93, 1.01) 1.02 (0.93, 1.10) 0.98 (0.91, 1.05) 
Maternal age 0.99 (0.93, 1.05) 1.00 (0.95, 1.05) 1.05 (0.98, 1.12) 1.05 (0.99, 1.10) 
BCG Scar 1.00 (0.98, 1.05) 1.05 (0.99, 1.10) 0.99 (0.93, 1.05) 1.02 (0.95, 1.10) 
Gravidity 1.00 (0.98, 1.05) 0.98 (0.93, 1.02) 1.05 (0.98, 1.12) 1.01 (0.93, 1.10) 
Infant gender 1.01 (0.98, 1.05) 1.01 (0.98, 1.05) 1.07 (1.00, 1.05) 1.07 (1.01, 1.12) 
Birth weight 0.98 (0.93, 1.02) 0.99 (0.95, 1.05) 0.93 (0.85, 1.00) 0.95 (0.87, 1.02) 
 
Data are crude GMR and 95% CI for 31 infants at all the time points. Linear regression 
with bootstrapping was used for analysis. Confidence intervals not including one (1) are 
highlighted in bold.  
  
 
 124 
                   Cord blood                   1 week post BCG              6 weeks post BCG 
A 
 
 
B 
 
 
C 
 
D 
 
 
Figure 4.2. The effect of maternal latent M. tuberculosis infection on frequencies of 
CD4+ T cells. Frequencies of PPD-specific IFN-γ+ (A), IL-2+ (B), TNF-α+ (C) and total 
cytokine
+
 (D) cells in cord blood and infant samples obtained at one and six weeks after 
BCG immunisation, comparing infants of mothers with and without LTBI. Statistical 
analysis was performed using Mann-Whitney test. n=14 and 17 for infants of mothers 
with and without LTBI, respectively. 
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Figure 4.3. The effect of maternal latent M. tuberculosis infection on frequencies of 
CD8+ T cells. Frequencies of PPD-specific IFN-γ+ (A), IL-2+ (B), TNF-α+ (C) and total 
cytokine
+
 (D) cells in cord blood, and infant samples obtained at 1 and 6 weeks post 
BCG immunisation, comparing infants of mothers with and without LTBI. Statistical 
analysis was performed using Mann-Whitney test. n=14 and 17 for infants of mothers 
with and without LTBI, respectively. 
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Table 4.4. Associations between frequencies of cytokine-expressing T cells and 
maternal LTBI. 
A. CD4+ T cells 
 
Cytokine/time point *Adjusted GMR  
Cord blood  
IFN-γ 0.96 (0.89, 1.05) 
TNF-α 0.99 (0.92, 1.07) 
IL-2 1.01 (0.99, 1.02) 
Total 0.97 (0.88, 1.07) 
1 week after BCG immunisation 
IFN-γ 0.94 (0.85, 1.04) 
TNF-α 0.97 (0.95, 0.99) 
IL-2 1.00 (0.98, 1.02) 
Total 0.91 (0.83, 0.99) 
6 weeks after BCG immunisation 
IFN-γ 1.02 (0.92, 1.13) 
TNF-α 1.04 (0.97, 1.11) 
IL-2 1.03 (0.99, 1.07) 
Total 1.04 (0.90, 1.20) 
 
B. CD8+ T cells 
 
Cytokine/time point *Adjusted GMR 
Cord blood 
IFN-γ 1.03 (0.97, 1.10) 
TNF-α 1.02 (0.96, 1.08) 
IL-2 1.02 (0.93, 1.11) 
Total 1.05 (0.94, 1.18) 
1 week after BCG immunisation 
IFN-γ 0.96 (0.91, 1.01) 
TNF-α 0.97 (0.88, 1.07) 
IL-2 1.02 (0.97, 1.07) 
Total 0.95 (0.83, 1.09) 
6 weeks after BCG immunisation 
IFN-γ 1.00 (0.95, 1.05) 
TNF-α 1.05 (0.93, 1.17) 
IL-2 0.97 (0.91, 1.03) 
Total 0.98 (0.88, 1.08) 
 
 
Data are aGMR and 95% CI for 31 infants at all the time points. Linear regression with 
bootstrapping was used for analysis. Confidence intervals not including one (1) are 
highlighted in bold.  *Adjusted for maternal age, parity and infant gender. 
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4.3. Results for the main infant BCG study 
The pilot infant BCG study gave some very interesting data on innate and (short term) 
adaptive responses, but was limited in scope and follow up.  Nevertheless, this data was 
used to apply for, and successfully obtain, funding to conduct a larger study (described 
here and in Chapter 5.0) with a longer follow up, principally to identify the peak 
response to BCG immunisation and the influence of maternal LTBI on the infant 
response to BCG. Infants were followed up from birth to one year of age. 
 
The timing and magnitude of the initial response to BCG immunisation, as well as 
comparison of responses in infants of mothers with and without LTBI are presented.  
The longitudinal changes in infant responses to PPD and ESAT-6/CFP-10 after 6-day 
stimulation of cord blood and infant samples obtained at 1, 4, 6, 10, 24 and 52 weeks 
post-BCG immunisation are presented. After a descriptive presentation of the socio-
demographic and clinical characteristics of the participants, results from the analysis of 
responses to PPD and ESAT-6/CFP-10 are presented. The specific objectives were: 
1. To analyse cytokines and chemokines in unstimulated samples, and in samples 
stimulated with PPD, ESAT-6/CFP-10 and PHA.  
2. To assess longitudinal infant responses to PPD and ESAT-6/CFP-10 with age. 
3. To examine the correlations in concentrations of individual cytokines and 
chemokines. 
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4.3.1. Participant characteristics for the main infant BCG study 
Between June 2014 and September 2015, 1176 women were approached to participate 
in the study and 1124 were screened for LTBI. Of these, 840 were excluded, in most 
cases for discordant T-SPOT.TB and TST test results and since there were more 
mothers who tested negative on both tests than those who tested positive, a systematic 
number of LTBI-negative mothers were recruited to balance numbers recruited and to 
avoid bias. The selection criteria are included in the Methods Chapter (section 2.1.6.1). 
284 mothers were enrolled and their infants were followed up to age one year. Of these, 
134 mothers were identified as LTBI-positive and 150 as LTBI-negative. A number of  
mothers and their infants (182 in total) missed some study appointments (4 at one week, 
10 at 4 weeks, 11 at 6 weeks, 20 at 10 weeks, 71 at 14 weeks and 66 at 24 weeks of 
age). The flow of participants through the study and details of samples for Luminex and 
ELISA assays are shown in Figures 2.12 and 2.13. 
 
For this analysis, infants who had completed follow up to age one year were considered, 
with 55 of them born to mothers with LTBI and 85 born to mothers without LTBI. 
Mothers with and without LTBI were comparable in terms of BCG scar (28.95% versus 
26.10, p=0.836), age (24 years versus 25 years, p=0.100), and gravidity status (33% 
versus 26% primigravida, p=0.750). Their infants were comparable in terms of male 
gender (58% versus 58%, p=1.000) and birth weight (3.19 versus 3.05, p=0.113) (Table 
4.5).   
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 129 
Table 4.5. Demographic and clinical characteristics of participants 
 
 
 
Characteristics of 
mothers and infants 
 
Mothers without 
LTBI 
(n=85) 
 
Mothers with 
LTBI 
(n=55) 
 
 
 
p-value 
 
Maternal factors 
 
 
BCG scar present, no (%) 
 
22 (28.95) 
 
12 (26.10) 
 
0.836 
 
Maternal age, years, mean 
 
24 
 
25 
 
0.100 
 
Primigravida, no (%) 
 
9 (33.33) 
 
5 (26.32) 
 
0.750 
 
Infant factors 
 
 
 
Male gender, no (%) 
 
38 (57.58) 
 
24 (58.54) 
 
1.000 
 
Birth weight (Kg) 
 
3.19 
 
3.05 
 
0.113 
 
The figures are given as numbers with percentage (%) in brackets, or as mean values. P 
value is based on unmatched t test for differences in maternal age and infant birth 
weight, and a two-sided Fisher’s exact test for differences in maternal LTBI, gravidity 
status and infant gender between scar-positive and scar-negative groups.  
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4.3.2. Comparison of cytokine and chemokine concentrations in unstimulated and 
stimulated samples 
The cytokine and chemokine responses were measured by a 17plex Luminex® assay, 
based on data from our collaborators at the LSHTM (Prof. Hazel M. Dockrell’s group) 
(358). Although all of the 17-cytokine datasets were analysed, only a selected few are 
graphically represented for the raw cytokine/chemokine data (without subtraction of 
background responses in unstimulated samples. (Figures 4.4 to 4.11). 
 
The complete dataset for all cytokines/chemokines (after subtraction of background) are 
shown in and Figures 4.12 to 4.14 for responses to PPD and Table 4.7 and Figures 4.15 
to 4.17 for responses to ESAT-6/CFP-10.  
 
In order to assess spontaneous production in unstimulated cultures, compared to that in 
stimulated cultures, cytokine and chemokine concentrations were measured in 
unstimulated samples (medium) (S1), and in samples stimulated with PPD (S2), ESAT-
6/CFP-10 protein (S3) and PHA (S4) for 6 days. The results are presented as raw 
median concentrations (before subtraction of negative control values) and illustrated in 
Figures 4.4 to 4.11. Concentrations of proinflammatory cytokines (represented by IFN-
γ, TNF-α, IL-1α), Th2 (IL-5 and IL-13), chemokines (represented by IP-10 and MIP-
1α) and a growth factor (GM-CSF) are shown. Overall, the median cytokine and 
chemokine concentrations in unstimulated samples were low, except for IL-8, IP-10 and 
MCP-1, where background concentrations were high.  
 
The raw median IFN-γ production was higher in PPD-stimulated samples than in 
ESAT-6/CFP-10-stimulated samples at all time points (Figure 4.4). For TNF-α, the raw 
median responses were overall lower in PPD-stimulated samples than in ESAT-6/CFP-
10-stimulated samples (Figure 4.5). The same pattern was observed for IL-1α (Figure 
4.6) and MIP-1α (Figure 4.10). For Th2 responses, PPD-stimulated cultures produced 
more IL-5 and IL-13 than ESAT-6/CFP-10-stimulated samples (Figures 4.7 and 4.8). 
As expected, the positive control (PHA) showed high responses, indicating that the cells 
in the whole blood cultures were functional and active. 
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                         Cord blood                                1 week post-BCG                            4 weeks post-BCG                             6 weeks post-BCG 
               
                   10 weeks post-BCG                        24 weeks post-BCG                         52 weeks post-BCG 
 
 
Figure 4.4. Changes in concentrations of IFN-γ in unstimulated and stimulated samples with age. Cytokines and chemokines were 
measured in supernatants obtained after 6-day stimulation of cultures with medium alone (unstimulated) (S1),  PPD (S2), ESAT-6/CFP-10- (S3) 
and PHA (S4) using a 17-plex assay. For responses to PPD, n=132 for cord blood, 63 for 1-week visit, 65 for 4-week visit, 57 for 6-week visit, 
62 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. For responses to ESAT-6/CFP-10, n=27 for cord blood, 12 for 1-week visit, 
22 for 4-week visit, 24 for 6-week visit, 34 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. 
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                        Cord blood                                 1 week post-BCG                             4 weeks post-BCG                        6 weeks post-BCG  
 
                 10 weeks post-BCG                        24 weeks post-BCG                         52 weeks post-BCG 
 
Figure 4.5. Changes in concentrations of TNF-α in unstimulated and stimulated samples with age. Cytokines and chemokines were 
measured in supernatants obtained after 6-day stimulation of cultures with medium alone (unstimulated) (S1),  PPD (S2), ESAT-6/CFP-10- (S3) 
and PHA (S4) using a 17-plex assay. For responses to PPD, n=132 for cord blood, 63 for 1-week visit, 65 for 4-week visit, 57 for 6-week visit, 
62 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. For responses to ESAT-6/CFP-10, n=27 for cord blood, 12 for 1-week visit, 
22 for 4-week visit, 24 for 6-week visit, 34 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. 
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                       Cord blood                                  1 week post-BCG                           4 weeks post-BCG                           6 weeks post-BCG 
  
                    10 weeks post-BCG                      24 weeks post-BCG                     52 weeks post-BCG 
 
Figure 4.6. Changes in concentrations of IL-1α in unstimulated and stimulated samples with age. Cytokines and chemokines were 
measured in supernatants obtained after 6-day stimulation of cultures with medium alone (unstimulated) (S1),  PPD (S2), ESAT-6/CFP-10- (S3) 
and PHA (S4) using a 17-plex assay. For responses to PPD, n=132 for cord blood, 63 for 1-week visit, 65 for 4-week visit, 57 for 6-week visit, 
62 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. For responses to ESAT-6/CFP-10, n=27 for cord blood, 12 for 1-week visit, 
22 for 4-week visit, 24 for 6-week visit, 34 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. 
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                        Cord blood                                 1 week post-BCG                          4 weeks post-BCG                            6 weeks post-BCG 
 
               10 weeks post-BCG                         24 weeks post-BCG                         52 weeks post-BCG 
 
Figure 4.7. Changes in concentrations of IL-5 in unstimulated and stimulated samples with age. Cytokines and chemokines were measured 
in supernatants obtained after 6-day stimulation of cultures with medium alone (unstimulated) (S1),  PPD (S2), ESAT-6/CFP-10- (S3) and PHA 
(S4) using a 17-plex assay. For responses to PPD, n=132 for cord blood, 63 for 1-week visit, 65 for 4-week visit, 57 for 6-week visit, 62 for 10-
week visit, 15 for 24-week visit and 103 for 52-week visit. For responses to ESAT-6/CFP-10, n=27 for cord blood, 12 for 1-week visit, 22 for 4-
week visit, 24 for 6-week visit, 34 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. 
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                         Cord blood                                 1 week post-BCG                          4 weeks post-BCG                         6 weeks post-BCG 
 
     
              10 weeks post-BCG                         24 weeks post-BCG                         52 weeks post-BCG 
 
Figure 4.8. Changes in concentrations of IL-13 in unstimulated and stimulated samples with age. Cytokines and chemokines were 
measured in supernatants obtained after 6-day stimulation of cultures with medium alone (unstimulated) (S1),  PPD (S2), ESAT-6/CFP-10- (S3) 
and PHA (S4) using a 17-plex assay. For responses to PPD, n=132 for cord blood, 63 for 1-week visit, 65 for 4-week visit, 57 for 6-week visit, 
62 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. For responses to ESAT-6/CFP-10, n=27 for cord blood, 12 for 1-week visit, 
22 for 4-week visit, 24 for 6-week visit, 34 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. 
  
 
 136 
 
                       Cord blood                                 1 week post-BCG                             4 weeks post-BCG                           6 weeks post-BCG 
                         
                 10 weeks post-BCG                        24 weeks post-BCG                         52 weeks post-BCG 
 
Figure 4.9. Changes in concentrations of IP-10 in unstimulated and stimulated samples with age. Cytokines and chemokines were 
measured in supernatants obtained after 6-day stimulation of cultures with medium alone (unstimulated) (S1),  PPD (S2), ESAT-6/CFP-10- (S3) 
and PHA (S4) using a 17-plex assay. For responses to PPD, n=132 for cord blood, 63 for 1-week visit, 65 for 4-week visit, 57 for 6-week visit, 
62 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. For responses to ESAT-6/CFP-10, n=27 for cord blood, 12 for 1-week visit, 
22 for 4-week visit, 24 for 6-week visit, 34 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. 
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                         Cord blood                                 1 week post-BCG                        4 weeks post-BCG                            6 weeks post-BCG 
             
                   10 weeks post-BCG                      24 weeks post-BCG                       52 weeks post-BCG 
 
Figure 4.10. Changes in concentrations of MIP-1α in unstimulated and stimulated samples with age. Cytokines and chemokines were 
measured in supernatants obtained after 6-day stimulation of cultures with medium alone (unstimulated) (S1),  PPD (S2), ESAT-6/CFP-10- (S3) 
and PHA (S4) using a 17-plex assay. For responses to PPD, n=132 for cord blood, 63 for 1-week visit, 65 for 4-week visit, 57 for 6-week visit, 
62 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. For responses to ESAT-6/CFP-10, n=27 for cord blood, 12 for 1-week visit, 
22 for 4-week visit, 24 for 6-week visit, 34 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. 
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                       Cord blood                                 1 week post-BCG                          4 weeks post-BCG                             6 weeks post-BCG 
                      
                   10 weeks post-BCG                        24 weeks post-BCG                         52 weeks post-BCG 
 
Figure 4.11. Changes in concentrations of GM-CSF in unstimulated and stimulated samples with age. Cytokines and chemokines were 
measured in supernatants obtained after 6-day stimulation of cultures with medium alone (unstimulated) (S1),  PPD (S2), ESAT-6/CFP-10- (S3) 
and PHA (S4) using a 17-plex assay. For responses to PPD, n=132 for cord blood, 63 for 1-week visit, 65 for 4-week visit, 57 for 6-week visit, 
62 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. For responses to ESAT-6/CFP-10, n=27 for cord blood, 12 for 1-week visit, 
22 for 4-week visit, 24 for 6-week visit, 34 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. 
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4.3.3. Longitudinal infant responses to BCG immunisation 
Having looked at the raw cytokine and chemokine responses (without subtraction of 
responses in unstimulated samples) in supernatants of infant samples stimulated with 
PPD and ESAT-6/CFP-10, and in the negative and positive controls to assess 
spontaneous and antigen/mitogen-stimulated production of cytokines and 
chemokines, the time course of the BCG-induced priming of the immune response, 
and the establishment of the peak in response after BCG immunisation in infancy was 
then assessed. This is important because little is known about the peak response 
following BCG immunisation, yet this peak should be targeted for boosting of 
responses primed by BCG immunisation. 
 
The median cytokine and chemokine concentrations (after subtracting the background) 
are shown in Table 4.6 and Figures 4.12 to 4.14 for responses to PPD, Table 4.7 and 
Figures 4.15 to 4.17 for responses to ESAT-6/CFP-10. For most cytokines and 
chemokines measured, the peak of the responses to PPD was between 6 to 24 weeks of 
age, and by 52 weeks responses waned to levels at 4 or 6 weeks of age. This is the first 
time the peak of response has been demonstrated in any study. Figure 4.18 illustrates 
the kinetics of the individual infant responses to PPD for IFN-γ and TNF-α. Individual 
infant responses peaked at different times. 
 
IL-2 responses continued to increase to 52 weeks of age, though with a lower magnitude 
than IFN-γ and TNF-α. Some chemokines responses developed early and were 
maintained at high concentrations over time (for example, IL-8 and IP-10). The 
concentrations of IL-8 and MCP-1 in the cord blood were higher than for the other 
cytokines and chemokines measured, and over time the concentrations were above the 
measurable range. Th2 responses (IL-5 and IL-13) appeared earlier (at one week) than 
for IFN-γ (at four weeks) for PPD-stimulated samples, and median IL-13 responses 
were higher than for TNF-α from one week of age.  
 
For ESAT-6/CFP-10, it was interesting that Th1 responses (IFN-γ and TNF-α) 
increased over time (Figures 4.15 and 4.19), indicating exposure to mycobacteria 
expressing these antigens after birth. There was more TNF-α produced at all time points 
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than IFN-γ, and there was overall low production of IL-2, IL-5, IL-10, IL-13 and IL-
17A cytokines, but high concentrations of IP-10, MCP-1, MIP-1α, MIP-1β chemokines. 
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Table 4.6. Cytokine and chemokine responses to PPD in infancy measured by Luminex® assay.  
 
 
Cytokine/ 
Chemokine 
 
Cord blood 
(n=132) 
1 week  
post-BCG 
(n=63) 
4 weeks 
post-BCG 
(n=65) 
6 weeks 
post-BCG 
(n=57) 
10 weeks 
post-BCG 
(n=62) 
24 weeks 
post-BCG 
(n=15) 
52 weeks 
post-BCG 
(n=103) 
IFN-γ 0 0 8.52 110.84 105.54 967.89 196.20 
TNF-α 2 3 24 66 107 133 70 
IL-2 0 0 4 2 7 13 16 
IL-1α 0 13 34 72 78 70 11 
IL-1β 32 49 48 70 87 30 33 
IL-8 1852 9059 9894 9570.31 10082 9790 9507 
IL-1Ra 243 209 224 279 183 95 99 
IL-12p40 0 0 0 0 0 4.32 0 
IL-10 0 0 0 0 0 0 0 
IL-5 0 3 47 48 55 59 29 
IL-13 0 7 84 120 132 220 84 
IL-17A 0 2 31 21 16 34 13 
GM-CSF 0 17 220 455 441 298 134 
IP-10 36.44 700.11 10591.33 10427.04 10359.72 10175.99 7905.36 
MCP-1 7779.65 8638.64 7135.33 5489.61 2872.78 4716.32 6139.65 
MIP-1α 16.60 23.76 71 223.10 250.23 153.91 47.05 
MIP-1β 15.22 22.21 53.80 270.19 309.59 123.55 44.08 
 
The values are shown as medians in pg/ml. The individual results are illustrated below in Figures 4.12 – 4.14 
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                                    IFN-γ                                                                 TNF-α                                                                  IL-2 
   
                                     IL-12p40                                                               IL-1α                                                                  IL-1β                                                                               
 
Figure 4.12. Longitudinal changes in concentrations of PPD-specific cytokines and chemokines during the first year of life measured by 
Luminex® assay. Each symbol represents an individual, and for each plot the horizontal line represents the median. Concentrations of IFN-γ, 
TNF-α, IL-2, IL-12p40, IL-1α and IL-1β are shown after subtraction of responses in unstimulated cultures. The numbers of infants tested at each 
time point are shown in Table 4.6. 
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                                  IL-1Ra                                                                   IL-5                                                                   IL-13 
 
                                      IL-10                                                                 L-17A                                                              GM-CSF 
 
Figure 4.13. Longitudinal changes in concentrations of PPD-specific cytokines and chemokines during the first year of life measured by assay. 
Each symbol represents an individual, and for each plot the horizontal line represents the median. Concentrations of IL-1Ra, IL-5, IL-13, IL-10, 
IL-13, IL-17A and GM-CSF are shown after subtraction of responses in unstimulated cultures. The numbers of infants tested at each time point 
are shown in Table 4.6. 
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                                     IL-8                                                                    IP-10                                                                 MCP-1 
                                   
MIP-1α                                                               MIP-1β                                                                            
 
Figure 4.14. Longitudinal changes in concentrations of PPD-specific cytokines and chemokines during the first year of life measured by 
Luminex® assay. Each symbol represents an individual, and for each plot the horizontal line represents the median. Concentrations of IL-8, IP-
10, MCP-1, MIP1α and MIP-1β are shown, after subtraction of responses in unstimulated cultures. The numbers of infants tested at each time 
point are shown in Table 4.6. 
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Table 4.7. Cytokine and chemokine responses to ESAT-6/CFP-10 in infancy measured by Luminex® assay.  
 
 
Cytokine/ 
Chemokine 
 
Cord blood 
(n=27) 
1 week  
post-BCG 
(n=12) 
4 weeks 
post-BCG 
(n=22) 
6 weeks 
post-BCG 
(n=24) 
10 weeks 
post-BCG 
(n=34) 
24 weeks 
post-BCG 
(n=15) 
52 weeks 
post-BCG 
(n=103) 
IFN-γ 0  0  3.37  4.90 8.14  43.99  41.68 
TNF-α 23.17  17.67  46.50  110.14  103.04  320.34  465.06  
IL-2 0  0  0  0  0  0  0  
IL-1α 349.15  456.24 162.39  271.33  243.24 252.27  107.61  
IL-1β 2811.96 2096.78  1384.24  1913.95  1422.79  1950.13  1709.88  
IL-8 10265.17  9238.75  9980.43  9524.42  9807.6  9790.12  10357.29  
IL-1Ra 946.67  621.21  281.36  225.34  146.83  98.08  168.49  
IL-12p40 19.36  78.82  22.4  54.22  32.30  25.97  40.90  
IL-10 0  0  0  0  0  5.85 2.38  
IL-5 0 0  0  0  0 0  0  
IL-13 0  1.04  0  0  0  0  0  
IL-17A 0  0  0.54  0  0  0 2.3  
GM-CSF 11.66  43.55  29.06  22.8  16.12  49.29 24.50  
IP-10 145.99 1244.72 1368.98  3006.54  1364.27  1148.45  2256.56 
MCP-1 9636.26  8129.11  6831.08  2256.03 2424.33  3857.69  5778.31  
MIP-1α 1053.05  6388.59  929.03  3847.71  3931.72  7579.76  2214.36  
MIP-1β 1426.77  3771.77  1864.06  4296.67  3105.35  2746.07  2333.22 
 
The values are medians in pg/ml. The individual results are illustrated below in Figures 4.15 – 4.17. 
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                                   IFN-γ                                                                   TNF-α                                                                 IL-2 
 
                                 IL-12p40                                                             IL-1α                                                                      IL-1β                                                                              
 
Figure 4.15. Longitudinal changes in concentrations of ESAT-6/CFP-10-specific cytokines and chemokines during the first year of life 
measured by Luminex® assay. Each symbol represents an individual, and for each plot the horizontal line represents the median. Concentrations 
of IFN-γ, TNF-α, IL-2, IL-12p40, IL-1α and IL-1β are shown after subtraction of responses in unstimulated cultures. The numbers of infants 
tested at each time point are shown in Table 4.7. 
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                                 IL-1Ra                                                                     IL-5                                                                    IL-13 
 
                                    IL-10                                                                   IL-17A                                                             GM-CSF 
 
Figure 4.16. Longitudinal changes in concentrations of ESAT-6/CFP-10-specific cytokines and chemokines during the first year of life 
measured by Luminex® assay. Each symbol represents an individual, and for each plot the horizontal line represents the median. Concentrations 
of IL-1Ra, IL-5, IL-13, IL-10, IL-13, IL-17A and GM-CSF are shown after subtraction of responses in unstimulated cultures. The numbers of 
infants tested at each time point are shown in Table 4.7. 
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                                       IL-8                                                                  IP-10                                                                MCP-1 
 
                                 MIP-1α                                                              MIP-1β                                                                            
 
Figure 4.17. Longitudinal changes in concentrations of ESAT-6/CFP-10-specific cytokines and chemokines during the first year of life 
measured by Luminex® assay. Each symbol represents an individual, and for each plot the horizontal line represents the median. Concentrations 
of IL-8, IP-10, MCP-1, MIP1α and MIP-1β are shown after subtraction of responses in unstimulated cultures. The numbers of infants tested at 
each time point are shown in Table 4.7. 
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Figure 4.18. Kinetics of individual infant IFN-γ and TNF-α responses. Longitudinal changes in concentrations of IFN-γ and TNF-α in 
supernatants from infant samples stimulated with PPD and measured by Luminex®assay. Each line represents an individual infant cytokine 
response. Concentrations of cytokines are shown after subtraction of responses in unstimulated cultures. n=132 for cord blood, 63 for 1-week 
visit, 65 for 4-week visit, 57 for 6-week visit, 62 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit.  
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Figure 4.19. Kinetics of individual infant IFN-γ and TNF-α responses. Longitudinal changes in concentrations of IFN-γ and TNF-α in 
supernatants from infant samples stimulated with ESAT-6/CFP-10 and measured by Luminex®assay. Each line represents an individual infant 
cytokine response. Concentrations of cytokines are shown after subtraction of responses in unstimulated cultures. n=27 for cord blood, 12 for 1-
week visit, 22 for 4-week visit, 24 for 6-week visit, 34 for 10-week visit, 15 for 24-week visit and 103 for 52-week visit. 
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4.3.4. Comparison of responses at the different time points in the main infant BCG 
study 
Having looked at the time course of the BCG-induced priming of the immune 
response, and the establishment of the peak in response after BCG immunisation in 
infancy, the associations between responses at the different time points was assessed.   
This is important because it can tell, for example, whether the peak in response to BCG 
immunisation is related to responses at the other time points. Tables 4.8 and 4.9 show 
the results for responses to PPD and ESAT-6/CFP-10, respectively.  
 
For PPD, responses at the early time points (up to week 4) were significantly different 
from responses at the later time points, for most cytokines and chemokines assessed, 
with higher responses at the later time points (Table 4.8). 
 
For ESAT-6/CFP-10, there were few significant differences observed overall. Notable 
significant differences were for IFN-γ and TNF-α between early and later time points, 
and between later time points, with higher responses at the later time points (Table 4.9).   
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Table 4.8. Comparison of responses to PPD at different time points in the main infant BCG study 
 
 
Cytokine/ 
Chemokine 
Age (weeks) 
0 
vs 
1 
0 
vs 
4 
0 
vs 
6 
0 
vs 
10 
0 
vs 
24 
0 
vs 
52 
1 
vs 
4 
1 
vs 
6 
1 
vs 
10 
1 
vs 
24 
1 
vs 
52 
4 
vs 
6 
4 
vs 
10 
4 
vs 
24 
4 
vs 
52 
6 
vs 
10 
6 
vs 
24 
6 
vs 
52 
10 
vs 
24 
10 
vs 
52 
24 
vs 
52 
IFN-γ ns s s s s s s s s s s s s s s ns ns ns ns ns ns 
TNF-α ns s s s s s s s s s s ns s s s ns ns ns ns ns ns 
IL-2 ns s s s s s s s s s s ns ns ns s ns ns s ns s ns 
IL-1α s s s s s s s s s ns ns ns ns ns s ns ns s ns s ns 
IL-1β ns ns s s ns ns ns ns ns ns ns ns ns ns ns ns ns s ns s ns 
IL-8 s s s s s s ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
IL-1Ra ns ns ns ns ns s ns ns ns ns s ns ns ns s ns ns s ns ns ns 
IL-12p40 ns ns s s s s ns s s s s ns ns ns s ns ns ns ns ns ns 
IL-10 ns ns ns ns s s ns ns ns s s ns ns s s ns ns s s s ns 
IL-5 s s s s s s s s s s s ns ns ns ns ns ns ns ns ns ns 
IL-13 s s s s s s s s s s s ns ns ns ns ns ns ns ns ns ns 
IL-17A s s s s s s s s s s s ns ns ns ns ns ns ns ns ns ns 
GM-CSF s s s s s s s s s s s ns ns ns ns ns ns ns ns s ns 
IP-10 s s s s s s s s s s s ns ns ns ns ns ns ns ns ns ns 
MCP-1 ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
MIP-1α ns s s s s s s s s s s ns s ns ns ns ns s ns s ns 
MIP-1β ns s s s s s s s s s s ns s ns ns ns ns s ns s ns 
 
Significant and non-significant differences are indicated as “s” and “ns”, respectively. The numbers of infants tested at each time point are 
shown in Table 4.6. A Kruskal-Wallis test was used to compare infants at the different time points, with adjustment for multiple comparisons 
using Dunn’s multiple comparisons test. 
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Table 4.9. Comparison of responses to ESAT-6/CFP-10 at different time points in the main infant BCG study 
 
 
Cytokine/ 
Chemokine 
Age (weeks) 
0 
vs 
1 
0 
vs 
4 
0 
vs 
6 
0 
vs 
10 
0 
vs 
24 
0 
vs 
52 
1 
vs 
4 
1 
vs 
6 
1 
vs 
10 
1 
vs 
24 
1 
vs 
52 
4 
vs 
6 
4 
vs 
10 
4 
vs 
24 
4 
vs 
52 
6 
vs 
10 
6 
vs 
24 
6 
vs 
52 
10 
vs 
24 
10 
vs 
52 
24 
vs 
52 
IFN-γ ns ns ns ns s s ns ns ns ns s ns ns ns s ns ns s ns s ns 
TNF-α ns ns ns ns s s ns ns ns s s ns ns ns s ns ns s ns s ns 
IL-2 ns ns ns ns ns ns ns ns ns ns ns ns ns ns s ns ns ns ns ns ns 
IL-1α ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
IL-1β ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
IL-8 ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
IL-1Ra ns s s s s s ns ns ns s ns ns ns ns ns ns ns ns ns ns ns 
IL-12p40 s ns s ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
IL-10 ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
IL-5 ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
IL-13 ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
IL-17A ns ns ns ns ns s ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
GM-CSF ns s ns ns s ns ns ns ns ns ns ns ns s ns ns s ns ns ns s 
IP-10 ns s s s ns s ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
MCP-1 s s s s s s ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
MIP-1α ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
MIP-1β ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns 
 
Significant and non-significant differences are indicated as “s” and “ns”, respectively. The numbers of infants tested at each time point are 
shown in Table 4.7. A Kruskal-Wallis test was used to compare infants at the different time points, with adjustment for multiple comparisons 
using Dunn’s multiple comparisons test.
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4.3.5. Correlations between production of individual cytokines and chemokines 
Having examined differences in responses to mycobacterial antigens between the 
different time points, the correlations between concentrations of IFN-γ and the 
cytokines and chemokines measured were examined using Spearman rank correlation to 
assess the strength and direction of any relationships. This is important as this analysis  
would determine whether there is a relationship, for example, between pro-and anti-
inflammatory cytokines. 
 
The results are shown in Table 4.10 and Appendix T for PPD-specific responses, and in 
Table 4.11 and Appendix U for responses to ESAT-6/CFP-10 stimulation. 
For PPD-specific responses, 9 out of 17 cytokines and chemokines measured at the 
different time points correlated strongly or very strongly (coefficient of 0.60 and above) 
with IFN-γ and these included TNF-α, IL-1α, IL-1 β, IL-5, IL-13, IL-17A, GM-CSF, 
IP-10 and MIP-1β (Table 4.10).  
 
Of the 17 cytokines and chemokines induced by stimulation with ESAT-6/CFP-10, nine  
showed strong/very strong correlation with IFN-γ and these included TNF-α, IL-1α, IL-
1β, IL-12p40, IL-10, GM-CSF, IP-10, MIP-1α and MIP-1β. Strongly positive 
correlations with TNF-α, IL-10 and MIP-1β with IFN-γ were also observed in cord 
blood (Table 4.11). 
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Table 4.10. Correlation between concentrations of IFN-γ and other cytokines and chemokines in PPD-stimulated culture supernatants measured 
by Luminex® assay. 
 
Cytokine/ 
Chemokine 
 
Cord blood 
(n=132) 
1 week  
post-BCG 
(n=63) 
4 weeks 
post-BCG 
(n=65) 
6 weeks 
post-BCG 
(n=57) 
10 weeks 
post-BCG 
(n=62) 
24 weeks 
post-BCG 
(n=15) 
52 weeks 
post-BCG 
(n=103) 
TNF-α 0.20 0.33 0.69 0.70 0.67 0.81 0.66 
IL-2 -0.04 0.29 0.31 0.49 0.34 -0.13 0.35 
IL-1α 0.11 -0.01 0.24 0.62 0.37 0.85 0.61 
IL-1β 0.18 -0.09 0.19 0.50 0.21 0.83 0.33 
IL-8 0.15 -0.10 0.11 0.00 0.08 -0.30 0.35 
IL-1Ra 0.01 -0.18 0.28 0.41 0.11 0.31 0.30 
IL-12p40 0.05 0.23 0.35 0.36 0.39 0.45 0.46 
IL-10 0.10 -0.11 0.11 0.25 0.21 0.26 0.23 
IL-5 0.16 0.13 0.35 0.40 0.25 0.68 0.63 
IL-13 0.27 0.15 0.62 0.66 0.72 0.72 0.75 
IL-17A 0.38 0.42 0.52 0.25 0.15 0.61 0.44 
GM-CSF 0.37 0.26 0.45 0.44 0.44 0.54 0.76 
IP-10 -0.05 0.11 0.19 0.21 0.21 -0.18 0.62 
MCP-1 0.11 -0.21 0.04 -0.02 -0.06 -0.44 0.04 
MIP-1α 0.17 0.11 0.44 0.58 0.29 0.32 0.48 
MIP-1β 0.10 0.10 0.33 0.64 0.27 0.30 0.45 
 
Values are correlation coefficients obtained using Spearman rho test. Coefficients ≥0.6 are shown in bold.  
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Table 4.11. Correlation between IFN-γ and other cytokines and chemokines in ESAT-6/CFP-10-stimulated culture supernatants measured by 
Luminex® assay. 
 
Cytokine/ 
Chemokine 
 
Cord blood 
(n=27) 
1 week  
post-BCG 
(n=12) 
4 weeks 
post-BCG 
(n=22) 
6 weeks 
post-BCG 
(n=24) 
10 weeks 
post-BCG 
(n=34) 
24 weeks 
post-BCG 
(n=15) 
52 weeks 
post-BCG 
(n=103) 
TNF-α 0.68 0.59 0.63 0.70 0.37 0.55 0.63 
IL-2 0.34 -0.36 0.45 0.39 -0.22 0.19 0.29 
IL-1α 0.40 0.38 0.54 0.27 0.22 0.79 0.58 
IL-1β 0.41 0.66 0.47 0.24 0.12 0.84 0.64 
IL-8 -0.12 0.17 0.33 -0.24 0.26 0.20 0.15 
IL-1Ra 0.17 -0.12 0.20 -0.08 -0.12 0.59 0.56 
IL-12p40 0.59 0.60 0.58 0.25 0.49 0.53 0.74 
IL-10 0.68 0.54 0.23 0.68 0.20 0.06 0.31 
IL-5 0.18 0.24 -0.03 -0.31 0.23 0.19 0.27 
IL-13 0.33 0.34 0.10 0.41 0.59 0.59 0.33 
IL-17A 0.44 0.42 0.31 -0.18 0.19 -0.20 0.19 
GM-CSF 0.45 0.66 0.38 0.19 0.38 0.62 0.55 
IP-10 0.32 0.58 0.51 0.01 0.27 0.07 0.61 
MCP-1 -0.25 -0.16 0.24 -0.25 0 0.07 0.19 
MIP-1α 0.58 0.58 0.34 0.13 0.21 0.85 0.53 
MIP-1β 0.65 0.43 0.37 -0.06 0.08 0.86 0.54 
 
Values are correlation coefficients obtained using Spearman rho test. Coefficients ≥0.6 are shown in bold. 
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4.3.6. The impact of maternal LTBI on infant responses to mycobacteria.  
In the previous section, longitudinal infant responses to mycobacterial antigens over 
time were shown.  Here I now show whether these responses differ according to 
maternal LTBI status. 
 
Crude associations between maternal and infant factors and the infant responses to 
mycobacterial antigens were examined using a random effects regression model. Tables 
4.12 and 4.13 show the results for responses to PPD and ESAT-6/CFP-10, respectively. 
For both mycobacterial antigens, infants of mothers with LTBI, compared to those 
without, had lower IL-1Ra response (crude mean difference, 95% confidence interval 
(CI) -0.25 (-0.36, -0.06) and -0.22 (-0.40, -0.04) for PPD and ESAT-6/CFP-10, 
respectively (Tables 4.12 and 4.13). For responses to ESAT-6/CFP-10, maternal BCG 
scar was associated with increased IL-12p40 responses (0.33 (0.11, 0.55), and infants of 
younger mothers, compared to those of older mothers, had lower MIP-1β responses (-
0.36 (-0.68, -0.03) (Table 4.13).  
 
In multivariate analysis, after adjusting for maternal BCG scar, maternal age, parity and 
infant gender the association between infant IL-1Ra to PPD and maternal LTBI was lost 
(adjusted mean difference, 95% CI -0.14 (-0.35, 0.07)). Infants of younger mothers, 
compared to the older mothers, produced more IL-1α to PPD stimulation (0.35 (0.02, 
0.68)) (data not shown). 
 
For responses to ESAT-6/CFP-10 stimulation, the negative association of infant IL-1Ra 
with maternal LTBI was lost (0.05 (-0.31, 0.42)). The association between maternal 
BCG scar and infant IL-12p40 responses was also lost (adjusted mean difference, 95% 
CI 0.07 (-0.30, 0.66)). However, the negative association between maternal age and 
infant MIP-1β responses was strengthened (-0.70 (-1.27, -0.13)).  There were also 
negative associations between infant IL-1Ra and female infant gender (-0.38 (-0.72, -
0.04)), infant IL-10 and maternal BCG scar (-0.44 (-0.85, -0.03)). Parity was positively 
associated with infant IL-13 responses to ESAT-6/CFP-10, in that the infants of 
multigravida mothers, compared to primigravida ones, had higher IL-13 concentrations 
(data not shown).  
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Table 4.12. Cytokine and chemokine responses to PPD in BCG-vaccinated infants, showing crude associations with maternal and infant factors. 
Cytokine/ 
Chemokine 
Maternal LTBI Maternal BCG scar Maternal age Parity Infant gender 
Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) 
 IFN-γ -0.06 (-0.33, 0.20) -0.11 (-0.37, 0.15) 0.09 (-0.19, 0.38) -0.00 (-0.43, 0.42) 0.03 (-0.22, 0.28) 
 TNF-α 0.00 (-0.16, 0.17) -0.06 (-0.24, 0.11) -0.03 (-0.21, 0.16) -0.26 (-0.55, 0.03) -0.02 (-0.19, 0.15) 
 IL-2 -0.001 (-0.15, 0.15) -0.03 (-0.17, 0.11) 0.02 (-0.13, 0.17) 0.01 (-0.21, 0.24) -0.12 (-0.26, 0.01) 
 IL-1α -0.07 (-0.26, 0.11) -0.03 (-0.20, 0.19) 0.08 (-0.12, 0.27) 0.03 (-0.27, 0.34) -0.02 (-0.20, 0.17) 
 IL-1β -0.01 (-0.29, 0.06) 0.02 (-0.14, 0.18) 0.06 (-0.09, 0.22) 0.13 (-0.14, 0.41) 0.01 (-0.13, 0.16) 
 IL-8 -0.05 (-0.32, 0.22) 0.09 (-0.11, 0.30) 0.05 (-0.19, 0.30) 0.07 (-0.23, 0.38) 0.09 (-0.13, 0.32) 
 IL-12p40 0.05 (-0.08, 0.18) -0.04 (-0.16, 0.08) -0.07 (-0.20, 0.06) 0.07 (-0.12, 0.26) 0.03 (-0.07, 0.14) 
 IL-1Ra -0.25 (-0.36, -0.06) 0.04 (-0.08, 0.17) 0.01 (-0.05, 0.07) -0.06 (-0.27, 0.14) 0.09 (-0.03, 0.22) 
 IL-10 -0.03 (-0.10, 0.04) -0.00 (-0.07, 0.06) 0.01 (-0.11, 0.13) -0.05 (-0.16, 0.06) 0.01 (-0.05, 0.07) 
 IL-5 -0.03 (-0.23, 0.17) -0.01 (-0.20, 0.18) -0.03 (-0.24, 0.17) -0.12 (-0.45, 0.20) -0.02 (-0.21, 0.16) 
 IL-13 -0.06 (-0.23, 0.15) -0.04 (-0.26, 0.18) 0.01 (-0.23, 0.24) 0.03 (-0.34, 0.40) -0.03 (-0.25, 0.18) 
 IL-17A 0.01 (-0.14, 0.16) 0.01 (-0.14, 0.15) -0.05 (-0.21, 0.11) -0.11 (-0.36, 0.14) -0.04 (-0.18, 0.11) 
 GM-CSF -0.03 (0.26, 0.11) -0.05 (-0.28, 0.18) 0.04 (-0.20, 0.29) -0.14 (-0.53, 0.26) -0.02 (-0.25, 0.21) 
 IP-10 -0.18 (-0.41, 0.05) -0.01 (-0.27, 0.24) 0.05 (-0.23, 0.34) -0.08 (-0.51, 0.35) -0.11 (-0.38, 0.15) 
 MCP-1 0.13 (-0.19, 0.43) 0.00 (-0.28, 0.28) 0.13 (-0.19, 0.45) -0.25 (-0.76, 0.26) -0.02 (-0.31, 0.26) 
 MIP-1α -0.07 (-0.26, 0.12) -0.12 (-0.30, 0.07) -0.03 (-0.23, 0.16) -0.13 (-0.45, 0.18) -0.05 (-0.23, 0.13) 
 MIP-1β -0.05 (-0.23, 0.14) -0.03 (-0.21, 0.15) -0.04 (-0.23, 0.15) -0.10 (-0.40, 0.20) -0.08 (-0.26, 0.09) 
 
The values are log coefficients and 95% confidence interval analysed using random effects regression model. 
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Table 4.13. Cytokine and chemokine responses to ESAT-6/CFP-10 in BCG-vaccinated infants, showing crude associations with maternal and 
infant factors. 
Cytokine/ 
Chemokine 
Maternal LTBI Maternal BCG scar Maternal age Parity Infant gender 
Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) 
 IFN-γ -0.01 (-0.26, 0.25) 0.21 (-0.06, 0.48) -0.28 (-0.60, 0.03) -0.21 (-0.88, 0.46) -0.05 (-0.35, 0.25) 
 TNF-α 0.02 (-0.22, 0.25) 0.03 (-0.22, 0.29) -0.15 (-0.45, 0.14) -0.39 (-1.00, 0.23) -0.26 (-0.54, 0.03) 
 IL-2 0.02 (-0.094, 0.12) 0.02 (-0.10, 0.14) -0.06 (-0.20, 0.08) 0.23 (-0.08, 0.54) 0.12 (0.00, 0.25) 
 IL-1α -0.12 (-0.34, 0.11) 0.17 (-0.07, 0.41) -0.13 (-0.42, 0.17) -0.03 (-0.53, 0.47) -0.17 (-0.45, 0.10) 
 IL-1β -0.14 (-0.36, 0.08) 0.10 (-0.13, 0.33) -0.15 (-0.41, 0.10) -0.16 (-0.69, 0.38) -0.17 (-0.45, 0.08) 
 IL-8 -0.09 (-0.46, 0.27) 0.29 (-0.09, 0.68) -0.27 (-0.71, 0.17) -0.46 (-1.30, 0.38) 0.13 (-0.30, 0.56) 
 IL-12p40 -0.10 (-0.31, 0.11) 0.33 (0.11, 0.55) -0.18 (-0.43, 0.07) 0.07 (-0.43, 0.58) -0.09 (-0.32, 0.15) 
 IL-1Ra -0.22 (-0.40, -0.04) 0.10 (-0.10, 0.30) -0.14 (-0.36, 0.07) -0.19 (-0.60, 0.23) 0.01 (-0.20, 0.22) 
 IL-10 -0.09 (-0.25, 0.07) -0.04 (-0.21, 0.14) -0.13 (-0.33, 0.08) -0.07 (-0.48, 0.33) 0.10 (-0.09, 0.29) 
 IL-5 -0.02 (-0.10, 0.06) 0.00 (-0.08, 0.08) -0.03 (-0.13, 0.07) 0.07 (-0.100, 0.23) 0.03 (-0.06, 0.13) 
 IL-13 -0.08 (-0.21, 0.06) 0.01 (-0.13, 0.15) 0.03 (-0.15, 0.21) 0.36 (-0.02, 0.74) 0.14 (-0.03, 0.31) 
 IL-17A -0.08 (0.09, 0.24) 0.03 (-0.15, 0.22) -0.07 (-0.30, 0.15) -0.12 (-0.59, 0.35) 0.0 (-5.16, 0.25) 
 GM-CSF -0.02 (-0.22, 0.17) 0.11 (-0.09, 0.32) -0.07 (-0.31, 0.17) 0.10 (-0.40, 0.61) -0.12 (-0.35, 0.10) 
 IP-10 -0.06 (-0.35, 0.23) 0.09 (-0.21, 0.40) -0.16 (-0.53, 0.21) -0.35 (-0.90, 0.19) -0.03 (-0.39, 0.32) 
 MCP-1 -0.08 (-0.53, 0.36) -0.03 (-0.47, 0.42) -0.14 (-0.65, 0.37) -0.39 (-1.40, 0.62) 0.22 (-0.28, 0.71) 
 MIP-1α -0.27 (-0.57, 0.02) 0.20 (-0.11, 0.52) -0.24 (-0.61, 0.13) -0.22 (-0.89, 0.45) -0.25 (-0.60, 0.10) 
 MIP-1β -0.20 (-0.46, 0.06) 0.16 (-0.12, 0.44) -0.36 (-0.68, -0.03) -0.22 (-0.83, 0.39) -0.25 (-0.56, 0.05) 
 
The values are log coefficients and 95% confidence interval analysed using random effects regression model.
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The lack of association between maternal LTBI and infant cytokine and chemokine responses 
was confirmed in cord blood, and in infant samples by comparing responses in infants of 
mothers with and without LTBI using a Kruskal-Wallis and Dunn’s multiple comparison 
tests. The results are illustrated in Figures 4.20A and 4.20B for responses to PPD, and 
Figures 4.21A and 4.21B for responses to ESAT-6/CFP-10.  
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                                                        Cord blood                                                                                                 1 week post-BCG 
 
                                              4 weeks post-BCG                                                                                            6 weeks post-BCG 
 
Figure 4.20A. Cytokine and chemokine responses to PPD measured by Luminex® assay. Clear and grey bars represent infants of mothers 
without (LTBI-) and with (LTBI+) LTBI, respectively. The horizontal lines represent the median. Statistically significant differences are shown 
by *. A Kruskal-Wallis test was used to compare infants in the two groups, with adjustment for multiple comparisons using Dunn’s multiple 
comparisons test. Numbers of infants for LTBI- and LTBI+ groups: 82 versus 50 for cord blood, 36 versus 27 for 1-week, 42 versus 23 for 4-
week, 32 versus 25 for 6-week, 37 versus 25 for 10 week, 9 versus 6 for 24-week, and 65 versus 38 for 52-week visits. 
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                                                     10 weeks post-BCG                                                                                  24 weeks post-BCG 
 
                                             52 weeks post-BCG 
 
Figure 4.20B. Cytokine and chemokine responses to PPD measured by Luminex® assay. Clear and grey bars represent infants of mothers 
without and with LTBI, respectively. The horizontal lines represent the median. Statistically significant differences are shown by *. A Kruskal-
Wallis test was used to compare infants in the two groups, with adjustment for multiple comparisons using Dunn’s multiple comparisons test). 
Numbers of infants for LTBI- and LTBI+ groups: 82 versus 50 for cord blood, 36 versus 27 for 1-week, 42 versus 23 for 4-week, 32 versus 25 
for 6-week, 37 versus 25 for 10 week, 9 versus 6 for 24-week, and 65 versus 38 for 52-week visits. 
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                                                       Cord blood                                                                                           1 week post-BCG 
 
                                               4 weeks post-BCG                                                                                           6 weeks post-BCG 
 
Figure 4.21A. Cytokine and chemokine responses to ESAT-6/CFP-10 measured by Luminex® assay. Clear and grey bars represent infants of 
mothers without and with LTBI, respectively. The horizontal lines represent the median. Statistically significant differences are shown by *. A 
Kruskal-Wallis test was used to compare infants in the two groups, with adjustment for multiple comparisons using Dunn’s multiple 
comparisons test). Numbers of infants for LTBI- and LTBI+ groups: 17 versus 10 for cord blood, 7 versus 5 for 1-week, 14 versus 8 for 4-week, 
13 versus 11 for 6-week, 21 versus 13 for 10 week, 9 versus 6 for 24-week, and 65 versus 38 for 52-week visits. 
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                                              10 weeks post-BCG                                                                                  24 weeks post-BCG 
 
                                                52 weeks post-BCG 
 
Figure 4.21B. Cytokine and chemokine responses to ESAT-6/CFP-10 measured by Luminex® assay. Clear and grey bars represent infants of 
mothers without and with LTBI, respectively. The horizontal lines represent the median. Statistically significant differences are shown by *. A 
Kruskal-Wallis test was used to compare infants in the two groups, with adjustment for multiple comparisons using Dunn’s multiple 
comparisons test). Numbers of infants for LTBI- and LTBI+ groups: 17 versus 10 for cord blood, 7 versus 5 for 1-week, 14 versus 8 for 4-week, 
13 versus 11 for 6-week, 21 versus 13 for 10 week, 9 versus 6 for 24-week, and 65 versus 38 for 52-week visit.
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4.4. Discussion 
As expected, a mycobacteria-specific immune response was detected in BCG 
immunised infants in both the pilot and the main infant BCG studies. The frequency of 
IFN-γ-producing CD4+ T cells after PPD stimulation peaked at one week after BCG 
immunisation in the pilot study and dropped at six weeks, while the proportion of IL-2 
and TNF-α-producing CD4+ T cells increased to six weeks. A peak in BCG-induced 
response was reported at 6-10 weeks post-BCG immunisation by Soares and colleagues 
(220). The pilot study was limited by a short follow up time of six weeks that did not 
enable an assessment of peak in response at later time points.  
 
In the pilot infant BCG study, maternal infection with M. tuberculosis was associated 
with lower infant CD4+ T cell responses to PPD at one week after neonatal BCG 
immunisation, as measured by flow cytometry. It is policy for BCG to be given at birth 
in most developing countries and LTBI is common in these countries. It is possible that 
the lower immune responses in early life may result in poor longer-term responses and 
the subsequent infection with M.tuberculosis or progression to active TB disease. It may 
further call for the treatment of LTBI in women of childbearing age. However, such a 
short-term effect of maternal LTBI on infant responses does not provide enough 
immunological evidence to advocate for treatment of LTBI in mothers.  
Jones et al., in a recent study showed no difference in BCG-induced responses between 
infants of mothers with and without M. tuberculosis infection at 10 weeks of age (359). 
The data presented in this thesis (Chapter 4 and published in Transactions of the Royal 
Society B (326)) differed with that of Jones and colleagues: first, both TST and T-
SPOT.TB were used to define maternal LTBI in this study, versus the QuantiFERON-
TB Gold test alone in Jones’s study. The non-stringent criteria used by Jones and 
colleagues might have resulted in loss of smaller differences between infants of mothers 
with and without LTBI. Second, this study used BCG-Russia, versus the Danish strain 
in Jones’ study, and as mentioned above, strain-specific differences in immune 
responses to BCG immunisation have previously been reported (277, 292). Third, 
infants in this study were immunised at birth, versus six weeks for Jones et al. Early 
effects of maternal LTBI on infants such as we have observed may have been missed 
since immune responses were only assessed at 10 weeks in Jones’ study. Fourth, a 24-
hour cell stimulation assay was used in this study, versus a 6-day WBA by Jones et al. 
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There are also obvious differences in the characteristics of the assays used (intracellular 
cytokine staining and flow cytometry in this study, versus WBA in the study by Jones 
and colleagues). Short-term cultures target memory cells, but unfortunately the 
frequencies of memory T cells are quite low in humans, which makes the responses 
from short-term cultures quite low. Longer-term cultures likely allow memory T cells to 
proliferate and expand in frequency, allowing for easier identification. Long term 
cultures, compared to short-term cultures, do not give an accurate measure of frequency 
however, but do allow for better detection of antigen-specific responses.  The choice of 
which assays to use should therefore be carefully considered.  For the pilot infant BCG 
study, a short term assay was used for looking at innate responses, and we took the 
opportunity to examine T cell responses by flow cytometry as an additional measure. In 
the main infant BCG study, a longer term culture was used to assess adaptive responses. 
Taken together, it would have been more appropriate to undertake a broader and less 
biased approach, such as cytometry by time of flight (CyTOF) (360-362), to further 
explore some of the findings in the pilot infant BCG study. 
 
A limitation of the pilot infant BCG study was the small sample size, and the many 
outcome measures. Since correction for multiple comparison testing was not done due 
to small sample size, some of the differences reported as statistically significant could 
have been by chance. We have therefore taken caution in interpreting the results. 
 
The importance of IFN-γ in immunity to TB has previously been demonstrated (156-
158). Although necessary, IFN-γ alone is not sufficient to provide protection against TB 
(199). It is therefore important to assay other cytokines and chemokines induced by 
BCG that might show promise as biomarkers of protection against TB. Up to 17 
cytokines and chemokines were measured in culture supernatants in response to 
stimulation of infant blood by mycobacterial antigens in the main infant BCG study. 
 
The median IFN-γ production in the 6-day cultures was higher in PPD-stimulated 
samples than in ESAT-6/CFP-10-stimulated samples at all time points. PPD is a crude 
antigen preparation from M.tuberculosis which contains mainly degraded protein 
antigens, most of which are cross-reactive with the antigens in the BCG vaccine, as well 
as NTM, thus explaining the higher responses. The ESAT-6 and CFP-10 antigens are in 
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the region of difference- (RD) 1 region that is deleted in the BCG vaccine (363, 364), 
but expressed in certain NTM species including M.kansasii, M.szulgai, M. marinum and 
M. rigadhense (365, 366). The prevalence of NTM in infants in Uganda is 3.7% (versus 
4.6% in adolescents), and M.szulgai (one of the ESAT-6/CFP-10-expressing NTM) was 
among the species recently isolated (367).  The lower IFN-γ responses to ESAT-6/CFP-
10 than to PPD may indicate reduced exposure to M. tuberculosis (or one of the other 
NTM that express these antigens, such as M.szulgai) in this setting. However, the Th1 
responses (IFN-γ and TNF-α) to ESAT-6/CFP-10 increased with age, showing the 
possibility of exposure to M.tuberculosis or NTM. It would be important to establish the 
prevalence of ESAT-6/CFP-10-expressing NTM, such as M.szulgai, in this setting as 
this can interfere with tests that use the RD1 antigens. 
 
The PPD-stimulated cultures also produced more Th2 cytokines (IL-5, IL-13) than 
ESAT-6/CFP-10-stimulated samples. It is possible that the Th2 responses observed in 
response to stimulation with PPD may be because of an overall stronger response to the 
antigen. In a study involving Malawian infants, there was evidence of Th2 responses 
following BCG immunisation (325). Th2 cytokines were also observed in unvaccinated 
infants in a study in The Gambia (225). There was good correlation between the Th1 
and Th2 cytokines measured. 
 
Some of the chemokines had overall high concentrations above the top standard value. 
The reagents come ready to use and were all pre-mixed. Ordering the analytes 
individually and making up the mix would be an alternative option, but this approach 
may be costly and time consuming. For studies of infant immunology, kits are perhaps 
not the best to use and testing individual cytokines and diluting where necessary should 
be advocated for.  
 
For most of the cytokines and chemokines measured, the peak of the response to PPD 
was around 24 weeks of age, later than the 6-10 week period reported by Soares and 
colleagues (220). The responses at the early time points were significantly lower than 
those at later time points, highlighting BCG-induced immune responses and maturation 
of responses with age. For IFN-γ and TNF-α, the responses to ESAT-6/CFP-10 at the 
early time points were also different from the responses at the later time points.  
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It is critical that we know when the peak of the immune response is, as that will inform 
future prime boost strategies based on BCG prime, as to when the boost should be 
given.  The absence of efficacy against M.tuberculosis infection or TB disease after 
boosting BCG-primed responses with MVA85A vaccine (200) may have resulted from 
not using the appropriate time point for boosting.  
Not all infants peaked at the same time point, highlighting individual differences in 
infant responses to vaccines. Studies in humans have demonstrated that BCG 
immunisation of infants induces immunological memory (231, 310). Most studies have 
shown that BCG immunisation induces CD4+ T cells with effector memory 
characteristics in both humans (226, 227, 237) and animal models (228, 368). Soares 
and colleagues previously reported that the memory CD4+ T cells induced by BCG 
immunisation of infants have a central memory phenotype, but with an effector memory 
function (220). Data will be available from the main infant BCG study to enable us to 
analyse the phenotype and function of T cells at the peak of BCG-induced immune 
responses, but is not part of this body of work.    
 
Concentrations of IFN-γ in the antigen-stimulated cultures correlated with several 
cytokines and chemokines produced in response to PPD or ESAT-6/CFP-10. This 
shows that infants in this study are capable of mounting complex mycobacteria-specific 
immune responses of various strength and direction.  
 
Overall, maternal LTBI was not associated with infant responses. Other factors that 
remained associated with infant responses after controlling for confounding factors 
included female infant gender (associated with lower IL-1Ra responses), maternal BCG 
scar (associated with lower infant IL-10 responses), maternal age (infants of older 
mothers produced more MIP-1β, but less IL-1α) and parity (infants of multigravid 
mothers produced more IL-13). These observations demonstrate the importance of 
looking at other maternal and infant factors when evaluating infant responses to 
vaccines.  
 
In summary, infant responses peaked around 24 weeks of age and overall, maternal 
infection with M.tuberculosis was not associated with the infant response to BCG 
immunisation. The poor efficacy of BCG vaccine in the tropics may therefore be as a 
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result of combination of factors, other than single infections such as M. tuberculosis 
infection. 
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Chapter 5  
Antibody responses in BCG immunised infants, and 
the influence of maternal LTBI 
Having shown the peak of infant response following BCG immunisation and the lack of 
associations between maternal LTBI and infant T cell responses, the infant IgG 
response to PPD and the effect of maternal LTBI on these responses were assessed. 
Although antibody responses are not thought to be central to immunity against 
intracellular pathogens such as M.tuberculosis, there has been recent interest in the B 
cell and antibody response in TB (164, 165, 369).  
5.1. Introduction 
Antibodies, produced by plasma cells and plasmablasts, are important in the host 
defense against infections. Newborns acquire IgG from their mothers through the 
placenta (370, 371), and these maternally derived antibodies play an important role in 
protecting the neonates from infections (372, 373). However, these antibodies have 
been reported to interfere with infant responses to vaccines (374). 
 
Several sero-epidemiological studies aimed at assessing the decay of maternal 
antibodies in infants have been carried out, but with conflicting results. Maternal 
antibodies to pertussis (375), respiratory syncytial virus (373) and CMV (376) 
infections have been shown to decay in less than three months after birth. In a study in 
Nigeria, the biological half-life of maternal measles virus antibodies was reported to be 
33 days (377). Other studies have reported the decay of maternal antibodies to be 
between 5-12 months (373, 376, 378-386). Differences in the rate of decay of maternal 
antibodies to dengue virus with the age of the infants has also been reported, where 
antibodies decayed faster in some infants than in others (379). Antibody decay has also 
been shown to vary during vaccination and natural infection: maternal antibodies to 
paramyxovirus infection decayed faster if the mothers were vaccinated (2.4 months) 
than when the mothers had natural infection (3.8 months) (387).  
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Maternal antibodies have been shown to impair infant responses to most childhood 
vaccines (388, 389) and this is thought to result in high mortality and morbidity from 
vaccine-preventable diseases. However, there are reports of reduced mortality (390) and 
morbidity (391) when neonates were immunised during the period when maternal 
antibodies were still high. 
 
The relationship between mycobacteria and the host is thought to be dynamic during 
LTBI. There may be differences in the concentrations of M.tuberculosis-specific 
antigens and antibodies in people with LTBI than those without.  Transplacental transfer 
of mycobacterial antigens has been demonstrated in animal models (392). Maternal 
LTBI might therefore lead to in utero sensitisation (287), or tolerance (such as reported 
for maternal helminths) (288, 289) of the fetus. There might also be interference of 
passively transferred maternal M.tuberculosis-specific antibodies with the BCG 
vaccine.  
 
To my knowledge, the decay in maternally acquired antibodies during M.tuberculosis 
infection, and the influence of maternal LTBI on the antibody responses have not 
previously been reported. Since there was no effect of maternal LTBI on infant T cell 
responses observed, it was expected that there would be no effect on antibody 
responses. 
 
In this chapter, the results of the kinetics of antibody responses in infants and the 
influence of maternal LTBI on the infant antibody responses are presented.  
The specific objectives included: 
1. Assessment of the longitudinal changes in infant antibody responses in the pilot 
infant BCG study and the main infant BCG study. 
2. To investigate the effect of maternal LTBI on infant antibody responses. 
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5.2. Results from the pilot BCG study 
5.2.1. Demographic and clinical characteristics of the participants 
The characteristics of the mothers and infants included for analysis of humoral 
responses were the same as for infant T-cell responses in the pilot study described in 
section 4.2.1. Briefly, compared to those without LTBI, mothers with LTBI were older 
(mean age 27.5 versus 23 years, p=0.002), less likely to have a BCG scar (47% versus 
70%, p =0.001) and less likely to be primigravida (32% versus 48%, p=0.001), and their 
children were more likely to be of male gender (53% versus 35%, p=0.001) (Table 4.1). 
5.2.2. Longitudinal changes in IgG concentrations 
Plasma samples obtained from cord blood and from infant samples obtained at one and 
six weeks after BCG immunisation were assayed for IgG specific for PPD and TT using 
an ELISA assay. The PPD-specific IgG response was the main outcome of interest. 
Antibodies to TT were analysed for comparison. At each time point, fifty-four samples 
were assayed, 38 from infants of mothers without LTBI and 16 from infants of mothers 
with LTBI. Figure 5.1 illustrates the distribution of concentrations of IgG specific for 
PPD and TT in the three sample types.  
 
There was a decrease in PPD-specific IgG concentrations at one week after birth (175 
ng/ml [0–1100], compared to the concentration in cord blood (median [IQR]: 5600 
ng/ml [3300–11050]), p=0.001) and again at six weeks (0.00 ng/ml [0.00–288], 
p=0.004; Figure 5.1A and Table 5.1). 
 
The concentration of TT-specific IgG, by contrast, was high in cord blood (46750 ng/ml 
[42000–49950], dropped by half one week after birth (21125 ng/ml [18988–22650] 
p=0.001) and did not change much between one and six weeks (19550 ng/ml [13750–
22038] p=0.252; Figure 5.1B and Table 5.1). 
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          A                                                                 B                                                         
 
Figure 5.1. Longitudinal changes in PPD- and TT-specific IgG concentrations with 
age. PPD- (A) and TT-specific (B) responses are shown. Cord blood and infant plasma 
samples were obtained at one and six weeks after birth. All infants were BCG 
vaccinated within 24 hours after birth. Tetanus vaccination was given at 6 weeks after 
birth. Concentrations of IgG in log10 (concentration +1) were measured by ELISA. 
Each symbol represents an individual infant antibody response. For each plot, the 
horizontal line represents the median differences in responses between the visits were 
analysed using the Mann–Whitney test; n=54 for all three time points. 
 
 
Figure 5.2. Longitudinal changes in PPD-specific IgG concentrations with age. 
Showing pilot infant BCG study samples re-tested using PPD from the main infant 
BCG study. n=10 for all three time points.  
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Table 5.1. IgG responses to PPD and TT in infancy.  
 
 
Sample/visit 
 
Number of 
observations 
 
Median responses to PPD 
 
IQR 
 
Median responses to TT 
 
IQR 
Cord blood 54 5600 3300-11050 46750 42000-49950 
1 week 54 175 0-1100 21125 18988-22650 
6 weeks 54 0 0-288 19550 13750-22038 
 
Antibodies were measured by ELISA. The values are shown as medians in ng/ml with the interquartile range (IQR).
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5.2.3. Impact of maternal infection with M. tuberculosis on PPD-specific immune 
responses in infancy. 
Having shown the longitudinal changes in infant antibody responses with age, the 
influence of maternal LTBI on these responses was analysed. This is important because 
if there was a difference in infant responses by maternal LTBI, then this may contribute 
to the poor efficacy of BCG in this setting or it may call for the treatment of pregnant 
women with LTBI. 
 
There were no differences in PPD-specific IgG concentrations between the infants of 
mothers with and without LTB, at any of the time points (Figure 5.3). 
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                   Cord blood                    1 week post-BCG              6 weeks post-BCG 
 
Figure 5.3. The impact of maternal infection with M. tuberculosis on the infant 
antibody responses. Cord blood was sampled and infant plasma samples were obtained 
at one and six weeks after birth, and compared between infants of mothers without and 
with LTBI; IgG concentrations were measured by ELISA. Each symbol represents an 
individual infant antibody response. For each plot, the horizontal line represents the 
median infant responses. Differences in responses between LTBI exposed and 
unexposed infants were analysed using the Mann–Whitney test. n=38 for infants of 
mothers without LTBI (open circles) and n=16 for infants of mothers with LTBI (closed 
circles). 
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5.3. Results from the main infant BCG study 
5.3.1. Longitudinal changes in IgG concentrations 
Having shown the kinetics of IgG responses in the pilot infant BCG study, responses in 
the main infant BCG study were examined. 
 
Plasma samples obtained from cord blood (n=222) and infant samples collected at 1 
(n=92), 4 (n=91), 6 (n=98, 10 (n=103), 14 (n=36), 24 (n=36) and 52 (n=102) weeks 
after BCG immunisation were analysed for IgG specific for PPD and TT using ELISA, 
with IgG antibodies to PPD as the main outcome. The distribution of concentrations of 
IgG specific for PPD and TT by age is illustrated in Figures 5.4A and 5.4B, 
respectively. Compared to the concentration in cord blood (median [IQR]: 8200 ng/ml 
[4000–12450]), PPD-specific IgG concentrations decreased at 1 week after birth (389.5 
ng/ml [279.25-611.5], p<0.0001) and then remained stable up to 52 weeks (291 ng/ml 
[156–365.25], Figure 5.4A, Table 5.2). 
 
By contrast, the concentration of TT-specific IgG was high in cord blood (618000 ng/ml 
[417000–808500], dropped less dramatically by 1 week after birth (396000 ng/ml 
[163000–590000] p<0.0001) and showed little change between 1 and 24 weeks (230000 
ng/ml [126500-354500], but dropped further at 52 weeks (63000 ng/ml [20000-
147000], Figure 5.4B, Table 5.2). 
 
The median PPD-and TT-specific antibody concentrations are shown in Figures 5.4C 
and 5.4D, respectively. There is a slight increase in IgG responses at 24 weeks of age, 
probably as a result of the DPT-HepB-Hib vaccine given at 6, 10, and 14 weeks after 
birth (shown by arrows).  
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         A                                                                 B 
 
         C                                                                D 
 
Figure 5.4. Longitudinal changes in PPD-and TT-specific IgG concentrations. Cord 
blood and infant plasma samples obtained at 1, 4, 6, 10, 14, 24 and 52 weeks after BCG 
immunisation were tested for IgG to PPD (A) and TT (B) by ELISA. Each symbol 
represents an individual infant antibody response. For each plot, the horizontal line 
represents the median (further illustrated for PPD-(C) and TT-specific (D) responses); 
n=222 for cord blood, n=92 for 1 week, n=91 for 4 weeks, n=98 for 6 weeks, n=103 for 
10 weeks, n=36 for 14 weeks, n=36 for 24 weeks and n=102 for 52 weeks time points. 
Arrows illustrate the timing of DPT vaccination in infants. 
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Table 5.2. IgG responses to PPD and TT in infancy.  
 
Samples/Visit Number of 
observations 
Median response to 
PPD 
IQR Median response to 
TT   
IQR 
Cord blood 222 8,200 4000-12450 618000 417000-808500 
1 week 92 3,89.5 279.25-611.5 396000 163000-590000 
4 weeks 91 441 328-640 284000 136000-452000 
6 weeks 98 372.5 239.25-591 168000 52000-328000 
10 weeks 103 370 250-542 144000 40000-318000 
14 weeks 36 297 215.25-393 166000 70000-265000 
24 weeks 36 335.5 245.25-364.5 230000 126500-354500 
52 weeks 102 291 156-365.25 63000 20000-147000 
 
The values are shown as medians in ng/ml with the interquartile range (IQR). 
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5.3.2. The impact of maternal LTBI on PPD-specific IgG responses in infancy. 
Having shown the longitudinal changes in infant antibody responses with age, the 
influence of maternal LTBI on these responses was examined. This is important because 
if there was a difference in infant responses by maternal LTBI, then this may contribute 
to the poor efficacy of BCG in this setting and argue for the treatment of LTBI in 
pregnant mothers. 
 
The impact of maternal LTBI on the infant IgG responses was assessed in cord blood, 
and in plasma samples obtained at 1, 4, 6, 10, 14, 24 and 52 weeks after birth, by 
comparing responses in infants of mothers with and without LTBI. This is illustrated in 
Figure 5.5. As with the pilot infant BCG study data, and in agreement with the results 
presented in Chapter 4, there were no differences in PPD-specific IgG concentrations 
between infants of mothers with and without LTBI at the different time points. 
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Figure 5.5. The impact of maternal infection with M. tuberculosis on the infant 
antibody responses. IgG concentrations were measured in cord blood, and in infant 
plasma samples obtained at 1, 4, 6, 10, 14, 24 and 52 weeks post-BCG by ELISA. Each 
symbol represents an individual antibody response. The horizontal line represents the 
median; the number of participants for LTBI-negative versus LTBI-positive at each 
time point were: 122 versus 100 for cord blood, 50 versus 42 for 1 week, 51 versus 40 
for 4 weeks, 56 versus 42 for 6 weeks, 55 versus 48 for 10 weeks, 15 versus 21 for 14 
weeks, 15 versus 21 for 24 weeks and 60 versus 42 for 52 weeks. Multiple comparisons 
of infants of mothers without (open circles) and with (closed circles) LTBI were 
performed using Kruskal-Wallis test. 
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5.4. Discussion 
There have been relatively few studies of antibodies in TB other than attempts to 
develop antibody-based diagnostic tests. However, maternal IgG antibodies can cross 
the placenta, and could influence the response of the infant to BCG immunisation.  
The concentration of maternally derived mycobacteria-specific antibodies dropped 
rapidly in the first week of life. This is the first time such a finding has been reported. 
For the pilot infant BCG study, the concentration of antibodies dropped further by six 
weeks of life, whereas in the main infant BCG study, antibody concentrations remained 
stable up to age one year.  
 
By contrast, the concentration of TT-specific IgG was high in cord blood, dropped less 
dramatically by one week after birth and changed little between one week and six weeks 
(pilot infant BCG study), and between one week and age one year (the main infant BCG 
study). 
 
In human studies, variations in the decay of maternally derived IgG antibodies have 
been reported, with some studies showing a shorter (373, 375-377) and others longer 
(373, 376, 378-380) clearance time. However, this has further been shown to depend on 
whether the antibodies are elicited as a result of immunisation of the mothers or due to 
natural infection (387). These two studies differed in important aspects: first, different 
lots of PPD were used in the two studies. Second, different BCG vaccine strains were 
used (BCG-Russia for the pilot infant BCG study, versus Danish strain for the main 
infant BCG study). Strain-specific differences in infant T cell responses have previously 
been reported (277, 292), but no one has looked at the antibody responses. Third, the 
pilot infant BCG study was conducted during the months of February to May 
(considered to be a wet season in Uganda), whereas the recruitment for the main infant 
BCG study was spread over a long period of time (covering both wet and dry seasons). 
The season of birth has been reported to influence T cell infant responses (393, 394). It 
is possible that there was a birth season effect on infant antibody responses to vaccines, 
though a study in the Gambia did not observe that (395). There is a plan to repeat these 
assays when samples are collected from the infants at all the time points using a new 
batch of PPD, as well as looking at responses to other mycobacterial antigens such as 
ESAT-6/CFP-10 and Ag85A. BCG immunisation has been reported to induce long-
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lived humoral responses in infants in this setting (174). It was a missed opportunity that 
we only measured total IgG responses instead of IgM responses, which would have 
indicated new antibodies produced by the infants.  
 
The rapid drop in infant antibody concentrations at one week was therefore unexpected. 
It is possible that antibodies to PPD bound to BCG vaccine or mycobacterial antigens, 
thus reducing their concentration in circulation. This may have an effect on the efficacy 
of BCG vaccine. Immune complexes formed between maternally derived antibodies and 
vaccine antigens (where the live-attenuated vaccines may be neutralized) or antigens 
from mycobacteria may be taken up by phagocytic cells or deposited in the tissues 
where they can initiate inflammatory responses or are presented to CD8+ T cells in the 
context of MHC class I molecules, inducing cell mediated responses (396). Antibodies 
may also block specific antigen sites (397-400) or change the stability of the antigens 
(401, 402). This can influence the processing and presentation of antigens and 
subsequent T cell responses. Other mechanisms by which maternal antibodies interfere 
with infant responses to vaccines include their effect on B cell responses by binding to 
FcγRIIB on neonatal B cells, masking of B cell epitopes thus inhibiting responses. 
Samples collected from a randomized comparison of delayed versus immediate BCG 
immunisation (352) would present an opportunity to assess the association between 
infant BCG immunisation and decline of maternally derived antibodies. The rapid drop 
in antibody responses to PPD at six weeks after BCG immunisation in the pilot infant 
BCG study, which was not observed in the main infant BCG study, could be a real 
phenomenon since different strains of BCG vaccine were used in the two studies (BCG 
Russia in the pilot infant BCG study, versus BCG Danish in the main infant BCG 
study). It is also possible that this was an assay-related difference since different batches 
of PPD antigen were used in the two studies. The PPD batches for the two studies were 
obtained from SSI. Re-testing antibodies in samples from the pilot infant BCG study 
using PPD from the main infant BCG study did not show the drop in antibodies 
observed at six week after BCG immunisation (Figure 5.2), indicating that the drop in 
antibody concentration at six weeks in the pilot infant BCG study is partly related to the 
batch of PPD used. PPD is a late stage treated culture supernatant from M.tuberculosis. 
It therefore has a lot of secreted antigens. However, it is very degraded and has many 
small peptides that may not bind well to the ELISA plate.  
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Maternally derived TT-specific antibodies, by contrast, dropped less dramatically by 
first week of life and remained stable over time in both the pilot and the main infant 
BCG study. However, in the main infant BCG study, there was no boost in TT-sspecific 
responses following priming. This may be as a result of inhibitory effects of maternally 
derived anti-TT antibodies (403, 404) or maternal antibodies are masking the generation 
of antibodies in infants. However, other studies have shown that infant responses to 
DPT are not affected by maternally derived antibodies (405, 406). This agrees well with 
the data presented here. Low potency and poor vaccine handling have also been 
reported by as possible cause of lack of boost in TT-specific responses (407). This is 
unlikely to be the cause in our studies, as the vaccines were handled and stored 
according to good clinical practice (GCP). Although the responses to TT were high they 
were within the measurable range for the assay as illustrated for standard curves (A, for 
pilot infant BCG study and B, for main infant BCG study) and sample IgG 
concentrations (C, for pilot infant BCG study and D, for main infant BCG study) in 
Figure 2.10. The same purified IgG standard (from GenScript, NJ, USA) was used in 
ELISAs for both studies. Also, samples from the same infant collected at different time 
points were run on the same plate. There could have been a boost in response after 
vaccination at 6, 10 and 14 weeks, but this could have been masked by the overall high 
combined maternally derived and infant antibody concentrations as illustrated by the 
hypothetical Figure 5.6. It was therefore difficult to separate infant antibody responses 
from maternally derived antibodies. Measurement of IgM, which would have been 
infant derived, would be recommended for future studies.  
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Figure 5.6. Possible dynamics of maternally derived and infant TT antibody 
concentrations. Maternally derived antibody decay is shown in red, infant antibody 
production shown in blue and combined maternal and infant antibody concentrations are 
shown in black. A, shows a situation where maternally derived antibodies decay slowly 
and B, is where maternally derived antibodies decay rapidly. The overall effect is high 
antibody responses to TT. 
 
There were some infants who did not generate antibody responses to PPD or TT at some 
time points in pilot infant BCG study. This could be due to the different strains of BCG 
vaccine used (BCG Russia in the piot infant BCG study, versus Danish strain in the 
main infant BCG study).  
 
There were no differences in PPD-specific IgG concentrations between the infants of 
mothers with and without LTBI at any of the time points.  
 
In conclusion, IgG response to PPD in the infants in these studies waned rapidly in the 
first week, but there were no associations with maternal latent M.tuberculosis infection.  
The data from the pilot infant BCG study supports waning of maternally derived 
antibodies in the first week of life.  Maternally derived TT antibodies remained stable 
over time and there was no effect of booster DPT dose on infant responses. 
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Chapter 6 
General discussion 
6.1. The hypothesis and major findings 
It was hypothesized that maternal latent infection with M.tuberculosis would influence 
the infant response to BCG immunisation. To test this, pregnant women were tested for 
LTBI and their infants followed up to one year after BCG immunisation. ELISA, 
Luminex®, intracellular cytokine staining by flow cytometry and gene expression 
microarray were used to analyse the maternal, cord blood and infant samples collected. 
6.1.1. The infant BCG studies  
Two studies were conducted: the pilot infant BCG study and the main infant BCG 
study. These studies differed in important respects: first, the number of study 
participants and follow up period varied (smaller sample size and short follow up time 
for the pilot infant BCG study, versus larger sample size and longer follow up of up for 
the main infant BCG study. In the pilot infant BCG study, cord blood and infant 
samples were obtained at one and six weeks, whereas in the main infant BCG study, 
cord blood and infant samples were collected at 1, 4, 6, 10, 14, 24 and 52 weeks after 
BCG immunisation. Second, different BCG vaccine strains were used (BCG-Russia for 
the pilot infant BCG study, versus BCG-Danish strain for the main infant BCG study). 
T cell responses and gene expression profiles have been reported to vary with BCG 
strain (277, 292, 408). Third, different immunological techniques were used for analysis 
of T cell responses in the two studies (intracellular cytokine staining by flow cytometry 
for the pilot infant BCG study, versus WBA and Luminex® for the main infant BCG 
study). Fourth, mononuclear cells were stimulated for 24 hours in the pilot infant BCG 
study, versus 6-day stimulation of whole blood in the main infant BCG study.  
The objectives of the two studies were also slightly different.  The pilot study was 
aimed at determining immediate cytokine secreting ability of cells (so innate cells such 
as monocytes and ILCs, effector T cells and perhaps a few effector memory cells), 
whereas the main infant BCG study was aimed specifically at measuring memory T cell 
responses.  So, the length of the assays measured slightly different cell subsets and this 
might account for any real differences observed. 
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6.1.2. Infant innate responses 
Innate responses in the pilot infant BCG study were tested by culturing whole maternal 
and cord blood samples with a number of stimuli that would activate TLR1/2, TLR2/6, 
TLR4, TLR7/8, TLR9, DC-SIGN and Dectin-1. The concentration of cytokines and 
chemokines in stimulated samples were moderately high in maternal blood and in cord 
blood. High concentrations of certain cytokines and chemokines have been reported in 
neonates and adults (337). In utero sensitisation to maternal infections has been shown 
to prime responses in the infants (287), a possible reason for similar responses observed 
in maternal and cord blood samples. Common genetic factors between the mothers and 
their neonates may also be responsible for the similarities in innate responses observed. 
Increased acute phase responses as a result of the normal delivery process has also been 
reported to increase responses in the neonates (334). So the birth process may have 
contributed to the similar responses in maternal and cord blood samples since none of 
the infants was born by caesarian section.  
6.1.3. Impact of maternal factors on innate responses 
Maternal LTBI was associated with higher IP-10 responses in the cord blood. IP-10 is a 
proinflammatory chemokine responsible for the trafficking of immune cells, including 
leucocytes, and with a role in apoptosis, cell growth and proliferation (409). Human and 
murine studies have shown increased Th1 responses in an IP-10 environment (181, 
410). IP-10 has also been shown to have a potential as a diagnostic marker for TB (411-
414). Further assessment of the role of IP-10 in immunity in infants is needed. 
There was a positive association between maternal BCG scar and cytokine responses in 
cord blood. This may be due to common genetic factors between the infants and their 
mothers that determine scar formation and subsequent infant responses, or that the 
factors associated with scar formation in the mothers are passed on to the infants. The 
differences in infant response may also relate either to the mother’s BCG immunisation 
status or to the quality of mothers’ BCG-induced responses. 
6.1.4. Maternal factors and gene expression profiles in infants  
Maternal LTBI was associated with down-regulated interferon and inflammatory 
response pathways at one week after BCG immunisation. Genes associated with the 
mitogen-activated protein kinase (MAPK) signaling pathway, such as JUNB (Jun B 
proto-oncogene), FOS (Fos proto-oncogene) and FOSB (FBJ murine osteosarcoma viral 
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oncogene homolog B), were also down-regulated one week after BCG immunisation. 
The MAPK signaling pathway is important in the regulation of innate immune 
responses as well as in the induction of inflammatory responses (415). Maternal LTBI 
was associated with up-regulated interferon and inflammatory response pathways at six 
weeks after BCG immunisation. It was thought that the down-regulated gene expression 
profile observed at one week would be maintained for some time, so the change in 
direction after six weeks was unexpected.  These observations support the hypothesis 
that in utero exposure to maternal M.tuberculosis influences the infant innate response 
to BCG, but only shortly after birth. A larger study is needed to confirm these findings.  
BCG immunisation has been reported to influence infant gene expression profiles (416, 
417) and different strains of BCG have been shown to induce different gene expression 
profiles in infants (408). A comparison of gene expression profiles in infants who 
received BCG-Russia in the pilot BCG study with the infants in the main infant BCG 
study who were given BCG-Danish would show if there are any differences in 
responses to different strains of BCG. This is now being done with our collaborators at 
the Universsity of Oxford. 
The expression of genes in the interferon and inflammation response pathways was 
increased in infants of mothers with a BCG scar at one and six weeks after BCG 
immunisation. DNA replication and cell cycle progression pathways were also up-
regulated in infants of mothers with a BCG scar at one week. These observations 
highlight the importance of assessing the influence of maternal immunisations on infant 
responses to vaccines as they show associations with important pathways in infants.  
6.1.5. The peak of BCG-induced infant T cell responses 
In the pilot infant BCG study, the frequency of CD4+ T cells expressing Th1 cytokines, 
combined, after stimulation with PPD peaked at one week after BCG immunisation. 
This might be expected if the focus was on innate responses. For the main infant BCG 
study, the peak of the response to PPD measured by Luminex® was around 24 weeks of 
age, later than the 6-10 week period reported by Soares and colleagues (220). Th1 
responses to ESAT-6/CFP-10 increased with age, showing the possibility of exposure to 
M.tuberculosis or NTM. These are two new findings.  
 
As discussed in section 6.1.1 above, the differences between the pilot infant BCG study 
and the main infant BCG study might have resulted in the differences observed. 
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Together, these two studies add to the knowledge on peak in response to BCG 
immunisation. The 24-hour stimulation of PBMCs gave a peak response at one week 
after BCG immunisation, whereas for 6-day stimulation of whole blood, the peak in 
response was around 24 weeks after BCG immunisation. A study in mice showed that 
response to PPD in the spleen (examined using ex vivo ELISPOT) peaked at 12-32 
weeks after BCG immunisation (418). 
6.1.6. Maternal factors and infant T cell responses 
In the pilot infant BCG study, maternal infection with M. tuberculosis was associated 
with impaired infant CD4+ T cell responses one week after neonatal BCG immunisation 
when responses were assessed using intracellular cytokine staining and flow cytometry 
after a 24-hour stimulation period. Jones et al. in a recent study showed no difference in 
BCG-induced responses after 6-day stimulation, measured by intracellular cytokine 
staining and flow cytometry and Luminex® assay, between infants of mothers with and 
without M. tuberculosis infection (359). As discussed in Chapter 4.4, there were 
important differences between Jones’ study and the pilot infant BCG study. First, the 
methods used for screening for maternal LTBI were different (both TST and T-
SPOT.TB in this study, versus the less stringent QuantiFERON-TB Gold test alone in 
Jones’s study). Second, the strains of BCG vaccine used were different (BCG-Russia in 
the pilot infant BCG study, versus the Danish strain in Jones’ study). Third, the infants 
in my studies were immunised at birth, versus six weeks for Jones et al. Fourth, a 24-
hour cell stimulation assay was used in this study, versus a 6-day WBA by Jones et al. 
In the main infant BCG study using 6-day cultures and Luminex® assays, overall, 
maternal LTBI was not associated with infant responses in agreement with the Jones 
study. These observations show that responses early in life may not reflect what 
happens later in life, and that it is important to carefully design studies aimed at 
evaluating infant responses to vaccines as different experiments may give different 
results. 
6.1.7. Maternally derived antibodies and BCG 
Maternally derived antibodies dropped rapidly in the first week of life. It is possible that 
the antibodies to PPD may have bound to the BCG vaccine or mycobacterial antigens 
derived from it, thus forming an immune complex that has the potential to either reduce 
or increase responses to childhood vaccines. Neutralization of live-attenuated vaccine 
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by maternally derived antibodies can reduce the effectiveness of vaccines or protective 
responses may be elicited when the immune complexes are taken up, processed and 
presented to T cells, such as reported for CD8+ T cells (396). This may explain why 
BCG vaccine has good efficacy against disseminated TB in childhood, but poor efficacy 
in adolescents and adults when maternally derived antibodies have waned. Maternal 
LTBI was not associated with infant antibody response to PPD. 
6.2. Characteristics of assays used 
There are important differences in the characteristics of the assays employed in the pilot 
infant BCG study and the main infant BCG study. These assays and the results obtained 
using them are illustrated in Table 6.1. As discussed in Chapter 4.4, it is important to 
carefully select which assays to use in studies like these since these may reflect different 
types of immune responses and give different results (419).  
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Table 6.1. Associations between maternal LTBI and maternal BCG scar and results obtained using the different immunological techniques 
 
 
 
Assays performed 
 
Longitudinal changes in 
infant responses 
Association between 
maternal LTBI and infant 
responses 
Association between 
maternal BCG scar 
and infant responses 
 
 
Comments 
 
 
ELISA 
Concentration of antibodies 
to PPD dropped rapidly in the 
first week of life 
 
No effect on antibody 
concentrations 
 
Effect of maternal BCG 
scar was not assessed 
 
Antibodies measured 
in plasma 
 
Flow cytometry 
Responses peaked at 1 week 
after BCG 
Responses impaired at 1 
week after BCG 
No associations observed Short-term (24 hour) 
PBMC cultures 
Luminex® for innate 
responses 
Only measured in cord blood 
samples 
 
No associations observed 
Increased pro-
inflammatory responses  
Short-term (24 hour) 
whole blood cultures 
Luminex® for 
adaptive responses 
Responses peaked around 24 
weeks after BCG 
 
No associations 
 
No association 
Long-term (6-day) 
whole blood cultures 
 
 
Gene expression 
microarray 
 
Only measured at 1 and 6 
weeks after BCG 
immunisation 
Interferon and inflammatory 
pathways down-regulated at 
1 week, but up-regulated at 
6 weeks after BCG  
Interferon and 
inflammatory pathways 
up-regulated at 1 week 
and 6 weeks after BCG  
Unstimulated whole 
blood samples were 
used 
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6.3. Limitations of the studies 
The pilot study was limited in that it was observational and exploratory in nature, and 
the sample size was small relative to the many outcomes assessed. The small sample 
size made adjustment for confounding factors difficult. As a result, only major 
exposures (maternal LTBI and maternal BCG scar) were adjusted for. Also, some 
important later time points were missed in the pilot infant BCG study. The assessment 
of innate immune responses was cross-sectional and only performed on cord blood. 
There were therefore no comparison time points after BCG immunisation, making 
examination of differences between responses pre-and post-BCG immunisation 
difficult. For infant gene expression profiles in the pilot infant BCG study, there was no 
comparison group pre-BCG immunisation. The only data available was for responses at 
one and six weeks after BCG immunisation. Whole blood was used for assessing the 
gene expression profile, thus the cellular source of genes or pathways was not known. 
Further analysis using programmes that look at functional dynamics in cells, based on 
gene expression profiles, would have shed more light on this (420). 
 
Up to 140 infants who had completed follow up to one year were considered for 
analysis of immune responses in the main infant BCG study. This number was 
determined by funds available for the reagents and the time frame within which the 
laboratory work had to be completed. The selection of infants was therefore not 
randomly done, highlighting the possibility of bias in the analysis. However, the 
samples were randomized for analysis of responses by Luminex®.  
 
Follow up of the infants in the main infant BCG study has just been completed. 
Cleaning of clinical, laboratory and socio-demographic characteristics of the 
participants is underway. As a result, some of the factors thought to be possible 
confounders, such as maternal helminth infection, have not been adjusted for in the 
results presented here but it is hoped they will be available by the time of viva voce 
examination. An analysis of results for all the infants is planned (although not as part of 
my PhD work).  
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6.4. Implications of the studies 
The increased innate responses in cord blood samples of infants of mothers with a BCG 
scar, compared to those without, has implications for responses to vaccines 
administered in childhood. The priming of the innate infant response might result in a 
better adaptive response, and this has important implications on vaccines and their 
schedule (267, 421).  Although no differences were seen for response to BCG in the 
long term, the use of other vaccine preparations, such as subunit vaccines might show 
differences.  Perhaps the nature of the live BCG gives enough innate signaling to 
override the subtle effects which may be seen early on.  Examination of such an effect 
using OPV, versus inactivated polio vaccine (IPV) in infants may shed more light.  
 
The main infant BCG study has provided evidence that the infant response to BCG 
immunisation peaks around 24 weeks after BCG. This is important since little is 
actually known about the peak of responses following BCG, yet this knowledge is 
required for vaccines that use a prime-boost strategy. It was expected that there would 
be differences in peak of response after 24-hour (at one week) and 6-day stimulations 
(at 24 weeks) as there are important differences between responses in short and long 
term cultures, and as the two infant studies used different strains of BCG. Several 
studies, including those that used viral infection models, have demonstrated that 
memory populations established after the peak effector phase are suitable to boost (220, 
252-255, 422, 423). Based on my data, it is possible that the failure in MVA85A 
vaccine to provide protection might be because of boosting responses too early (200). 
Based on the observation in the main infant BCG study, it would therefore be 
recommended that boosting of responses primed by BCG should be performed after the 
peak in response because the size of the pool of cells recruited into the primary 
immune response directly affects the resulting pool of memory T-cells capable of 
responding to subsequent infection (356). A lower recruitment of cells into the 
priming phase may affect the BCG-specific immunological memory set point. Since 
correlates of protective immunity to TB are not known, more understanding of what 
immune responses should be boosted is required. 
 
Delaying boosting to a later time point, for example at 52 weeks, would be optimal, but 
this introduces the challenges of exposure to NTM (424) and M.tuberculosis (425), with 
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subsequent establishment of LTBI, as reported in section 4.3.3. These results therefore 
highlight the need to properly optimize the use of vaccines designed for a prime-boost 
strategy in areas with a high prevalence of NTM and M.tuberculosis.  
 
The studies presented in this thesis have shown associations between maternal factors 
and infant responses. The positive association between maternal BCG scar and 
increased infant responses is an important observation. Infant BCG scar has been 
associated with innate training and subsequent heterologous effects in infants (260-269), 
although a recent study by Kjaergaard and colleagues did not observe nonspecific 
beneficial effects of BCG vaccination against childhood infection in a high-income 
setting (271). A recent systematic review of the available literature did not show 
sufficient evidence of non-specific immunological effects of BCG immunisation (272). 
The finding that infants of mothers with a BCG scar, compared to those without, had 
increased innate responses highlights the importance of further understanding host 
factors such as genetics (or epigenetics) that may be common between the mothers and 
their infants, and how maternal immunisations and the resulting immune responses 
influence responses in the newborns.  
 
The finding in the pilot infant BCG study that maternal LTBI was associated with 
impaired infant T cell responses at one week of life following BCG immunisation might 
call for the treatment of women with LTBI in pregnancy or those intending to conceive. 
Tuberculosis screening of women during pregnancy when attending antenatal clinics 
would identify those latently infected who could benefit from treatment. The first-line 
drugs for the treatment of TB (with exception of streptomycin which is ototoxic to the 
fetus) have been shown to be safe for use during pregnancy (426-428), but little is 
known about treatment-associated complications during pregnancy, including isoniazid-
induced hepatitis (426, 429). Another important factor to consider is the cost of 
treatment, which is US$40.0 per person for the 6-month course (1). However, the later 
time points did not show an effect of maternal LTBI on infant responses. Again, 
preliminary analysis of flow cytometry data (not as part of this PhD work) from the 
main infant BCG study seems to support the results from the Luminex® assays in that 
no differences were observed between infants of mothers with and without LTBI. It 
may therefore be difficult to advocate for treating mothers with LTBI based on the short 
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term effect at one week against a lack of effect at later time points. The pilot infant 
study had a small sample size, used a different BCG strain and different technique from 
the main infant BCG study and the responses may therefore have had a stronger effect. 
There are reports that after a series of passages, the potency of BCG-SSI has changed 
over time (430, 431), and high responses to PPD and ESAT-6/CFP-10 were observed in 
the infants in the main infant BCG study. A much larger follow up study would be 
needed to examine TB cases in the infants of mothers with or without LTBI and those 
with and without a BCG scar. Very few infants have developed TB (12 with probable 
TB disease) in the CiSP cohort of about 1474 infants (323), so such a study would need 
a considerably larger sample size. 
 
The finding that maternally derived antibodies, particularly to PPD, in the infants 
decayed rapidly in the first week of life needs further understanding, as this may be one 
of the mechanisms through which BCG exerts its protective effects in childhood or lack 
of it in adolescent and adult populations. 
 
The results finally highlight the importance of carefully considering assays for use in 
studies, as different results were observed with the different assays employed. 
6.5. Future perspectives 
Studies relating the increased infant innate responses observed in the pilot infant BCG 
study to adaptive responses would give a complete picture of responses following BCG 
immunisation. The innate and adaptive responses are closely linked and there may also 
be innate effects from cytokines produced in the adaptive response. Immunological 
memory within the innate immune system has been a hot topic for discussion recently. 
It is therefore important that both arms of the immune response are analysed in future 
studies.   
 
Further investigations of the decay in antibody responses soon after birth, and the 
mechanisms involved would be important. If the antibodies bound to BCG vaccine as is 
suggested, it is also important to examine the type of immune responses elicited by the 
immune complexes formed. This has implications for vaccine development and for the 
efficacy of BCG vaccination later in life. 
 
  
 
 
 
196 
If pregnant mothers with LTBI were to be treated, this would offer opportunities for 
studies on the effect of maternal LTBI treatment on immune responses in their infants. 
 
The main infant BCG study offers opportunities to relate the peak in response following 
BCG to the phenotype and function of cells involved. Flow cytometry results are 
available to be analysed for this objective. Samples are also available to perform gene 
expression microarray for longitudinal responses, including cord blood that was missed 
in the pilot infant BCG study. 
 
In conclusion, there was evidence of an influence of maternal LTBI on infant responses 
in the pilot infant BCG study, but not in the main infant BCG study. There is still a need 
to understand better what BCG does, in order to design better TB vaccines, but also to 
carry out more studies on the non-specific effects of giving this vaccine to infants so 
soon after birth. 
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Appendix C 
       
 
OBSERVATIONAL/INTERVENTIONS RESEARCH ETHICS COMMITTEE 
 
08 November 
Alison M. Elliott 
Dear Alison 
 
Study Title: The impact of maternal M. tuberculosis and helminth co-
infection on infant immune responses to BCG immunisation: a 
pilot study. 
LSHTM ethics ref: 6062 
Department: Infectious and Tropical Diseases 
  
Thank you for your email of 3 November responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
The further information has been considered  on behalf of the Committee by the Chair.  
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis described in the application form, protocol and 
supporting documentation as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
Approval is dependent on local ethical approval having been received, where relevant.   
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date      
LSHTM ethics application  n/a    
Protocol V2.0 04/11/11   
Information Sheet V2.0 04/11/11   
Consent form  V2.0 04/11/11   
After ethical review 
Any subsequent changes to the application must be submitted to the Committee via an 
E2 amendment form.    
 
Yours sincerely, 
 
 
Professor Andrew J Hall 
Chair 
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Appendix D 
 
Uganda Virus Research Institute / Entebbe Hospitals 
 
The impact of maternal M. tuberculosis and helminth co-infection on infant 
immune responses to BCG immunisation: a pilot study. 
 
Consent for procedures to study the impact of maternal M. tuberculosis and 
helminth co-infection on infant immune responses to BCG immunisation. 
 
Dear Mothers, 
 
Tuberculosis (TB) is still a great problem in Uganda and many other countries. Many 
people are infected with TB, although a much smaller number of people actually suffer 
from TB disease. BCG immunisation has some benefit for young children in tropical 
countries like Uganda, but it is not so effective here as it is in Northern countries.  The 
reason for the lower effect of BCG in countries like ours is not yet known. 
 
It is possible that when a mother herself has been infected with TB or worms this may 
alter the development of the immune response in her unborn child in such a way that the 
baby’s BCG immunisation, given soon after birth, is less effective. The aim of this 
study is to find out whether this is so. It is a small study conducted in preparation for a 
planned bigger project. 
 
A clinical test called tuberculin skin test (TST) and a laboratory test known as T-spot 
are available to tell us whether someone has been infected with the organisms that cause 
TB disease, even if they do not have the disease.  Tests are also available to tell us 
whether someone is infected with worms. If you agree, we would like to use these tests 
to find out whether you are infected with TB and worms, and to find out whether this 
TB or worm infection in you will affect your newly born baby’s response to BCG.  
 
We would also like to follow up your child until he/she is six weeks of age. We would 
like to do this to see the immediate effect of mothers’ TB or worm infection or lack of it 
on infants’ responses to BCG at one week, and later effects at six weeks of age.  The 
results will provide useful information as to whether the mother’s infection with TB 
organisms or worms has an influence on the baby’s response to BCG immunisation.  
 
We also hope that the results of this study will provide important information that will 
contribute to finding better ways of immunising against TB in countries like Uganda. 
 
If you agree to take part in this study with your child this is what will happen: 
 At delivery, a sample of cord blood will be taken after your baby has been delivered. 
 The rest of the following procedures will only take place if the delivery goes well, the 
cord blood is obtained successfully, and both you and your baby are healthy. 
 After delivery you will be asked questions about your health and home environment.   
 At one week after delivery, we will ask you for a blood sample (2 teaspoons). We will 
use this blood for an HIV test, for a T-spot test to test for TB infection, and for tests of 
your immune responses. You will also be given a tuberculin skin test (TST) and you 
will be asked to come back (or to be visited at home) for this to be read after two or 
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three days. This is the usual test for TB infection, and will be done for comparison with 
the results of 
 T-spot test. We will also check your stool and blood to find out whether you have 
worms.  
 We will also ask for a blood sample from your child (half a teaspoon) one week after 
BCG immunisation. We will also ask for another blood sample from your child after six 
weeks (half a teaspoon). We will use this blood for tests of immunity.   
 If you have a positive blood test for TB infection or a positive tuberculin skin test you 
will be checked for TB disease by a doctor and sent for a chest X-ray.  If you are found 
to have TB disease you will be treated.  
 If you are found to have worms, you will be given anti-worm treatment. 
 Transport will be provided to take you home from the hospital and field workers may 
visit you at home to check on your skin test result and on the baby’s progress, and to 
remind you about your follow up visits. A transport refund will be given for each visit 
when you are asked to come to the clinic. 
Taking part in this study is not expected to cause any major problems for you or your 
child. However, there will be some discomfort from having blood samples taken and the 
smaller discomfort of tuberculin skin testing.  In general, blood samples will be used for 
tests of immunity and some may be stored for other tests in future.  All the information 
collected, and the results of tests, will be completely confidential.   
Your right to refuse or withdraw from the research study 
Your participation in this study is voluntary.  You and your child are free to drop out of 
the study at any time.  Dropping out of the study will not affect your entitlement to 
routine government health care and management or to the provision of treatment for TB 
or worms if you need it. 
If you have any questions about your participation in this study, please feel free to 
ask the responsible midwife, doctor or field worker.  If you prefer, you may speak 
to one of the principal investigators for this study: Dr Elliott (telephone:  0417 
704000) or Mr Mawa Akusa Patrice (telephone: 0417 704000).  If you have any 
questions about your rights as a research subject, you may also speak with the 
Ethics Committee Chairman from Uganda Virus Research Institute, Dr. Tom 
Lutalo on 0414 320631.  The programme staff will let you use a phone for the call.   
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Appendix E 
 
Uganda Virus Research Institute / Entebbe Hospitals 
 
The impact of maternal M. tuberculosis and helminth co-infection on infant 
immune responses to BCG immunisation: a pilot study. 
 
Consent for procedures to investigate the impact of maternal M. tuberculosis and 
helminth co-infection on infant responses to BCG immunisation. 
 
Mother’s names …………………………………. Child’s names 
………………………………….         
 
Mother’s IDNO  |___|___|___|___|                         Child’s IDNO  
|___|___|___|___|/|___| 
 
I have read and/or been fully explained the information sheet concerning I and my 
child’s participation in this study and I understand what will be required if we take part 
in the study. 
Our participation is voluntary.  
My questions concerning this study have been answered by 
………………………………………… 
I understand that at any time I and my child may withdraw from this study without 
giving a reason and without affecting our entitlement to routine government health care 
and management  
 
“My signature / thumb print below indicates that I agree for my child and I to take part 
in this study, for TST test to be performed on me and for blood to be drawn from us” 
 
 
 
 
 
 
……………………………………………………… 
Signature        Or right thumb print 
 
Name of mother ……………………………………………… 
 
Date    …………………………………… 
 
Witness*: 
 
Name  ……………………………            Signature  
………………………………………. 
*for those using a thumb print, this witness must not be a member of the research staff 
or a study participant 
Date    …………………………………… 
 
Investigator: 
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Name  ………………………………… Signature  
………………………………………. 
 
Date    …………………………………… 
Note: form to be completed and signed in duplicate.  One copy to be given to the 
mother; one copy to be retained at the clinic. 
 
 
Uganda Virus Research Institute / Entebbe Hospitals 
The impact of maternal M. tuberculosis and helminth co-infection on infant 
immune responses to BCG immunisation: a pilot study. 
 
Consent to use samples and records for future studies 
 
Mother’s names ……………………………Child’s names 
………………………………….   
       
Mother’s IDNO  |___|___|___|___|                            Child’s IDNO  
|___|___|___|___|/|___| 
 
I have been asked for permission to use my samples and records and that of my child for 
future studies. I have read the foregoing information or it has been fully explained to 
me. I had the opportunity to ask questions about it and any questions I have asked have 
been answered to my satisfaction.  
 
“My signature / thumb print below indicates that I agree for part of my specimen and 
that of my child to be stored for future studies”. 
 
 
 
 
……………………………………………………… 
Signature        Or right thumb print 
 
“My signature / thumb print below indicates that I do not agree for part of my specimen 
and that of my child to be stored for future studies”. 
 
 
 
 
……………………………………………………… 
Signature        Or right thumb print 
 
Name of mother ……………………………………………… 
 
Date    …………………………………… 
 
Witness*: 
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Name  ……………………………………………  Signature  
………………………………………. 
*for those using a thumb print, this witness must not be a member of the research staff 
or a study participant 
Date    …………………………………… 
 
Investigator: 
 
Name  ………………………………Signature  ………………………………………. 
 
Date    …………………………………… 
Note: form to be completed and signed in duplicate.  One copy to be given to the 
mother; one copy to be retained at the clinic. 
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Appendix F 
 
11/10/2011       BCG study:         ELIGIBILITY Form I                            (ELIG-I) 
 
 
NAME: ……………………………………… |___|___|___|___|___|___|/|___|___|  
ANCNO    
 
Screening Number:                                                                  |___|___|___|___|  SCRNO 
 
 
Date:                                                          |___|___|/|___|___|/|___|___|___|___| DATEI
    
 
 Fill these questions in order. If the mother is not eligible, go to Q7 and indicate it.  
 
ELIGIBILITY FOR BCG STUDY:  
 
To be eligible Q1 to Q5 should be “YES” 
 
  
       
1.   Is the participant resident in Entebbe municipality                                                          
EBBMUN  or Katabi Sub-county- Kabale Sabaddu B  
& Nkumba Parish? (Resident=expected to live in entebbe for at-least 2 years) 
       
If yes to Q.1, Read to her the consent notes: 
 
2.   Is she willing to participate in the BCG study?                                             PSTUDY 
 
3.   Does she wish to know her HIV test result?                                                   TKHIV  
 
4.   Is she HIV negative based on ANC record?                                                     MHIV 
                                                                                                          
5.   Is the pregnancy normal?                                                                               NPREG 
 
6. (a) Did she take an anti-worm drug during pregnancy?                               AWDRUG     
 
    (b) If yes to Q.6a, which drug? (1=albendazole, 2=praziquantel,                   WDRUG 
3=other 
 
7.   Is the participant eligible for the BCG study? (1=Yes, 2=                           ELIG                          
 
 
 
 
 
 
 
 
  1=Yes   2=No 
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Appendix G 
 
04-10-2011       BCG study:      ELIGIBILITY Form  II                            (ELIG-II) 
                                               (When they bring stool sample)    
 
NAME: ……………………………………___|___|___|___|___|___|/|___|___|   
ANCNO   
 
Screening Number:                                                             |___|___|___|___|   SCRNO   
  
Date:                                                     |___|___|/|___|___|/|___|___|___|___|    DATEII
   
Please fill all boxes. 
To be eligible all these should be “YES” 
                                                                                                                         
 
Eligibility form “I” filled and eligible?                                                     FILLED  
 
2.   Is the consent form signed?                                                                       SIGNED 
             
 
3.   Clinical form (Screening form) filled?                                                    CLINFIL 
4a.   Is this pregnancy normal?                                                                      PRGNORM 
4b.   Is severe liver disease ABSENT?                                                     LIVERDIS 
 
5.   Is the pregnancy greater than 14 weeks old ?                                        PRG14WKS 
 
If no to Q.5, give appointment after 14 weeks will be complete. 
                                                                                        
6.   Study/Blood samples taken at last visit?                                                   BLOOD 
      
 
7.   Stool sample brought?                                                                               STOOL  
 
8.   Haemoglobin result (Hb): |___|.|___|  g/dl                                       HB 
 
9.   Is this result   8 g/dl  ?                                                                                     
GREATER 
 
  If yes to all (questions 1-9) above, give study drug. 
 
If no to questions 1-7, wait till “yes” if possible.  
 
11.   Study drug number:                WS|___|___|___|___|                        WSIDNO    
 
  If no to Q.9, refer to clinician to consider treatment for hookworm & anaemia.  
(1=Yes,  2=No)                                                                   |___| REFER  
 
 
 
1=Yes 
 
 
No=2 
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Appendix H  
 
20/02/2012         BCG STUDY:         SCREENING FORM                               
(BCGSCREEN) 
 
Q1.a. Name of mother … 
………………………….....................................................................NAME  
      b. Identity Number:                                                                                 
|___|___|___|___|    IDNO                 
Q2.   Age |___|___| AGE    Date of Birth (dd/mm/yyyy)   
|___|___|/|___|___|/|___|___|___|___|   DOB 
Q3. ADDRESS: 
Current Residence/ L.C.1 / Barracks:                                                                                       
  
……………………………………………….……………………………………..……
……………… 
 Phone 
number................................................................................................................................. 
(c)   Name of L.C.1 
Chairperson………………..………………………….…………………………………
……………..  
(d)  Description of how to find the home (e.g nearest shop/bar/market/hotel e.t.c): 
………………………….……………………….………………………………………
…………………………...……….………………………………………………………
…………….......................................... 
(e) Two people whom we could contact if we cannot contact the mother: 
Name1 ................................................................................... Phone 
number2………………………..  
Name1 ................................................................................... Phone number 2........ 
………………….      
PREVIOUS PREGNANCIES: 
Q4. Is this your first pregnancy?                                                              |___|   FPREG  
       (1=Yes, 2=No)           
WORM TREATMENT:     
Q5.  Have you ever had any medicine for worms?                                  |___| WMED 
        (1=Yes, 2=No, 3=Don’t know) 
Q6.  If yes to Q5, When was the most recent?                                           ___| RECENT 
            1 = During this pregnancy                                                4 = As a child                     
   
            2 = Within last year but before the last menstrual period     5 = Never   
            3 = More than 1 year ago                   6 = Don’t Know   
           
Q7. If yes to Q5,                                                                                                
            1 = Mebendazole                                                Worm drug 1  |___| WDRG1 
            2 = Praziquantel                                                                         Worm drug 2  
|___| WDRG2 
            3 = Albendazole                                                    Worm drug 3  |___| WDRG3 
            4 = Other specify ………………………………….……………  Q7SPEC 
            5 = Don’t know                                                                          |___| DKNOW                                                                                
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TB HISTORY:  
Q8. Have you ever received treatment for TB disease?    |___| TTB        Year: 
|___|___|___|___| YTB 
       (1=Yes, 2=No, 3=Uncertain) 
Q9. Was the treatment during this pregnancy?                                                              
|___| TTBP         
        (1=Yes, 2=No, 3=Uncertain) 
Q10. If yes to Q9,  
What is the start date of treatment for TB? (dd/mm/yyyy) 
|___|___|/|___|___|/|___|___|___|___|   STBRX 
What is the finish date of treatment for TB? 
(dd/mm/yyyy)|___|___|/|___|___|/|___|___|___|___|   FTBRX 
Q11. Is TB treatment still on-going?                                                                                       
|___| TTBON                   
        (1=Yes, 2=No) 
Q12. Have you ever received treatment to prevent TB?       |___| TBP    Year: 
|___|___|___|___|    YTBP 
         (1=Yes, 2=No, 3=Uncertain) 
Q13. Was the treatment during this pregnancy?                                                                      
|___| TTBP         
         (1=Yes, 2=No, 3=Uncertain)        
Q14. If yes to Q13,   
What is the start date of treatment for TB? (dd/mm/yyyy)    
|___|___|/|___|___|/|___|___|___|___|   STBP 
 What is the finish date of treatment for TB? (dd/mm/yyyy) 
|___|___|/|___|___|/|___|___|___|___|    FTBP 
Details of TB or preventive treatment 
history............................................................................................................ 
Ask if they have their TB treatment card to see at home and bring to next visit. 
Q15. Have you ever lived in a house with someone with TB? |___| HHTB  Year: 
|___|___|___|   YHHTB 
         (1=Yes, 2=No, 3=Uncertain) 
Q16. If yes, how close you were to the patient (indicate the closest contact) |___| HHR 
        (1=shared bed, 2=shared bedroom, 3=shared living room, 9=can’t tell) 
BCG Scar        
Q17.  Any previous BCG vaccination scar?                                   |___|   BCGSC  
         (1=Yes, 2=No, 3=Uncertain)                             
Q18. If yes, how many BCG scars?                    |___|   BCGNO 
BCG vaccine data 
Manufacturer……………………………………..…………………  …BCGMAN 
Lot number…………………………………….........................................BCGLOT 
Polio vaccine data 
Manufacturer………………………………………………………    …POLMAN 
Lot number……………………………………………………………   POLLOT 
Name of Interviewer: ……………………………………………………………. 
Signature of Interviewer:………………………..  
Date: (dd/mm/yyyy)                      ___|___|/|___|___|/|___|___|___|___|   DATE 
 
THANK YOU. 
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Appendix I 
 
Major equipment, supplies and reagents 
 Biosafety Cabinet Class 2  (Walker Safety Cabinets, United Kingdom)  
 Water-bath (Julabo Labortechnik Gmbh, Seelbach, Germany) 
 Incubator (Revco Habitat, Thermo Fisher Scientific, Washington, DC, USA) 
 Fridge/freezers (+4/-200 C) (Lec Medical, Merseyside, United Kingdom) 
 Freezer (-80°C) (New Brunswick Scientific, United Kingdom) 
 Centrifuge (Rotanta, HAHN Gastedern Gmbh Waldstrasse, Germany) 
 Microscope (Olympus corporation, Tokyo, Japan) 
 Vortex (Scientific industries, Boloemia, NY, USA) 
 Pipette AID (Jencons, San Diego, CA, USA) 
 P200-1000µL multi-channel pipetter (Thermo Fisher Scientific, Washington, DC, USA) 
 96 well (round bottomed) tissue culture plates with lids (Beckton Dickinson, NJ, USA) 
 10µL-1000µL pipette tips (Gilson, Luton, Bedfordshire, United Kingdom) 
 Microtubes (National Scientific supply, Claremont, California) 
 Weighing scale 
 Thermometer 
 Stethoscope 
 Syringes and needles 
 Working tray 
 Transparent ruler 
 Ball pen 
 Sharps and disposal container 
 Blood collection tubes 
 RPMI 1640 medium (Life Technologies Corporation, NY, USA) 
 Hepes buffer (Sigma-Aldrich, MO, USA). 
 Penicillin/Streptomycin (Sigma-Aldrich, MO, USA)  
 L-glutamine 200mM (Sigma-Aldrich, MO, USA). 
 Tuberculin PPD  (RT 23 (Statens Serum Institut, Copenhagen, Denmark) 
 BCG vaccine  
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Appendix J  
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Appendex K 
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Appendix L 
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Appendix M 
 
MRC/UVRI/Entebbe Hospital/Kisubi Hospital 
 
The impact of maternal infection with Mycobacterium tuberculosis on the infant 
response to BCG immunisation 
 
Dear Mothers, 
 
Tuberculosis (TB) is still a great problem in Uganda and many other countries. Many 
people are infected with TB, although a much smaller number of people actually suffer 
from TB disease. BCG immunisation has some benefit for young children in tropical 
countries like Uganda, but it is not so effective here as it is in Northern countries.  The 
reason for the lower effect of BCG in countries like ours is not yet known. 
 
It is possible that when a mother herself has been infected with TB, that this may alter 
the development of the immune response in her unborn child in such a way that the 
baby’s BCG immunisation, given soon after birth, is less effective. The aim of this 
study is to find out whether this is so.  Immune responses are the body’s way of 
protecting you against infections. 
 
A clinical test called tuberculin skin test (TST) and a laboratory test known as 
TSPOT.TB are available to tell us whether someone has been infected with the 
organisms that cause TB disease, even if they do not have the disease. If you agree, we 
would like to use these tests to find out whether you are infected with TB or not, and to 
find out whether this infection in you will affect your newly born baby’s response to 
BCG.  
 
We would also like to follow up your child until he/she is one year of age. We would 
like to do this to see the immediate and longer term effects of a mother’s TB infection, 
or lack of it, on their infants’ responses to BCG at one week, and later effects at four, 
six, ten and 52 weeks of age.  The results will provide useful information as to whether 
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the mother’s infection with TB organisms or worms has an influence on the baby’s 
response to BCG immunisation.  
 
We also hope that the results of this study will provide important information that will 
contribute to finding better ways of immunising against TB in countries like Uganda. 
 
If you agree to take part in this study with your child this is what will happen:  
 At delivery, a sample of cord blood (2 teaspoons) will be taken after your baby has been 
delivered. 
 A sample of the placenta will also be obtained to check for malaria and for studies of 
immune responses, as well as gene and gene expression studies. 
 The rest of the following procedures will only take place if the delivery goes well, the 
cord blood is obtained successfully, and both you and your baby are healthy. 
 After delivery you will be asked questions about your health and home environment.   
 At one week after delivery, we will ask you for a blood sample (2 teaspoons). We will 
use this blood for an HIV test, for a test for TB infection, tests of your immune 
responses and for tests of gene and gene expression. If you are found to be HIV 
positive, you will be counselled and referred to an appropriate care provider.  You will 
not be asked to continue with the study. 
 You will not be able to be identified as a result of agreeing for us to use your DNA 
or RNA.  These studies are for research purposes only, and no personal 
information will be attached to the results of these studies.  
 You will also be asked to provide a stool sample to test for worm infections 
 You will also be given a tuberculin skin test (TST) and you will be asked to come back 
(or to be visited at home) for this to be read after two or three days. This is the usual test 
for TB infection. We will also check your stool and blood to find out whether you have 
worms and malaria. 
 When you return to have your TST result read, we may ask you to continue with the 
study, based on your TST and TB blood test results.   
 We will ask you (and your baby) to continue in the study if you are confirmed to have a 
TB infection.   
 Mothers without TB infection (and their babies) will be chosen to continue by a simple 
lottery method.   
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 If you are positive on one TB test and negative on the other, you will not be asked to 
continue with the study.  A test result such as this probably means that you do not have 
TB.   
 We will also ask for a blood sample from your child (half a teaspoon) one or four weeks 
after BCG immunisation. We will also ask for another blood sample (half a teaspoon) 
from your child after six weeks (if your baby gave blood at one week), or at ten weeks 
(if your baby gave blood at four weeks). We will use this blood for tests of immunity. 
 We will collect blood (one teaspoon) from your baby when they return at age one year, 
and will also ask you to provide a stool sample from your infant when you arrive. 
 If you have a positive blood test for TB infection or a positive tuberculin skin test you 
will be checked for TB disease by a doctor and sent for a chest X-ray.  If you are found 
to have TB disease you will be treated and your baby will be given treatment to prevent 
TB.  
 If you are found to have worms, you will be given anti-worm treatment. 
 Transport will be provided to take you home from the hospital and field workers may 
visit you at home to check on your skin test result and on the baby’s progress, and to 
remind you about your follow up visits. A transport refund will be given for each visit 
when you are asked to come to the clinic. 
 If you are chosen to continue in the study, we will ask you to continue for 
approximately one year 
 To complete the full study, we expect to recruit 150 mothers with TB infection (and 
their babies), and 150 mothers without TB infection (and their babies)  
Taking part in this study is not expected to cause any major problems for you or your 
child. However, there will be some discomfort from having blood samples taken and the 
smaller discomfort of tuberculin skin testing.  In general, blood samples will be used for 
tests of immunity and some may be stored for other tests in future.  All the information 
collected, and the results of tests, will be completely confidential. 
Your right to refuse or withdraw from the research study 
Your participation in this study is voluntary.  You and your child are free to drop out of 
the study at any time.  Dropping out of the study will not affect your entitlement to 
routine government health care and management or to the provision of treatment for TB 
if you need it. 
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If you have any questions about your participation in this study, please feel free to 
ask the responsible midwife, doctor or field worker.  If you prefer, you may speak 
to one of the principal investigators for this study: Dr Stephen Cose (telephone:  
041 7704180) or Prof. Alison M. Elliott (telephone: 041 7704180).  If you have any 
questions about your rights as a research subject, you may also speak with the 
Ethics Committee Chairman from the Uganda Virus Research Institute, on 0414 
321962.  
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Appendix P 
 SCREENING II CHECK LIST  
 
Date of Form: (dd/mm/yyyy) 
 
                                              |__|__|/|__|__|/|__|__|__|__| 
 
 
Mothers Name: 
 
     
…………………………………………………………
……………………………… 
 
   
Date of delivery: 
(dd/mm/yyyy) 
 
                                            |__|__|/|__|__|/|__|__|__|__| 
 
   
   
Check that this visit is complete by ticking the boxes corresponding to 
activities/procedures that have been done. Items not ticked should be reviewed for 
completeness before the mother is reimbursed. All relevant information worth 
noting should be documented in the comments column. 
 
Activities/procedures Response 
(tick) 
Comment, if any: 
Participants reviewed and examined by 
clinician 
 
  
4ml blood sample taken off from mother for 
repeat HIV test and storage (EDTA 
vacutainer) 
  
6ml blood sample taken off from mother for 
T-Spot assay (Heparin vacutainer) 
  
TST placed on mother’s forearm   
Stool sample received from mother 
 
  
Mother’s contact details updated 
 
  
Mother’s transport costs reimbursed   
 
 
Date of TST Reading: (dd/mm/yyyy)                                              
|__|__|/|__|__|/|__|__|__|__| 
 
 
Name of staff…………………………………       
…………………………………………….Initials|__|__|__| 
 
 
 
 
 
 
 
 
 
  
 
 
 
248 
Appendix Q 
          
 SCREENING II ELIGIBILITY ASSESSMENT  
 
ELIG SC-
II 
Date of Form: 
(dd/mm/yyyy) 
 
                                                                       
|__|__|/|__|__|/|__|__|__|__|  
 
 
DATE2 
Mothers Name:                                     
……………………………………………… 
 
MNAME 
 
Mothers age: 
 
                                                                                 
|__|__|years  
 
MAGE 
Mothers weight:  
                                                                       
|__|__|.|__|Kg  
 
MWT 
Mothers height:  
                                      |__|__|__|.|__|cm / |__|__|.|__|m  
 
MHT 
Body Mass 
Index: 
 
                                                               
|__|__|.|__|__|Kg/m²  
 
BMI 
ELIGIBILITY FOR INFANT BCG STUDY  
To be eligible, all responses should be “YES” except Qn 7=No 
 
 
1. Eligibility form “I” filled and eligible?                           
FILLED 
2. Is the consent form signed and dated?               
   
  
SIGNED 
3. Address form filled and completed?   
ADDFIL 
4. Did the mother have a normal vaginal delivery? 
 
  
NDEL 
5. Cord blood collected at delivery?   
CORDBL 
6. Was birth weight greater or equal to 2.5Kg?    
BWT 
7. No major congenital abnormalities?  ABNORM 
8. Did the baby receive the Danish BCG vaccine from project 
stocks? 
  
BCGDAN 
9. Is the baby well enough to participate in the study?   
CWELL 
10. Is the mother happy for her and her baby to continue 
participating in the study? 
  
HAPPY 
If eligible, collect mothers stool sample, draw blood for repeat HIV test 
and T-Spot assay; then place TST antigen on mother’s forearm and give 
appointment for TST reading. 
 
Date of TST Reading+/-Enrolment:     |__|__|/|__|__|/|__|__|__|__| 
 
Name of staff…………………………………Initials |__|__|__| 
 
 
INS 
 
1=Yes, 2=No 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
249 
Appendix R.  
 
Maternal BCG scar is associated with increased infant proinflammatory immune 
responses. Mawa, P.A, Webb, E.L., Filali-Mouhim, A., Sekaly, R.P., Nkurunungi, G., 
Lule, S.A., Prentice, S., Nash, S., Dockrell, H.M., Elliott, A.M., and Cose, C”. The 
original article (in press) is found at the end of the thesis. 
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Appendix S.  
 
“The impact of maternal infection with Mycobacterium tuberculosis on the infant 
response to bacille Calmette-Guérin immunisation”. Mawa, P.A., Nkurunungi, G., 
Egesa, M., Webb, E.L., Smith, S.G., Kizindo, R., Akello, M., Lule, S.A., Muwanga, M., 
Dockrell, H.M., Cose, S., Elliott, A.M. Philos Trans R Soc Lond B Biol Sci. 2015 Jun 
19; 370 (1671)”. The original article (pages 1-9) is found at the end of the thesis. 
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Appendix T.  
                Cord blood, r=0.20                                1 week, r=0.33                              4 weeks, r=0.69                                  6 weeks, r=0.70 
 
                   10 weeks, r=0.67                                24 weeks, r=0.81                               52 weeks, r=0.66 
 
Correlations between concentrations of PPD-induced IFN-γ and TNF-α. Cytokines and chemokines were measured from supernatants after 
6-day stimulation of cord blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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                  Cord blood, r=0.11                               1 week, r=-0.01                           4 weeks, r=0.24                                  6 weeks, r=0.62 
 
 
                     10 weeks, r=0.37                               24 weeks, r=0.85                                52 weeks, r=0.61 
 
Correlations between PPD-induced IFN-γ and IL-1α. Cytokines and chemokines were measured in supernatants after 6-day stimulation of 
cord blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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                 Cord blood, r=0.16                             1 week, r=0.13                                 4 weeks, r=0.35                                  6 weeks, r=0.40 
 
                    
                     10 weeks, r=0.25                             24 weeks, r=0.68                                52 weeks, r=0.63 
 
Correlations between PPD-induced IFN-γ and IL-5. Cytokines and chemokines were measured in supernatants after 6-day stimulation of cord 
blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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                    Cord blood, r=0.27                          1 week, r=0.15                                   4 weeks, r=0.62                                 6 weeks, r=0.66 
 
 
 
                     10 weeks, r=0.72                              24 weeks, r=0.72                              52 weeks, r=0.75 
 
Correlations between PPD-induced IFN-γ and IL-13. Cytokines and chemokines were measured in supernatants after 6-day stimulation of 
cord blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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                   Cord blood, r=0.37                           1 week, 0.26                                        4 weeks, r=0.45                                6 weeks, r=0.44 
 
 
                       10 weeks, r=0.44                             24 weeks, r=0.54                               52 weeks, r=0.76 
 
Correlations between PPD-induced IFN-γ and GM-CSF. Cytokines and chemokines were measured in supernatants after 6-day stimulation of 
cord blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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                   Cord blood, r=-0.05                          1 week, r=0.11                                4 weeks, r=0.19                                 6 weeks, r=0.21 
 
                      10 weeks, r=0.21                                24 weeks, r=-0.18                           52 weeks, r=0.62 
 
Correlations between PPD-induced IFN-γ and IP-10. Cytokines and chemokines were measured in supernatants after 6-day stimulation of 
cord blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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                   Cord blood, r=0.17                        1 week, r=0.11                                   4 weeks, r=0.44                                 6 weeks, r=0.58 
 
 
                 
                     10 weeks, r=0.29                              24 weeks, r=0.32                               52 weeks, r=0.48 
 
Correlations between PPD-induced IFN-γ and MIP-1α. Cytokines and chemokines were measured in supernatants after 6-day stimulation of 
cord blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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                   Cord blood, r=0. 15                          1 week, r=0. 82                                4 weeks, r=0.75                                6 weeks, r=0.85 
 
                   10 weeks, r=0. 64                               24 weeks, r=0.75                            52 weeks, r=0.91 
 
Correlations between PPD-induced IL-5 and IL-13. Cytokines and chemokines were measured in supernatants after 6-day stimulation of cord 
blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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Appendix U.  
                 Cord blood, r=0. 68                              1 week, r=0.59                               4 weeks, r=0.63                                6 weeks, r=0.70 
 
                    10 weeks, r=0.37                               24 weeks, r=0.55                           52 weeks, r=0.63 
 
Correlations between ESAT-6/CFP10-specific IFN-γ and TNF-α. Cytokines and chemokines were measured in supernatants after 6-day 
stimulation of cord blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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                 Cord blood, r=0.40                               1 week, r=0.38                                4 weeks, r=0.54                                6 weeks, r=0.27 
 
                     10 weeks, r=0.22                               24 weeks, r=0.79                           52 weeks, r=0.58 
 
Correlations between ESAT-6/CFP10-specific IFN-γ and IL-1α. Cytokines and chemokines were measured in supernatants after 6-day 
stimulation of cord blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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                Cord blood, r=0.59                              1 week, r=0.60                                4 weeks, r=0.58                                6 weeks, r=0.25 
 
 
                  10 weeks, r=0.49                               24 weeks, r=0.53                           52 weeks, r=0.74 
 
Correlations between ESAT-6/CFP10-specific IFN-γ and IL-12p40. Cytokines and chemokines were measured in supernatants after 6-day 
stimulation of cord blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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                    Cord blood, r=0.32                           1 week, r=0.58                                 4 weeks, r=0.51                               6 weeks, r=0.01 
 
 
                   10 weeks, r=0. 27                              24 weeks, r=0.07                          52 weeks, r=0.61 
 
Correlations between ESAT-6/CFP10-specific IFN-γ and IP-10. Cytokines and chemokines were measured in supernatants after 6-day 
stimulation of cord blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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                 Cord blood, r=0.58                             1 week, r=0.58                                  4 weeks, r=0.34                                6 weeks, r=0.13 
 
 
 
                     10 weeks, r=0.21                             24 weeks, r=0.85                            52 weeks, r=0.53 
 
Correlations between ESAT-6/CFP10-specific IFN-γ and MIP-1α. Cytokines and chemokines were measured in supernatants after 6-day 
stimulation of cord blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay. 
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                Cord blood, r=0.45                                1 week, r=0.66                                 4 weeks, r=0.38                              6 weeks, r=0.19 
 
 
              
                    10 weeks, r=0.38                               24 weeks, r=0.62                         52 weeks, r=0.55 
 
Correlations between ESAT-6/CFP10-specific IFN-γ and GM-CSF. Cytokines and chemokines were measured in supernatants after 6-day 
stimulation of cord blood, and infant blood obtained at 1, 4, 6, 10, 24 and 52 weeks after birth using a 17-plex Luminex® assay.  
